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Ankylosing spondylitis (AS; from Greek αγκύλος: stiff and σπόνδυλος: vertebrae) is a 
rheumatic disease that predominantly affects the axial skeleton and sacroiliac joints. The 
disease is characterized by the fascinating combination of inflammation, bone formation, and 
bone loss causing severe pain, stiffness, and impaired functioning. Leonard Trask (1805-1861) 
was the first documented patient with AS in the American literature. He suffered as a young 
male from contortion of his neck and spine, which started after he fell from a horse. 
Interestingly, some manifestations of AS were clearly described: “His neck and back have 
continued to curve, more and more, every year, drawing his head downward on his breast.” 
and “It was not until he had exercised for some time and got warmed up that he could perform 
any labor, without suffering the most excruciating pains”. Mr. Trask’s condition remained a 
medical mystery during his life, but he was diagnosed post mortem with AS.1,2 
 
Epidemiology and etiology  
In mid-Europe, AS has an estimated prevalence of 0.3-0.5%. The disease usually begins in the 
second or third decade of life and onset after 45 years of age is rare.3 AS occurs more often in 
males than in females (ratio 2-3:1), but this may partly be explained by the fact that most 
women tend to experience milder symptoms and are therefore underdiagnosed.4 The cause of 
AS is multifactorial and includes both genetic and environmental factors. There is a strong 
association with the major histocompatibility complex (MHC) class I human leukocyte antigen 
(HLA)-B27. Approximately 90% of patients with AS are positive for HLA-B27. Furthermore, 
bacterial antigens have been suggested to be involved in the pathogenesis of AS.3 
 
Clinical manifestations 
The main clinical features of AS are chronic inflammatory back pain (IBP) and spinal stiffness. 
The IBP is often of insidious onset and improves with exercise and worsens with rest. This pain 
can be poorly localized by patients, but is most often felt in the sacroiliac region or deep in the 
gluteal area with sometimes radiation of the pain to the upper leg. Other frequent symptoms 
are peripheral arthritis, which mostly affects the shoulders and hips, and enthesitis, which can 
occur at classic sites (i.e. Achilles tendon and plantar fascia) or at the spine. Furthermore, AS is 
associated with extra-articular manifestations, such as acute anterior uveitis, psoriasis, and 
inflammatory bowel disease (IBD).3 
 
Bone formation as well as bone loss 
AS is characterized by excessive bone formation, which can lead to the formation of 
syndesmophytes, ankylosis of the spine and sacroiliac joints, and bony formations at enthesal 
sites. Eventually, complete fusion or ankylosing of vertebrae can result in a so-called ‘bamboo 
spine’.3 The relation between chronic inflammation and new bone formation is not fully 
understood. The long-standing assumption is that inflammation and bone formation are 
clearly linked and that inflammatory lesions are preferentially seen at sites that later on 
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develop bony proliferations and ankylosis. The alternative hypothesis is that inflammation and 
bone formation are simultaneously triggered and are uncoupled during disease progression.5  
In addition to bone formation, bone loss is a well-recognized complication of AS and 
osteoporosis can already be observed at early stages of the disease. Vertebral bone loss can be 
associated with severe complications, particularly vertebral fractures and increased spinal 
deformity.6,7 
 
From AS to axial SpA: classification and diagnosis 
For a long period of time, radiographic sacroiliitis, the hallmark of AS, was obligatory for the 
diagnosis of AS. According to the modified New York criteria, patients are classified with AS if 
radiographic sacroiliitis (grade ≥2 bilaterally or grade 3-4 unilaterally) is associated with at least 
one clinical criterion.8 However, structural changes are often not visible on radiographs during 
the first years of the disease, which results in a diagnostic delay. To shorten this delay, the 
Amor and European Spondyloarthropathy Study Group (ESSG) criteria have been developed, 
in which radiographic sacroiliitis is optional to classify patients with spondyloarthritis (SpA).9,10 
The introduction of magnetic resonance imaging (MRI) made it possible to detect both 
inflammation and early structural changes. The recently developed Assessment in 
SpondyloArthritis international Society (ASAS) classification criteria for axial SpA included the 
MRI as an important tool to identify patients with early disease. According to these criteria, 
patients with back pain for >3 months and age at onset <45 years are classified as having axial 
SpA if sacroiliitis on imaging (radiographs or MRI) is associated with at least one other SpA 
feature, or if a patient is HLA-B27 positive and at least two other SpA features are present.11,12 
An important remark is that these criteria sets have been developed as classification criteria 




The standard treatment for axial symptoms of patients with AS consists of nonsteroidal  
anti-inflammatory drugs (NSAIDs) and physical therapy. There is no evidence that  
disease-modifying antirheumatic drugs (DMARDs), such as sulfasalazine or methotrexate, are 
effective for the axial manifestations in AS, but the use of DMARDs can be considered in case 
of peripheral arthritis.13  
The introduction of tumor necrosis factor-alpha (TNF-α) blocking agents has been the most 
important development in the treatment of AS in the past decades.14,15 These agents block the 
effect of the proinflammatory cytokine TNF-α, which has been found at increased levels in 
serum and synovium of affected patients.16 TNF-α blocking therapy is available for AS patients 
with persistently active disease, who do not respond to conventional treatment.13 
Currently, four TNF-α blocking agents are approved for AS: infliximab (2003), etanercept 
(2004), adalimumab (2006), and golimumab (2009). Randomized controlled trials (RCTs) have 




clinical assessments such as fatigue, physical function, and disease-related quality of life in 
patients with AS.17-20 
 
ASAS group 
The ASAS working group, consisting of international experts in the field of AS, was initiated in 
1995. The mission of the ASAS group is to support and promote the research of AS to 
improve the well-being and outcome of patients with AS. This goal is achieved by increasing 
awareness and early diagnosis of the disease, by the development and validation of assessment 
tools, and by the evaluation of treatment modalities.21 In 2009, the ASAS group published the 
ASAS handbook, a guide to assess spondyloarthritis, which includes many important tools and 
recommendations for AS.22 As far as available, we followed these guidelines while conducting 
the cohort study presented in this thesis. 
 
GLAS study 
The Groningen Leeuwarden Ankylosing Spondylitis (GLAS) study is an ongoing prospective 
longitudinal observational cohort study with follow-up visits according to a fixed protocol. The 
general research goal of the GLAS study is to evaluate different aspects of TNF-α blocking 
therapy in AS patients in daily clinical practice. A second goal is to obtain more knowledge on 
AS-related bone formation and bone resorption, also in relation to TNF-α blocking therapy. 
Data from observational studies such as the GLAS cohort are important, since they provide 
information closer to clinical practice than RCTs. 
Since November 2004, consecutive AS outpatients who start TNF-α blocking therapy at the 
Medical Center Leeuwarden (MCL) and the University Medical Center Groningen (UMCG) 
are included in the GLAS study. The inclusion was extended to all consecutive AS outpatients 
who are treated by the rheumatologists at the MCL and UMCG in 2009. Inclusion criteria are 
fulfilling the modified New York criteria for AS and being 18 years or older. In 2009, fulfilling 
the ASAS axial SpA criteria including MRI was added in order to include also patients with 
early disease. Exclusion criteria are no informed consent and legal incapacity. 
According to the ASAS consensus statement,23 starting TNF-α blocking therapy is based on 
active disease (Bath AS disease activity index (BASDAI) ≥4, range 0-10) despite treatment with 
2 different NSAIDs for four weeks and/or positive expert opinion to start with TNF-α blocking 
agents (physician’s global disease activity ≥4, range 0-10) based on clinical signs and/or rapid 
radiological progression. The choice of the TNF-α blocking agent is based on the judgment of 
the treating rheumatologist and/or the specific preference of the patient. 
Patients treated with TNF-α blocking therapy are evaluated at baseline, after 3 and 6 months, 
and then every 6 to 12 months. Patients without anti-TNF-α treatment are evaluated yearly. In 
line with the ASAS core set of domains and measuring instruments that can be used for the 
assessment of AS,22 standardized follow-up includes assessments of disease activity, physical 
function, spinal mobility, quality of life, inflammation of entheses, and radiology. In addition, 
 Introduction 
 11 
bone mineral density (BMD) is assessed and serum, plasma, and urine samples are collected 
and stored to measure e.g. bone turnover markers (BTM) and vitamin D levels.  
All manuscripts from this thesis are based on data derived from the GLAS cohort. 
 
Outline of this thesis 
This thesis covers several important topics of AS. The first part concerns different aspects of 
AS-related bone loss (chapter 2) and investigates the effect TNF-α blocking therapy on BTM 
and BMD (chapter 3). The second part focuses on response to TNF-α blocking therapy. 
Potential biomarkers to monitor or predict response are studied (chapters 3-4), baseline 
predictors of response to TNF-α blocking therapy are identified (chapters 5-6), and the effects 
of antibodies against TNF-α blocking therapy are investigated (chapter 7). The last part 
(chapter 8) describes a study comparing different methods to assess physical activity in AS. 
  
Bone turnover 
In AS, excessive bone formation can lead to the formation of syndesmophytes and ankylosing 
of the spine, where on the other hand bone loss can result in low BMD and vertebral fractures. 
This combination seems fascinating and the knowledge about the pathophysiology of  
AS-related bone formation and bone loss is limited.  
BTM reflect the metabolic activity of bone and can easily be measured in blood or urine. BTM 
are traditionally categorized as markers of bone formation and bone resorption. Procollagen 
type 1 N-terminal peptide (PINP; a product of collagen synthesis), bone-specific alkaline 
phosphatase (BALP; an enzyme secreted by osteoblasts, which plays a key role in the 
mineralization process), and osteocalcin (OC; a matrix protein with a regulating function in the 
process of bone formation) are frequently used markers of bone formation. Furthermore, 
serum type I collagen C-telopeptide (sCTX; a product of collagen degradation) is a well-known 
marker of bone resorption.24,25 Measuring these BTM may provide a better insight in the bone 
physiology of AS.26,27 
A challenge of working with BTM is that they change with age and that there are differences 
for gender (Figure 1). We have the unique availability of a healthy reference cohort on BTM, 
which enables us to correct the BTM levels of individual AS patients for the normal influence 








Figure 1. Bone turnover markers in males and females of a healthy reference cohort. A: procollagen type 1 
N-terminal peptide (PINP), B: bone-specific alkaline phosphatise (BALP), C: osteocalcin (OC), D: serum 
type I collagen C-telopeptide (sCTX) (personal communication, Dr. E. van der Veer).  
 
 
Chapter 2 investigates the relation between BMD, BTM, vitamin D, and clinical assessments 
of disease activity and physical function in order to obtain more knowledge on AS-related 
osteoporosis. Furthermore, the prevalence of low BMD and vertebral fractures is assessed to 
show the importance of monitoring bone loss in AS. Finally, parameters that are related to low 
BMD (osteopenia or osteoporosis) are identified.  
TNF-α blocking agents have been shown to be effective in controlling inflammation and 
improving clinical outcome in patients with AS. The next important question is whether TNF-α 
blocking therapy also leads to a beneficial effect on bone turnover. To investigate this issue, 
the effect of 3 years of TNF-α blocking therapy on BTM and BMD is described in chapter 3. 
 
Predictors of response 
In clinical practice, continuation of TNF-α blocking therapy is mainly based on subjective 
measures such as the BASDAI and the global opinion of the patient and the physician. It would 
be valuable to include also an objective measure in this evaluation process. In contrast to 
patients with rheumatoid arthritis (RA), erythrocyte sedimentation rate (ESR) and C-reactive 
protein (CRP) are elevated in only a minority of patients with AS.28,29 In search of a useful 
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objective biomarker in AS, chapter 3 investigates the predictive value of early changes in BTM 
for discontinuation of TNF-α blocking therapy. Subsequently, chapter 4 evaluates whether 
matrix metalloproteinase-3 (MMP-3), an enzyme involved in degradation of extracellular 
matrix components, can serve as a biomarker for monitoring and predicting response to 
etanercept treatment. 
Identifying characteristics of patients with AS before start of treatment which are able to 
predict a beneficial response to TNF-α blocking therapy is relevant, especially in view of the 
high costs and potential side effects of these agents. In chapter 5, baseline predictors of 
response and discontinuation of TNF-α blocking therapy are identified in AS patients in daily 
clinical practice. Chapter 6 provides an overview of clinical trials and observational studies 
investigating baseline predictors of response after 3 to 6 months of TNF-α blocking therapy 
and baseline predictors of long-term anti-TNF-α treatment continuation in AS. 
Although the majority of AS patients respond very well to TNF-α blocking therapy, 
approximately 30% fail to reach efficacy. This may in part be explained by the formation of 
antibodies against TNF-α blocking agents. Chapter 7 investigates the influence of antibody 
formation to TNF-α blocking agents on clinical response in AS patients treated with infliximab, 
etanercept, or adalimumab. Furthermore, the association between the development of 
autoantibodies and the formation of antibodies to TNF-α blocking agents is explored. 
 
Daily physical activity 
Physical activity seems to improve clinical assessments in patients with AS,30 but can also have 
beneficial effects on BMD.31 Physical activity questionnaires are considered to be the most 
applicable method to assess daily physical activity in population studies because of participant 
convenience and minimal cost.32,33 However, the measurement properties of physical activity 
questionnaires are not known in AS. Chapter 8 evaluates the construct validity and test-retest 
reliability of the International Physical Activity Questionnaire (IPAQ) and Short QUestionnaire 
to ASsess Health-enhancing physical activity (SQUASH) in patients with AS. Furthermore, the 
relation between the amount of daily physical activity (i.e. household, work, transport, and 
leisure time activities) and clinical assessments of disease activity, physical function, spinal 
mobility, and quality of life is described in AS. 
 
This thesis ends with a summary and general discussion provided in English and Dutch in 
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Summary: Osteoporosis is a well recognized complication of ankylosing spondylitis (AS). 
This study indicates that increased bone turnover, inflammation, and low vitamin D levels are 
important in the pathophysiology of AS-related osteoporosis, and that bone turnover markers 
(BTM) are valuable markers to detect bone loss in AS. 
Introduction: The aim of this study was to elucidate the pathophysiology of AS-related 
osteoporosis by investigating the relation between bone mineral density (BMD), BTM, vitamin 
D, and clinical assessments of disease activity and physical function, as well as to identify 
parameters that are related to low BMD (osteopenia or osteoporosis) in AS patients with 
active disease. 
Methods: One hundred twenty-eight consecutive Dutch AS outpatients were included in this 
cross-sectional study. Bath AS Disease Activity Index (BASDAI), erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP), AS Disease Activity Score (ASDAS), Bath AS Functional 
Index (BASFI), bone formation markers procollagen type 1 N-terminal peptide (PINP) and 
osteocalcin (OC), bone resorption marker serum C-telopeptides of type I collagen (sCTX),  
25-hydroxyvitamin D (25OHvitD), lumbar spine and hip BMD, and vertebral fractures were 
assessed. Z-scores of BTM were calculated using matched 10-year-cohorts of a Dutch 
reference group to correct for the normal influence that age and gender have on bone 
turnover. 
Results: sCTX Z-score, OC Z-score, BASDAI, age, and gender were independently related to 
low BMD. In addition, PINP Z-score, ESR, 25OHvitD, age, and gender were independently 
related to sCTX and/or OC Z-score. 
Conclusions: This study indicates that increased bone turnover, inflammation, and low 
vitamin D levels are important in the pathophysiology of AS-related osteoporosis. 
Furthermore, sCTX and OC Z-scores seem to be valuable markers to detect bone loss in AS 
patients in daily clinical practice where BMD of the lumbar spine, measured by DXA, may be 




Bone turnover in ankylosing spondylitis 
 19 
INTRODUCTION 
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the axial 
skeleton. The disease is characterized by new bone formation, which leads to the formation of 
syndesmophytes and ankylosis of the spine and sacroiliac joints. Osteoporosis is also a  
well-recognized complication of AS and is already observed in early stages of the disease. Early 
vertebral bone loss can be accompanied by severe complications. Previous studies have shown 
that, in contrast to non-vertebral fractures, the risk of clinical vertebral fractures is increased in 
AS patients1,2 and that vertebral fractures are frequently present in AS.3 
Knowledge about the pathophysiology of AS-related osteoporosis is limited. Various studies 
have shown involvement of inflammatory processes in the complex pathophysiological 
mechanism of AS-related osteoporosis.4-9 Furthermore, various other factors such as drug 
intake and decreased mobility in relation to pain and stiffness may contribute to the 
development of osteoporosis in AS patients.10 In addition, recent studies in AS have suggested 
that alterations in vitamin D metabolism are associated with inflammatory activity and bone 
mineral density (BMD).7,11-13 Non-invasive assessment of biochemical bone turnover markers 
(BTM) may provide more information about the pathophysiology of osteoporosis.14-16 So far, 
conflicting data have been published about the relation between BTM, BMD, and disease 
activity in AS.4,9,14,15,17-21  
BMD is usually monitored with dual-energy x-ray absorptiometry (DXA).22 However, previous 
studies have shown that the anterior-posterior lumbar spine BMD in AS can be overestimated 
by the presence of syndesmophytes, ligament calcifications, and fusion of facet joints.23-25 
Furthermore, measuring only hip BMD by DXA may not be sufficient to identify all patients 
with AS-related osteoporosis since bone loss may primarily occur in the spine.23 Currently, 
quantitative computed tomography (QCT) is considered to be the best technique to measure 
spinal BMD in patients with advanced AS, since this technique can measure only trabecular 
BMD.17,24,26 However, QCT is expensive and has a high radiation dose compared to DXA.27 
Therefore, an alternative method to monitor bone loss in AS patients is desirable. 
The aim of the present study was to elucidate the pathophysiology of AS-related osteoporosis 
by investigating the relation between BMD, BTM, vitamin D, and clinical assessments of 
disease activity and physical function in a cross-sectional cohort of AS patients with active 
disease, and to identify parameters that are related to low BMD (osteopenia or osteoporosis) 






Between November 2004 and February 2009, 128 consecutive Dutch AS outpatients from the 
Medical Center Leeuwarden (MCL, n=97) and the University Medical Center Groningen 
(UMCG, n=31) were included in this cross-sectional study. All patients were over 18 years of 
age, fulfilled the modified New York criteria for AS,28 and fulfilled the criteria for anti-tumor 
necrosis factor alpha (anti-TNF-α) treatment according to the Assessments in Ankylosing 
Spondylitis (ASAS) consensus statement.29 Data collected before start of anti-TNF-α treatment 
were used in this cross-sectional study. Excluded were patients with the concomitant presence 
of inflammatory bowel disease, chronic renal or hepatic disease, diabetes mellitus, parathyroid 
or thyroid disease, recent fractures, malnutrition, or drug intake affecting bone metabolism 
(bisphosphonates, glucocorticoids, anticonvulsants, coumarin derivatives, or diuretics).  
The study was approved by the local ethics committees of the MCL and UMCG, and all 
patients provided written informed consent to participate in this study. 
 
Clinical and laboratory assessments 
Disease activity was assessed using the Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI; on a scale of 0-10),30 erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), 
and Ankylosing Spondylitis Disease Activity Score (ASDAS) calculated from BASDAI questions 
2, 3, and 6, patient’s global assessment of disease activity, and CRP.31,32 Physical function was 
assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI; on a scale of 0-10).33 
Bone turnover was studied by assessment of bone formation markers procollagen type 1  
N-terminal peptide (PINP) and osteocalcin (OC), and bone resorption marker serum  
C-telopeptides of type I collagen (sCTX).14 PINP was measured by radioimmunoassay (RIA; 
Orion Diagnostica, Espoo, Finland; inter-assay coefficient of variation (IE-CV) 9.0%). OC was 
measured by immunoradiometric assay (IRMA; BioSource Europe S.A; IE-CV 9.4%).  sCTX was 
measured by electrochemiluminescence immunoassay (ECLIA; Elecsys 2010 Roche 
Mannheim, Germany; IE-CV 10.8%). Serum 25-hydroxyvitamin D (25OHvitD) levels were 
measured by RIA (DiaSorin, Stillwater, MN, USA; IE-CV 15%; UMCG and MCL until July 2008) 
or ECLIA (Modular Analytics E170, Roche Mannheim, Germany; IE-CV 7.1%; MCL since July 
2008). 25OHvitD <50 nmol/liter was defined as a poor vitamin D status. Serum samples were 
stored at -20ºC until analysis. 
Z-scores of BTM were used to correct for the normal influence that age and gender have on 
bone turnover. Z-scores, the number of standard deviations (SD) from the normal mean for 
age and gender, were calculated using matched 10-year-cohorts of a Dutch reference group 
(150 men or 350 women), checked for serum 25OHvitD levels >50 nmol/liter as well as for 
lumbar spine and hip BMD T-score >-2.5 after 50 years of age.  
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BMD measurement 
BMD of lumbar spine (anterior-posterior projection at L1-L4) and hip (total proximal femur) 
were measured using DXA (Hologic QDR Discovery (UMCG) or Hologic QDR Delphi (MCL), 
Waltman, MA, USA). According to the World Health Organization (WHO) classification, 
osteopenia was defined as a T-score between -1 and -2.5 and osteoporosis as a T-score ≤-2.5.34 
Patients were categorized by the lowest T-score of the lumbar spine or hip. T-scores, the 
number of SD from the normal mean obtained from young healthy adults, were calculated 
using the NHANES reference database. DXA measurements of lumbar spine and hip were 
available for 106 and 108 patients, respectively. 
 
Vertebral assessment 
Anterior, middle, and posterior heights of vertebrae T4 to L4 were measured on lateral 
radiographs by two independent observers using a ruler. According to the Genant 
classification, a vertebral fracture was defined based on reduction in anterior, middle, and/or 
posterior height: grade 1, 20-25% reduction; grade 2, 25-40% reduction; and grade 3, >40% 
reduction.35 In case of discrepancy between the two observers, a third independent observer 
measured vertebral height in order to confirm the presence or absence of a vertebral fracture. 
Radiographs were available for 106 patients. 
 
Statistical analysis 
Statistical analysis was performed with SPSS 16.0 software (SPSS, Chicago, IL, USA). Results 
were expressed as mean ± SD or median (range) for parametric and nonparametric data, 
respectively. Pearson’s and Spearman’s correlation coefficients were used as appropriate to 
analyze the relationship between BMD, BTM, vitamin D, and clinical measures of disease 
activity and physical function. Predictor analysis for low BMD, defined as lumbar spine or hip 
BMD T-score ≤-1, was performed using univariate logistic regression and multivariate logistic 
regression with conditional stepwise backward inclusion of variables that had a p-value ≤0.3 in 
univariate analysis, together with variables that significantly correlated with lumbar spine or 
hip BMD T-scores. The probability of P for stepwise removal was 0.10. Predictor analyses for 
sCTX and OC Z-scores were performed using univariate linear regression and multivariate 
linear regression with backward inclusion of variables that had a p-value ≤0.3 in univariate 
analysis, together with variables that significantly correlated with sCTX or OC Z-scores. The 







Mean age of the 128 AS patients was 41.0 years (SD ± 11.1), median disease duration was 14 
years (range 1-53), and 73% were male. Of the patients, 89% had a BASDAI score ≥4, 74% had 
increased ESR levels, and 77% had increased CRP levels (Table 1). 
 
 
Table 1. Characteristics of the AS study population (n = 128) 
Age (yrs) 41.0 ± 11.1   
Gender (male) (n, %) 93 (73)   
Disease duration (yrs) 14 (1-53)   
HLA-B27+ (n, %) 102 (84)   
NSAID use (n, %) 100 (78)   
DMARD use (n, %) 18 (14)   
BASDAI (range 0-10) 6.0 ± 1.6 BASDAI ≥4 (n, %) 116 (89) 
ESR (mm/h) 20 (2-90) Increased ESR (n, %) 95 (74) 
CRP (mg/l) 14 (2-92) Increased CRP (n, %) 99 (77) 
ASDAS 3.7 ± 0.8   
BASFI (range 0-10) 5.6 ± 2.0   
LS BMD T-score -0.68 ± 1.41 Osteopenia LS (n, %) 41 (39) 
  Osteoporosis LS (n, %) 9 (9) 
Hip BMD T-score -0.52 ± 1.06 Osteopenia hip (n, %) 42 (39) 
  Osteoporosis hip (n, %) 2 (2) 
VF (n, %) 41 (39) VF grade 1 (n, %) 27 (25) 
  VF grade 2 (n, %) 14 (13) 
  VF grade 3 (n, %) 0 (0) 
PINP (μg/l) 42.7 (16.0-101.5)   
PINP Z-score 0.14 (-1.74-3.55)   
sCTX (pg/ml) 200.3 (13.4-780.9)   
sCTX Z-score -0.36 (-2.58-5.90)   
OC (μg/l) 12.7 (0.1-24.9)   
OC Z-score -0.28 (-2.86-2.52)   
25OHvitD (nmol/l) 61.4 (13.8-186)  Poor vitD status (n, %) 30 (26) 
Values are mean ± SD or median (range) unless otherwise indicated.  
AS: ankylosing spondylitis; HLA-B27+: human leukocyte antigen B27 positive; NSAID: non-steroidal 
anti-inflammatory drug; DMARD: disease-modifying antirheumatic drug; BASDAI: Bath ankylosing 
spondylitis disease activity index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; ASDAS: 
ankylosing spondylitis disease activity score; BASFI: Bath ankylosing spondylitis functional index;  
LS: lumbar spine; BMD: bone mineral density; VF: vertebral fracture; PINP: procollagen type 1  
N-terminal peptide; sCTX: serum C-telopeptides of type I collagen; OC: osteocalcin; 25OHvitD:  
25-hydroxyvitamin D. 
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Correlations between biochemical and clinical assessments 
Correlations between BMD, BTM, vitamin D, and clinical assessments of disease activity and 
physical function were calculated to obtain more knowledge about the pathophysiology of  
AS-related osteoporosis (Table 2). There was a significant positive correlation between lumbar 
spine and hip BMD T-scores. Lumbar spine BMD T-score correlated positively with BASDAI 
(p<0.05) and hip BMD T-score correlated negatively with OC and sCTX Z-scores 
(p<0.05).There were significant positive correlations between all BTM Z-scores. PINP Z-score 
correlated positively with age (p<0.05) and PINP and sCTX Z-scores correlated positively with 
disease duration (p<0.05). Finally, ESR, CRP, ASDAS, or BASFI were not significantly correlated 
with any of the BMD T-scores or BTM Z-scores.  
 
 
Table 2. Correlations between clinical and biochemical assessments in AS patients with active disease 
(n=128) 
 Age Disease 
duration 
BASDAI ESR CRP ASDAS BASFI 
Disease duration 0.600* -      
BASDAI  NS NS -     
ESR NS NS NS -    
CRP NS NS NS 0.693* -   
ASDAS NS 0.187* 0.651* 0.374* 0.668* -  
BASFI  NS 0.203* 0.561* NS NS 0.472* - 
PINP Z-score 0.362* 0.266* NS NS NS NS NS 
sCTX Z-score NS 0.200* NS NS NS NS NS 
OC Z-score NS NS NS NS NS NS NS 
LS BMD T-score NS NS 0.205* NS NS NS NS 
hip BMD T-score NS NS NS NS NS NS NS 
25OHvitD NS NS NS NS NS NS NS 
 
Table 2. (Continued) 




sCTX Z-score 0.443* -    
OC Z-score 0.578* 0.601* -   
LS BMD T-score NS NS NS -  
hip BMD T-score NS -0.380* -0.272* 0.626* - 
25OHvitD NS NS NS NS NS 







The difference between lumbar spine and hip BMD T-score correlated positively with disease 
duration (ρ=0.340, p<0.05). As shown in Figure 1, patients with long disease duration never 
had a lumbar spine BMD T-score that was much lower than their hip BMD T-score, which 
indicates that osteoproliferation in the lumbar spine has resulted in an overestimation of the 





Figure 1. The difference between lumbar spine and hip BMD T-score correlated positively with disease 
duration (ρ=0.340, p<0.05). Patients with long disease duration never had a lumbar spine BMD T-score 
that was much lower than their hip BMD T-score, which indicates that osteoproliferation in the lumbar 




Of the patients, 39% had at least 20% reduction in anterior, middle, and/or posterior vertebral 
height, indicating vertebral fracture. In total, 74 vertebral fractures were detected; 59 wedge 
fractures, 14 biconcave fractures, and one crush fracture. No significant differences between 
patients with and without vertebral fractures were found in age (mean 43.1 years ± SD 11.1 vs. 
39.9 years ± 11.0; p=0.149), disease duration (median 15 years (range 1-47) vs. 12 years (1-53); 
p=0.925), BMD T-scores (lumbar spine -0.70 ± 1.33 vs. -0.71 ± 1.51; p=0.984, hip -0.47 ± 1.03 
vs. -0.59 ± 1.10; p=0.591), and BTM Z-scores (PINP 0.15 (-1.74-3.08) vs. 0.22 (-1.65-3.55); 
p=0.493), sCTX -0.21 (-2.28-5.90) vs. -0.23 (-2.58-3.92); p=0.778, OC -0.31 (-2.86-1.50) vs. 
 -0.18 (-2.66-2.52); p=0.460, respectively). 
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Predictors of low BMD 
Predictor analysis was performed to identify parameters that are related to low BMD. In total, 
57% of patients had a lumbar spine or hip BMD T-score of -1 or less, indicating low BMD. Male 
gender, lower BASDAI score, higher PINP Z-score, higher OC Z-score, and higher sCTX  
Z-score were significantly associated with low BMD in univariate regression analysis. Since 
male gender was significantly associated with low BMD, variables that significantly differed 
between men and women were included in multivariate analysis: age, ESR, OC Z-score, sCTX 
Z-score, and 25OHvitD. Multivariate regression analysis showed that older age (odds ratio 
(OR): 1.066, 95% confidence interval (CI): 1.008-1.129), lower BASDAI score (OR: 0.648, 
0.445-0.923), higher ESR (OR: 1.025, 0.994-1.057), and higher sCTX Z-score (OR: 2.563, 1.370-
4.794) were independently related to low BMD (Table 3). OC Z-score was not included in 
multivariate analysis, probably due to the strong correlation between sCTX Z-score and OC  
Z-score (ρ=0.601, p=0.000). However, higher OC Z-score was also independently related to 
low BMD in the presence of age, BASDAI, and ESR (OR: 2.255, 95%CI: 1.238-4.107), indicating 
that both sCTX Z-score and OC Z-score are important. The Nagelkerke R2 of the multivariate 
models including sCTX Z-score and OC Z-score were 0.381 and 0.338, respectively. 
 
 
Table 3. Results of univariate and multivariate logistic regression analysis for low BMD 
 Univariate analysis Multivariate analysis 
 OR (95% CI) p-value OR (95% CI) p-value 
Age (yrs)a 1.017 (0.981-1.055) 0.353 1.066 (1.008-1.129) 0.026 
Genderb 4.368 (1.791-10.652) 0.001  * 
Disease duration (yrs)a 1.012 (0.974-1.052) 0.539  * 
BASDAI (range 0-10)c 0.728 (0.554-0.957) 0.023 0.648 (0.455-0.923) 0.016 
ESR (mm/h)c 1.012 (0.980-1.034) 0.287 1.025 (0.994-1.057) 0.112 
CRP (mg/l)c 1.018 (0.994-1.042) 0.143  * 
ASDASc 0.769 (0.461-1.283) 0.315  ** 
BASFI (range 0-10)c 0.959 (0.790-1.165) 0.674  ** 
PINP Z-scorec 1.602 (1.043-2.461) 0.031  * 
sCTX Z-scorec 1.878 (1.262-2.794) 0.002 2.563 (1.370-4.794) 0.003 
OC Z-scorec 1.766 (1.135-2.749) 0.012  * 
25OHvitD (nmol/l)c 0.998 (0.983-1.013) 0.787  * 
VFd 0.902 (0.385-2.109) 0.811  ** 
OR refers to the risk of low BMD (lumbar spine or hip BMD T-score ≤ -1): a — per year; b — if gender is 
male (versus female); c — per 1 grade or 1 point; d — if vertebral fracture is present (versus absent).  
See Table 1 for definitions. 
* The variable was not selected during multivariate regression analysis.  
** The variable was not tested in multivariate regression analysis because of a p-value > 0.3 in univariate 
regression analysis, no significant correlation with lumbar spine or hip BMD T-scores, and no significant 
difference between men and women. 
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Predictors of sCTX and OC Z-scores 
Since sCTX and OC Z-scores seem to be valuable markers to detect bone loss, predictor 
analyses for these markers were performed to get more information about the 
pathophysiology of AS-related osteoporosis. Gender, PINP Z-score, OC Z-score, and 
25OHvitD were significantly associated with sCTX Z-score in univariate regression analysis. 
Since gender was significantly associated with sCTX Z-score, the previous mentioned variables 
that significantly differed between men and women were included in multivariate analysis. 
Multivariate regression analysis showed that ESR (B: 0.012, 0.000-0.025), PINP Z-score  
(B: 0.292, 0.022-0.563), OC Z-score (B: 0.505, 0.243-0.768), and 25OHvitD (B: -0.009,-0.018-
0.000) were independently related to sCTX Z-score (Table 4). The R2 of this multivariate 
model was 0.424. 
Gender, PINP Z-score, and sCTX Z-score were significantly associated with OC Z-score in 
univariate regression analysis. Since gender was significantly associated with OC Z-score, the 
previous mentioned variables that significantly differed between men and women were 
included in multivariate analysis. Multivariate regression analysis showed that age (B: -0.018, 
 -0.034--0.001), gender (B: -0.607, -0.999--0.214), PINP Z-score (B: 0.464, 0.282-0.646), and 
sCTX Z-score (B: 0.243, 0.110-0.377) were independently related to OC Z-score (Table 5). The 
R2 of this multivariate model was 0.509. 
 
 
Table 4. Results of univariate and multivariate linear regression analysis for sCTX Z-score 
 Univariate analysis Multivariate analysis 
 B (95% CI) p-value B (95% CI) p-value 
Age (yrs)a 0.018 (-0.004-0.041) 0.112  * 
Genderb -0.680 (-1.211--0.148) 0.013  * 
Disease duration (yrs)a 0.018 (-0.005-0.041) 0.114  * 
BASDAI (range 0-10)c -0.060 (-0.213-0.092) 0.436  ** 
ESR (mm/h)c 0.011 (-0.002-0.025) 0.102 0.012 (0.000-0.025) 0.069 
CRP (mg/l)c 0.007 (-0.007-0.021) 0.303  * 
ASDASc 0.156 (-0.174-0.486) 0.351  ** 
BASFI (range 0-10)c 0.004 (-0.124-0.132) 0.953  ** 
PINP Z-scorec 0.581 (0.384-0.777) 0.000 0.292 (0.022-0.563) 0.035 
OC Z-scorec 0.774 (0.577-0.971) 0.000 0.505 (0.243-0.768) 0.000 
25OHvitD (nmol/l)c -0.011 (-0.020--0.002) 0.020 -0.009 (-0.018-0.000) 0.041 
B refers to the influence on sCTX Z-score: a — per year; b — if gender is male (versus female); c — per 1 
grade or 1 point. 
See Table 1 for definitions. 
* The variable was not selected during multivariate regression analysis.  
** The variable was not tested in multivariate regression analysis because of a p-value > 0.3 in univariate 
regression analysis, no significant correlation with sCTX Z-score, and no significant difference between 
men and women. 
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Table 5. Results of univariate and multivariate linear regression analysis for OC Z-score 
 Univariate analysis Multivariate analysis 
 B (95% CI) p-value B (95% CI) p-value 
Age (yrs)a 0.008 (-0.011-0.027) 0.409 -0.018 (-0.034--0.001) 0.036 
Genderb -0.687 (-1.129--0.244) 0.003 -0.607 (-0.999--0.214) 0.003 
Disease duration (yrs)a 0.007 (-0.012-0.026) 0.460  ** 
BASDAI (range 0-10)c -0.029 (-0.155-0.098) 0.655  ** 
ESR (mm/h)c 0.006 (-0.005-0.018) 0.284  * 
CRP (mg/l)c 0.009 (-0.003-0.022) 0.130  * 
ASDASc 0.052 (-0.222-0.326) 0.708  ** 
BASFI (range 0-10)c 0.035 (-0.071-0.141) 0.651  ** 
PINP Z-scorec 0.605 (0.453-0.756) 0.000 0.464 (0.282-0.646) 0.000 
sCTX Z-scorec 0.464 (0.346-0.582) 0.000 0.243 (0.110-0.377) 0.000 
25OHvitD (nmol/l)c -0.007 (-0.016-0.001) 0.076  * 
B refers to the influence on OC Z-score: a — per year; b — if gender is male (versus female); c — per 1 
grade or 1 point. 
See Table 1 for definitions. 
* The variable was not selected during multivariate regression analysis.  
** The variable was not tested in multivariate regression analysis because of a p-value > 0.3 in univariate 
regression analysis, no significant correlation with OC Z-score, and no significant difference between 




The present cross-sectional study in AS patients with active disease showed that sCTX and OC 
Z-scores are independently related to low BMD, which indicates that sCTX and OC Z-scores 
are valuable markers to detect bone loss in AS. An accurate and easily accessible marker of 
bone loss is needed in patients with advanced AS, since the anterior-posterior lumbar spine 
BMD measured by DXA can be overestimated by the presence of syndesmophytes, ligament 
calcifications, and fusion of facet joints in these patients.23-25 Our finding that the difference 
between lumbar spine and hip BMD correlated positively with disease duration indicates that 
this overestimation also occurred in this study. Furthermore, our high prevalence of vertebral 
fractures and of low BMD (osteopenia or osteoporosis) underlines the importance of 
monitoring bone loss in AS. 
In order to obtain more knowledge about the pathophysiology of AS-related osteoporosis, we 
investigated the relation between BMD, BTM, vitamin D, and clinical assessments. Our results 
demonstrate that increased bone turnover plays a significant role in the development of 
osteoporosis in AS patients. First, significant positive correlations were found between age or 
disease duration and PINP Z-score, a marker of bone formation, as well as between disease 
duration and sCTX Z-score, a marker of bone resorption. Since the use of Z-scores corrects for 
the normal influence that age and gender have on bone turnover, these correlations 
demonstrate that AS is characterized by both increased bone formation and increased bone 
resorption. Second, significant negative correlations were found between sCTX or OC  
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Z-scores and hip BMD T-score, and a higher sCTX or OC Z-score was independently related to 
low BMD, which indicates that high bone turnover is associated with bone loss in AS. This 
finding is in agreement with the previous studies.4,14,15 
The results of this study also demonstrate involvement of inflammatory processes in the 
complex pathophysiological mechanism of AS-related osteoporosis. A higher ESR was 
independently related to low BMD. Furthermore, ESR had independent influence on sCTX  
Z-score. The importance of inflammatory processes was also shown in previous studies.4-9  
Finally, our finding that 25OHvitD level had an independent significant inverse influence on 
sCTX Z-score suggests that low vitamin D levels play a role in the development of AS-related 
osteoporosis. The importance of vitamin D was also suggested in previous studies.7,11-13,36 
Amento et al. reported that vitamin D is an endogenous modulator of the immune response, 
which may slow down the inflammatory process by suppressing active T cells and cell 
proliferation.36 Lange et al. found negative correlations between serum levels of vitamin D and 
markers of disease activity or inflammation in AS patients. They also showed that AS patients 
with osteoporosis had significantly lower vitamin D levels compared to AS patients with 
normal BMD.7,11 Finally, Obermayer et al. suggested a close association of BMD, bone 
metabolism, and inflammatory activity with Fok1 polymorphisms of the vitamin D receptor 
gene in male AS patients.13 
Unexpectedly, a lower BASDAI score was independently related to low BMD in this study. 
 A possible explanation for this finding may be that complaints related to new bone formation 
influence the BASDAI, a subjective measure of disease activity, in AS patients with active 
disease. The significant positive correlation between BASDAI and lumbar spine BMD T-score 
found in this study seems to confirm this suggestion. Another explanation may be that BMD, 
measured by DXA, reflects the influence of the disease on bone over time, while BASDAI 
reflects the current status of disease activity. 
There are some strengths and limitations to this study. The main limitation is that the study is 
cross-sectional and that only AS patients with active disease were included. Further studies 
with longer follow-up are needed to confirm the usefulness of sCTX and OC Z-scores in 
monitoring bone loss in AS patients, as well as the importance of increased bone turnover, 
inflammation, and low vitamin D levels in the development of AS-related osteoporosis. 
Another limitation is that body mass index (BMI) was not assessed in this study. Therefore, it 
was not possible to correct for low BMI in multivariate analysis. Finally, it was not clear if the 
vertebral fractures occurred recently or if they were already present for many years. Therefore, 
analyses investigating the relation between BTM and vertebral fractures were difficult. The 
main strength is that Z-scores of BTM were calculated to correct for the influence that age and 
gender have on bone turnover in healthy persons. In this way, male and female patients of 
different age groups could be analyzed together. 
In conclusion, this cross-sectional study in AS patients with active disease indicates that 
increased bone turnover, inflammation, and low vitamin D levels are important in the 
pathophysiology of AS-related osteoporosis. Furthermore, sCTX and OC Z-scores seem to be 
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valuable markers to detect bone loss in AS. Combining biochemical BTM and BMD 
measurements may be useful to identify AS patients with osteoporosis in daily clinical practice 
where lumbar spine BMD, measured by DXA, may be overestimated due to osteoproliferation 
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Introduction: The aim of this study was to investigate the effect of 3 years of tumor necrosis 
factor-alpha (TNF-α) blocking therapy on bone turnover as well as to analyze the predictive 
value of early changes in bone turnover markers (BTM) for treatment discontinuation in 
patients with ankylosing spondylitis (AS). 
Methods: Prospective cohort study of 111 consecutive AS outpatients who started TNF-α 
blocking therapy. Clinical assessments and BTM were assessed at baseline, 3 and 6 months, as 
well as 1, 2, and 3 years. Z-scores of BTM were calculated to correct for age and gender. Bone 
mineral density (BMD) was assessed yearly. 
Results: After 3 years, 72 patients (65%) were still using their first TNF-α blocking agent. In 
these patients, TNF-α blocking therapy resulted in significantly increased bone-specific alkaline 
phosphatase, a marker of bone formation; decreased serum collagen-telopeptide (sCTX),  
a marker of bone resorption; and increased lumbar spine and hip BMD compared to baseline. 
Baseline to 3 months decrease in sCTX Z-score (HR: 0.394, 95% CI: 0.263-0.591), AS disease 
activity score (ASDAS; HR: 0.488, 95% CI: 0.317-0.752), and physician’s global disease activity 
(HR: 0.739, 95% CI: 0.600-0.909) were independent inversely related predictors of time to 
treatment discontinuation because of inefficacy or intolerance. Early decrease in sCTX Z-score 
correlated significantly with good long-term response regarding disease activity, physical 
function, and quality of life.  
Conclusions: Three years of TNF-α blocking therapy results in a bone turnover balance that 
favors bone formation (especially mineralization), in combination with continuous 
improvement of lumbar spine BMD. Early change in sCTX can serve as an objective measure in 
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INTRODUCTION 
Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects the axial 
skeleton. Bone formation and bone loss are both present in AS. New bone formation can lead 
to the formation of syndesmophytes, ankylosis of the spine and sacroiliac joints, and bone 
formations on enthesal sites,1, 2 whereas bone loss can result in osteoporosis and vertebral 
fractures.3-5  
Randomized controlled trials (RCTs) have shown that the tumor necrosis factor-alpha (TNF-α) 
blocking agents infliximab, etanercept, and adalimumab are effective in controlling 
inflammation and improving clinical assessments in AS.6-8 Previous studies could not 
demonstrate a significant effect of 2 years of TNF-α blocking therapy on radiographic 
progression in AS.9-11  
Although the majority of patients responds very well, a significant proportion of patients has to 
withdraw from TNF-α blocking therapy due to inefficacy or adverse events.12-14 Currently, 
subjective measures of disease activity, such as the Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI) or the global opinion of the physician, are most important in the 
evaluation of TNF-α blocking therapy in AS. The recently developed Ankylosing Spondylitis 
Disease Activity Score (ASDAS) captures both subjective (patient-reported measures) and 
objective (acute phase reactant) aspects of disease activity.14-17 However, it would be useful to 
include also a purely objective measure in this evaluation process. 
The early effect of TNF-α blocking therapy on bone turnover may be helpful in predicting 
treatment outcome. Bone turnover can be monitored using bone turnover markers (BTM).18 
The bone formation markers bone-specific alkaline phosphatase (BALP) and osteocalcin (OC) 
were reported to be increased after 2 to 52 weeks and 2 to 22 weeks of TNF-α blocking 
therapy, respectively.19-21 On the other hand, the bone resorption markers serum type I 
collagen N-telopeptide and C-telopeptide (sNTX and sCTX) remained unchanged up to 46 
weeks of TNF-α blocking treatment.19,21,22 Visvanthan et al. showed that an early increase in 
BALP was associated with significant increases in bone mineral density (BMD) of the spine and 
hip after 2 years of TNF-α blocking therapy.23 
The first aim of the present study was to investigate the effect of 3 years of TNF-α blocking 
therapy on bone turnover. The second aim was to investigate whether the early effect of  
TNF-α blocking therapy on BTM can serve as an objective predictor of treatment 






Between November 2004 and December 2007, 111 consecutive Dutch outpatients with AS, 
who started TNF-α blocking therapy at the University Medical Center Groningen (UMCG; 
n=28) and the Medical Center Leeuwarden (MCL; n=83), were included in this longitudinal 
analysis. All patients participated in the Groningen Leeuwarden Ankylosing Spondylitis (GLAS) 
study, a prospective longitudinal observational cohort study with follow-up visits according to 
a fixed protocol. For the present analysis, patients with recent fractures and/or use of 
bisphosphonates were excluded because of major influence on bone metabolism. All patients 
were over 18 years of age, fulfilled the modified New York criteria for AS (n=109)24 or the 
Assessments in Ankylosing Spondylitis (ASAS) criteria for axial spondyloarthritis including 
MRI (n=2).25 The patients started treatment with the TNF-α blocking agents infliximab (n=22), 
etanercept (n=71), or adalimumab (n=18) because of active disease (BASDAI ≥4 and/or expert 
opinion), according to the ASAS consensus statement.26 As described previously,14 infliximab 
(5 mg/kg) was given intravenously at 0, 2, and 6 weeks and then every 8 weeks. In case of 
inadequate response, the frequency of infliximab treatment was raised to every 6 weeks. 
Etanercept was administered as a subcutaneous injection once (50 mg) or twice (25 mg) a 
week. Adalimumab (40 mg) was administered as a subcutaneous injection on alternate weeks. 
In 2004 and 2005, patients started treatment with either infliximab or etanercept as 
adalimumab was only registered in the Netherlands from 2006. The choice of the TNF-α 
blocking agent was based on the judgment of the treating rheumatologist and/or the specific 
preference of the patient. Continuation of treatment was based on decrease in the BASDAI of 
at least 50% or 2 units compared with baseline and/or expert opinion in favor of treatment 
continuation. Reasons for discontinuation of TNF-α blocking therapy were classified into the 
categories intolerance due to adverse events, inefficacy, or other reasons. Patients were 
allowed to receive concomitant medication as usual in daily clinical practice. The GLAS study 
was approved by the local ethics committees of the UMCG and the MCL. All patients 
provided written informed consent according to the Declaration of Helsinki. 
 
Clinical and laboratory assessments 
Patients were evaluated at baseline and after 3 months (mean 3.3 mo, SD ± 0.5), 6 months 
(mean 6.4 mo, SD ± 0.8), 1 year (mean 1.0 yr, SD ± 0.1), 2 years (mean 2.1 yr, SD ± 0.1), and 3 
years (mean 3.1 yr, SD ± 0.1) of TNF-α blocking therapy. Disease activity was assessed using 
the BASDAI (on a scale of 0-10), physician’s and patient’s global assessment of disease activity 
(GDA; on a scale of 0-10), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and 
ASDASCRP (calculated from BASDAI questions 2, 3 and 6, patient’s GDA, and CRP).15,16 
Increased ESR and CRP levels were based on local standardized values. Physical function was 
assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI; on a scale of 0-10). 
Spinal mobility assessments included chest expansion, modified Schober test, occiput to wall 
distance, and lateral lumbar flexion (left and right). Quality of life was assessed using the 
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Ankylosing Spondylitis Quality of Life questionnaire (ASQoL; on a scale of 0-18). Peripheral 
arthritis was defined as at least one swollen joint (excluding the hip) at baseline. 
Bone turnover was studied by assessment of the bone formation markers bone-specific 
alkaline phosphatase (BALP) and procollagen type 1 N-terminal peptide (PINP), and the bone 
resorption marker serum type I collagen C-telopeptide (sCTX).5 BALP was measured by 
enzyme-linked immunosorbent assay (ELISA; Metra Biosystems, Mountain View, CA, USA; 
inter-assay coefficient of variation (IE-CV) 5.5%), PINP by radioimmunoassay (RIA; Orion 
Diagnostica, Espoo, Finland; IE-CV 9.0%), and sCTX by electrochemiluminescence 
immunoassay (ECLIA; Elecsys 2010 Roche Mannheim, Germany; IE-CV 10.8%). Serum samples 
were stored within one hour at -20ºC until analysis. 
Z-scores of BTM were used to correct for the normal influence that age and gender have on 
bone turnover. Z-scores, the number of standard deviations (SD) from the normal mean 
corrected for age and gender, were calculated using matched 10-year-cohorts of a Dutch 
reference group (200 men or 350 women) checked for serum 25-hydroxyvitamin D levels >50 
nmol/liter as well as for the absence of osteoporosis (BMD T-score >-2.5) after 50 years of age. 
Z-scores were calculated as follows: (BTM value of individual patient — mean BTM value of 
matched 10-year-cohort of reference group) / SD of matched reference cohort. 
 
BMD measurement 
BMD of the lumbar spine (anterior-posterior projection at L1-L4) and hip (total proximal 
femur) was assessed at baseline and after 1 year (mean 1.1 yr, SD ± 0.1), 2 years (mean 2.2 yr, 
SD ± 0.2), and 3 years (mean 3.2 yr, SD ± 0.2) of TNF-α blocking therapy. BMD was measured 
using DXA (Hologic QDR Discovery (UMCG) or Hologic QDR Delphi (MCL), Waltman, MA, 
USA). T-scores, the number of SD from the normal mean obtained from young healthy adults, 
and Z-scores, the number of SD from the normal mean corrected for age and gender, were 
calculated using the NHANES reference database. According to the World Health 
Organization (WHO) classification, osteopenia was defined as a T-score between -1 and -2.5 
and osteoporosis as a T-score ≤-2.5.27 
 
Statistical analysis 
Statistical analysis was performed with PASW Statistics 18 (SPSS, Chicago, IL, USA). Results 
were expressed as mean ± SD or median (range) for normally distributed and non-normally 
distributed data, respectively. Predictor analysis of time to discontinuation of TNF-α blocking 
therapy (yes/no) was performed using forward conditional Cox regression of variables with a 
p-value ≤0.3 in univariate Cox regression. The probability of F for entry was 0.05. Receiver 
Operating Characteristic (ROC) analysis was performed to determine the accuracy of early 
change in BTM to predict discontinuation of TNF-α blocking therapy during the first 3 years. 
Area under the curve (AUC) <0.70 was interpreted as poor accuracy, 0.70< AUC <0.90 as 
moderate accuracy, and AUC >0.90 as high accuracy.28 Pearson’s and Spearman’s correlation 
coefficients were used as appropriate to analyze the relation between early change in BTM and 
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clinical assessments. Generalized estimating equations (GEE) were used to analyze clinical 
assessments, BTM, and BMD over time within subjects. Pairwise contrasts were used to 




Mean age of the 111 AS patients was 42.2 years (SD ± 10.3), 70% were male, and median 
disease duration was 16 years (range 1-49). All baseline characteristics are shown in Table 1. 
After 3 years, 72 patients (65%) continued to use their first TNF-α blocking agent. In these 
patients, all assessments of disease activity (Table 2), physical function, spinal mobility, and 
quality of life (data not shown) improved after 3 months and remained significantly better 
compared to baseline up to 3 years of TNF-α blocking therapy.  
The remaining 39 patients (35%) discontinued treatment after a median follow-up of 7.0 
months (range 1.1-36.2). Reasons for discontinuation of TNF-α blocking therapy were 
inefficacy (n=17; 44%), adverse events (n=11; 28%: diarrhea or inflammatory bowel disease 
(IBD; n=4); infection (n=3); allergic reaction (n=2); cardio-vascular disease (n=1); 
demyelization problems (n=1)), both inefficacy and adverse events (n=5; 13%: diarrhea or IBD 
(n=2); infection (n=1); allergic reaction (n=1); uveitis (n=1)), or other reasons (n=6; 15%: good 
initial response, own choice (n=3); pregnancy wish (n=2); lost to follow up (n=1)). 
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Table 1. Baseline characteristics of the AS study population (n=111) 
Age (yrs) 42.2 ± 10.3   
Gender (male) (n, %) 78 (70)   
Duration of symptoms (yrs) 16 (1-49)   
Time since diagnosis (yrs) 9 (0-37)   
HLA-B27+ (n, %) 88 (81)   
History of IBD (n, %) 11 (10)   
History of uveitis (n, %) 31 (28)   
History of psoriasis (n, %) 9 (8)   
Peripheral arthritis (n, %) 21 (19)   
Current NSAID use (n, %) 98 (88)   
Current DMARD use (n, %) 26 (23)   
BASDAI (range 0-10) 6.1 ± 1.7 BASDAI ≥4 (n, %) 98 (88) 
ASDASCRP 3.8 ± 0.8 ASDASCRP ≥2.1 (n, %) 105 (96) 
Physician’s GDA (range 0-10) 5 (1-9)   
Patient’s GDA (range 0-10) 7 (1-10)   
ESR (mm/h) 22 (2-90) Increased ESR (n, %) 86 (78) 
CRP (mg/l) 15 (2-99) Increased CRP (n, %) 84 (76) 
BASFI (range 0-10) 6.1 ± 2.0   
Chest expansion (cm) 3.0 (0.5-10.0)   
Modified Schober test (cm) 2.9 (0.1-7.0)   
Occiput to wall distance (cm) 5.0 (0.0-28.0)   
Lateral lumbar flexion L (cm) 8.7 ± 4.1   
Lateral lumbar flexion R (cm) 8.4 ± 4.3   
ASQoL (range 0-18) 10 ± 4   
BALP (U/L) 17.2 (1.6-36.5)   
BALP Z-score 0.28 (-2.59-5.16)   
PINP (μg/l) 45.6 (16.0-98.0)   
PINP Z-score 0.35 (-1.75-3.63)   
sCTX (pg/ml) 206.0 (13.4-657.1)   
sCTX Z-score -0.34 (-2.58-4.01)   
LS BMD T-score -0.58 ± 1.41 Osteopenia LS (n, %) 34 (34) 
  Osteoporosis LS (n, %) 9 (9) 
LS BMD Z-score  LS Z-score ≤-2.0 (n, %) 9 (9) 
Hip BMD T-score -0.53 ± 1.12 Osteopenia hip (n, %) 38 (37) 
  Osteoporosis hip (n, %) 2 (2) 
Hip BMD Z-score  Hip Z-score ≤-2.0 (n, %) 4 (4) 
Values are mean ± SD or median (range) unless otherwise indicated.  
AS: Ankylosing Spondylitis; HLA-B27+: human leukocyte antigen B27 positive; IBD: inflammatory bowel 
disease; NSAID: non-steroidal anti-inflammatory drug; DMARD: disease-modifying antirheumatic drug; 
BASDAI: Bath ankylosing spondylitis disease activity index; ASDAS: ankylosing spondylitis disease 
activity score; GDA: global disease activity; ESR: erythrocyte sedimentation rate; CRP: C-reactive 
protein;  BASFI: Bath ankylosing spondylitis functional index; L: left; R: right; BALP: bone-specific-alkaline 
phosphatase; PINP: procollagen type 1 N-terminal peptide; sCTX: serum C-telopeptide of type I 
collagen; LS: lumbar spine; BMD: bone mineral density. 
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Table 2. The effect of 3 years of TNF-α blocking therapy on clinical assessments and bone turnover in patients 
with AS (n=72) 
 Baseline 3 months p* 6 months p* 
BASDAI 6.0 ± 1.7 2.5 ± 1.6 0.000 2.3 ± 1.7 0.000 
ASDASCRP 3.9 ± 0.8 1.7 ± 0.7 0.000 1.6 ± 0.7 0.000 
Physician’s GDA 5 (1-9) 2 (0-5) 0.000 1 (0-8) 0.000 
Patient’s GDA 6 (1-10) 2 (0-8) 0.000 2 (0-8) 0.000 
ESR (mm/h) 22 (2-90) 5 (2-35) 0.000 6 (2-36) 0.000 
CRP (mg/l) 16 (2-99) 3 (2-20) 0.000 3 (2-21) 0.000 
BALP Z-score 0.19 (-1.64-3.91) 0.94 (-1.49-5.12) 0.000 0.48 (-1.26-4.37) 0.000 
PINP Z-score 0.36 (-1.75-3.63) 0.50 (-1.54-4.55) 0.047 0.54 (-1.47-5.33) 0.054 
sCTX Z-score -0.02 (-2.58-4.01) -0.74 (-2.53-2.29) 0.000 -0.55 (-2.25-3.99) 0.002 
LS BMD Z-score -0.36 ± 1.56     
Hip BMD Z-score -0.40 ± 1.0     
 
 
Table 2. (Continued) 
 12 months p* 24 months p* 36 months p* 
BASDAI 2.7 ± 2.1 0.000 2.5 ± 1.8 0.000 2.6 ± 1.7 0.000 
ASDASCRP 1.9 ± 0.9 0.000 1.9 ± 0.8 0.000 1.8 ± 0.8 0.000 
Physician’s GDA 1 (0-7) 0.000 0 (0-6) 0.000 0 (0-3) 0.000 
Patient’s GDA 2 (0-10) 0.000 2 (0-8) 0.000 2 (0-7) 0.000 
ESR (mm/h) 7 (2-52) 0.000 9 (2-46) 0.000 8 (2-48) 0.000 
CRP (mg/l) 3 (2-38) 0.000 3 (2-61) 0.000 3 (2-57) 0.000 
BALP Z-score 0.87 (-1.34-6.69) 0.000 0.58 (-1.46-6.11) 0.000 1.09 (-1.33-9.27) 0.000 
PINP Z-score 0.28 (-1.52-5.53) 0.102 0.57 (-1.51-7.17) 0.013 0.28 (-1.45-2.43) 0.247 
sCTX Z-score -0.45 (-2.23-3.11) 0.011 -0.34 (-2.15-4.31) 0.119 -0.70 (-2.50-4.15) 0.019 
LS BMD Z-score 0.04 ± 1.42 0.000 0.20 ± 1.39 0.000 0.48 ± 1.61 0.000 
Hip BMD Z-score -0.32 ± 0.91 0.000 -0.24 ± 1.01 0.000 -0.16 ± 1.03 0.000 
Values are mean ± SD or median (range).  
See Table 1 for abbreviations.  
* p-value compared to values recorded at baseline. 
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Effect of TNF-α blocking therapy on bone turnover 
Data of the 72 AS patients who were still using their first TNF-α blocking agent after 3 years 
were analyzed to investigate the effect of TNF-α blocking therapy on bone turnover (Table 2).  
TNF-α blocking therapy resulted in a significant increase in the bone formation marker BALP  
Z-score after 3 months (p<0.001) and BALP Z-score continued at a higher level up to 3 years. 
The bone formation marker PINP Z-score was found to be significantly increased only after 3 
and 24 months of TNF-α blocking therapy (p<0.05). The bone resorption marker sCTX Z-score 
decreased significantly after 3 months (p<0.001) and remained decreased during 3 years of 
treatment (Figure 1). The course of the absolute BTM values, analyzed separately for male and 
female patients because of gender differences in BTM, were in line with the results for the 





Figure 1. The effect of 3 years of TNF-α blocking therapy on bone formation markers BALP (A) and PINP 
(B), and bone resorption marker sCTX (C) in patients with AS (n=72). Z-scores were calculated to correct 
for the normal influence that age and gender have on bone turnover. Data were available for 100%, 
92.6%, 95.4%, 97.2%, 97.2%, and 90.3% of the patients at 0, 3, 6, 12, 24, and 36 months, respectively.  
Box-and-whisker plots (Tukey): boxes indicate medians with interquartile ranges; + indicate means; 
whiskers indicate 1.5 times the interquartile distances; • indicate outliers. a: p<0.001 compared to values 
recorded at baseline. b: p<0.05 compared to values recorded at baseline. c: p<0.05 and p<0.01 compared 
to values recorded at 6 and 24 months, respectively. d: p<0.05 and p<0.01 compared to values recorded 
at 12 and 24 months, respectively.  
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Lumbar spine and hip BMD Z-scores improved significantly after 1 year of TNF-α blocking 
therapy (p<0.001). Subsequently, the lumbar spine BMD Z-score increased further after 2 and 
3 years (p<0.05 and p<0.01, respectively). The hip BMD Z-score tended to increase further 
after 2 years (p=0.050), but remained stable after 2 to 3 years of treatment (p=0.780) (Figure 
2).   
 
 
          
 
Figure 2. The effect of 3 years of TNF-α blocking therapy on lumbar spine (A) and hip (B) BMD in 
patients with AS (n=72). Z-scores were calculated to correct for age and gender. Data were available for 
92.4%, 93.1%, 89.6%, and 64.6% of the patients at 0, 12, 24, and 36 months, respectively.  
Box-and-whisker plots (Tukey): boxes indicate medians with interquartile ranges; + indicate means; 
whiskers indicate 1.5 times the interquartile distances; • indicate outliers. a: p<0.001 compared to values 
recorded at baseline. b: p<0.05 compared to values recorded at 12 months. c: p<0.001 and p<0.01 
compared to values recorded at 12 and 24 months, respectively. 
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Predictive value of early change in bone turnover 
Data of 105 AS patients were analyzed to investigate the predictive value of early change  
(0-3 months) in BTM for treatment discontinuation; 72 patients who continued versus 33 
patients who discontinued their first TNF-α blocking agent because of inefficacy and/or 
adverse events. Patients who discontinued treatment due to other reasons (n=6) were 
excluded from this analysis. Baseline to 3 months decrease in BASDAI, ASDASCRP, patient’s 
GDA, physician’s GDA, and sCTX Z-score were inversely associated with time to 
discontinuation of TNF-α blocking therapy in univariate Cox regression. Multivariate analysis 
showed that baseline to 3 months decrease in sCTX Z-score (HR: 0.394, 95% CI: 0.263-0.591), 
ASDASCRP (HR: 0.488, 95% CI: 0.317-0.752), and physician’s GDA (HR: 0.739, 95% CI: 0.600-
0.909) were independent inversely related predictors of time to discontinuation of TNF-α 
blocking therapy (Table 3).  
When the ASDAS was excluded from the analysis, baseline to 3 months decrease in sCTX  
Z-score (HR: 0.402, 95% CI: 0.273-0.593), BASDAI (HR: 0.702, 95% CI: 0.574-0.858), and 
physician’s GDA (HR: 0.732, 95% CI: 0.602-0.891) were selected during multivariate analysis. 
Since the number of female patients was relatively small, multivariate analysis using absolute 
BTM values was performed only in male patients. Baseline to 3 months decrease in sCTX  
(HR: 0.986, 95% CI: 0.979-0.993), BASDAI (HR: 0.707, 95% CI: 0.569-0.878) or alternatively, 
ASDASCRP, and physician’s GDA (HR: 0.685, 95% CI: 0.522-0.898) were identified as 
independent inversely related predictors of time to treatment discontinuation.  
 
 
Table 3. Predictive value of baseline to 3 months change in clinical and laboratory parameters for time to 
discontinuation of TNF-α blocking therapy (n=105) 
 Univariate analysis Multivariate analysis 
Assessment HR (95% CI) p-value HR (95% CI) p-value 
Δ0-3m BASDAI 0.672 (0.579-0.780) 0.000  * 
Δ0-3m ASDASCRP 0.434 (0.327-0.577) 0.000 0.488 (0.317-0.752) 0.001 
Δ0-3m physician’s GDA 0.643 (0.543-0.772) 0.000 0.739 (0.600-0.909) 0.004 
Δ0-3m patient’s GDA 0.735 (0.641-0.844) 0.000  * 
Δ0-3m CRP 0.977 (0.954-1.002) 0.068  * 
Δ0-3m ESR 0.975 (0.950-1.001) 0.064  * 
Δ0-3m BALP Z-score 1.291 (0.969-1.720) 0.081  * 
Δ0-3m PINP Z-score 1.014 (0.688-1.493) 0.944  ** 
Δ0-3m sCTX Z-score 0.513 (0.367-0.717) 0.000 0.394 (0.263-0.591) 0.000 
Δ0-3m: change from baseline to 3 months. See Table 1 for other abbreviations. 
HR refers to the risk of anti-TNF-α treatment discontinuation per 1 grade or 1 point. 
* The variable was not selected during multivariate Cox regression analysis (p≥0.05). 





The accuracy of baseline to 3 months change in sCTX Z-score to discriminate between 
patients who continued and discontinued TNF-α blocking therapy during the first 3 years was 
moderate, with an AUC of 0.741 (95% CI: 0.640-0.841), and comparable to the accuracy of 
early change in ASDASCRP (AUC: 0.790, 95% CI: 0.699-0.880) or in physician’s GDA (AUC: 
0.730, 95% CI: 0.624-0.837). 
In addition, baseline to 3 months change in sCTX Z-score was significantly associated with 
disease activity (BASDAI, ASDASCRP, physician’s and patient’s GDA, ESR, and CRP), physical 
function (BASFI), spinal mobility (chest expansion), and quality of life (ASQoL) at last  
follow-up (defined as at 3 years of TNF-α blocking therapy or at the moment of treatment 
discontinuation) (Table 4). 
 
 
Table 4. Correlations between baseline to 3 months change in bone resorption marker sCTX and clinical 
assessments at last follow-up (n=105) 
 Δ0-3 sCTX Z-score 
Assessment at last follow-upa correlation p-value 
BASDAI (range 0-10) -0.388 0.000 
ASDASCRP -0.463 0.000 
Physician’s GDA (range 0-10) -0.321 0.001 
Patient’s GDA (range 0-10) -0.260 0.010 
ESR (mm/h) -0.273 0.006 
CRP (mg/l) -0.288 0.004 
BASFI (range 0-10) -0.268 0.008 
Chest expansion (cm) 0.260 0.010 
Modified Schober test (cm) -0.031 0.762 
Occiput to wall distance (cm) 0.095 0.350 
Lateral lumbar flexion L (cm) 0.096 0.346 
Lateral lumbar flexion R (cm) 0.169 0.097 
ASQoL (range 0-18) -0.296 0.003 
See Tables 1 and 3 for abbreviations. 
a Defined as at 3 years of TNF-α blocking therapy or at the moment of treatment discontinuation. 
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DISCUSSION 
This is the first study that investigates the predictive value of early changes in bone turnover 
with regard to discontinuation of TNF-α blocking therapy in AS. Currently, in clinical practice, 
continuation of TNF-α blocking therapy is mainly based on subjective measures such as the 
BASDAI and the global opinion of the patient and the physician. Recent studies showed the 
usefulness of the ASDAS as a more objective measure of disease activity.14-17,21 However, a 
purely objective measure is still lacking in the evaluation process of TNF-α blocking therapy. 
The present analysis shows that baseline to 3 months decrease in sCTX Z-score was inversely 
related to time to discontinuation of TNF-α blocking therapy. Interestingly, sCTX Z-score 
remained a significant predictor of treatment discontinuation in the presence of ASDAS and 
physician’s GDA, which underlines the value of sCTX in addition to the currently used 
measures. The accuracy of decrease in sCTX Z-score from baseline to 3 months in predicting 
treatment continuation was comparable to the moderate accuracy of early decrease in ASDAS 
or physician’s GDA. Furthermore, early decrease in sCTX Z-score was significantly associated 
with good long-term response regarding disease activity, physical function, spinal mobility, and 
quality of life. Based on these results, early change in sCTX can be useful as an objective 
biomarker in the evaluation of TNF-α blocking therapy in patients with AS. A major advantage 
of BTM is that they can easily be measured in the blood of patients at different time points 
with relatively low costs. sCTX is widely available on automated immunoassay analysers or as 
ELISA. However, it is important to standardize the serum sample collection to reduce 
variability within and between patients.18 
Until now, several studies investigated the influence of TNF-α blocking therapy on bone 
formation and bone resorption up to 1 year of treatment.19-23 The present study shows that 3 
years of TNF-α blocking therapy resulted in a significant increase in the bone formation marker 
BALP, which plays a central role in the mineralization process of bone, at all time point 
compared to baseline, while the effect on the bone formation marker PINP, a product of 
collagen formation, was found to be less evident. Furthermore, a significant decrease in the 
bone resorption marker sCTX, a product of collagen degradation, was found during 3 years of 
TNF-α blocking therapy. The significant increase in bone formation is in line with previous 
findings after 1 year of TNF-α blocking therapy.19-21 Until now, no clear effect of TNF-α blocking 
therapy on bone resorption was reported.19,21-23 In the present study, we had the unique 
availability of a healthy reference cohort on BTM, which allows us to correct the BTM levels of 
an individual AS patient for age and gender (using Z-scores). In this way, the rate of bone 
turnover can be studied without the confounding influence of age and gender, similar to the 
methodology of interpreting BMD. Nevertheless, our findings using the absolute BTM values 
(analysis split for gender) were in line with the results for the BTM Z-scores (data not shown).  
The changes in BTM over time found in this study cannot be specifically attributed to TNF-α 
blocking therapy because a placebo group is lacking. Visvanathan et al. showed no significant 
changes in BALP or sCTX during 24 weeks of placebo treatment,23 which indicates that the 
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present significant changes in BTM compared to baseline are the result of TNF-α blocking 
therapy. How these results fit into the pathogenesis of AS remains to be studied. 
Importantly, the present results regarding BTM should not be extrapolated to any possible 
effect of TNF-α blocking therapy on radiographic progression in AS since no imaging method 
was used to measure new bone formation resulting in the formation of syndesmophytes and 
joint ankylosis. Furthermore, long-term observation is needed in order to see any effect of 
TNF-α blocking therapy on new bone formation in patients with AS. 
Interestingly, both lumbar spine and hip BMD improved significantly during 3 years of TNF-α 
blocking therapy, which can be explained by the increase in mineralization and decrease in 
bone resorption. Alternatively, the increase in lumbar spine BMD may in part be confounded 
by the progression of formation of ligament calcifications and fusion of facet joints.5,29,30 
However, we expect that excessive bone formation will only have minor influence on the 
increase in lumbar spine BMD found in the present study, since previous studies reported a 
radiological progression of approximately one point in modified stoke ankylosing spondylitis 
spinal score (mSASSS; on a scale of 0-72) after 2 years of TNF-α blocking therapy.31-33 
Moreover, the improvement in lumbar spine and hip BMD after TNF-α blocking therapy is in 




This prospective longitudinal observational cohort study shows that 3 years of TNF-α blocking 
therapy results in a bone turnover balance that favors bone formation (especially 
mineralization), in combination with continuous improvement of lumbar spine BMD. 
Furthermore, baseline to 3 months decrease in sCTX Z-score is identified as a significant 
inversely related predictor of time to treatment discontinuation, independent from ASDAS 
and physician’s GDA. Based on these results, early change in the bone resorption marker sCTX 
seems useful as a purely objective biomarker in the evaluation of TNF-α blocking therapy in AS, 
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Objective: To investigate whether level of serum matrix metalloproteinase-3 (MMP-3) can 
serve as a biomarker for monitoring and predicting response to etanercept treatment in 
patients with ankylosing spondylitis (AS) in daily clinical practice. 
Methods: Ninety-two consecutive AS outpatients with active disease who started etanercept 
treatment were included in this longitudinal observational study. Clinical data were collected 
prospectively at baseline and after 3 and 12 months of treatment. At the same time points, 
serum MMP-3 levels were measured retrospectively by ELISA. 
Results: Since baseline serum MMP-3 levels were significantly higher in male compared to 
female patients with AS, data analysis was split for gender. Changes in serum MMP-3 levels 
after etanercept treatment correlated positively with changes in clinical assessments of disease 
activity and physical function in both male and female patients. Receiver operating 
characteristic analysis in male patients showed that baseline serum MMP-3 levels had poor 
accuracy (AUC: <0.7) to discriminate between Assessments in Ankylosing Spondylitis 20 
(ASAS20) or ASAS40 responders and nonresponders after 3 or 12 months of treatment. The 
accuracy of change in serum MMP-3 levels from baseline to 3 months in predicting response 
after 3 or 12 months of treatment was poor for ASAS40 (AUC: <0.7) or moderate for ASAS20 
(AUC: 0.752 and 0.744, respectively), and was not superior to the accuracy of change in the 
currently used objective biomarkers erythrocyte sedimentation rate and C-reactive protein. 
Conclusion: Although significant changes in serum MMP-3 levels were found after 
etanercept treatment, data analysis indicates that serum MMP-3 levels are not very useful for 
monitoring and predicting response to etanercept treatment in patients with AS in daily 
clinical practice. 
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INTRODUCTION 
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the axial 
skeleton. New bone formation can lead to the formation of syndesmophytes and ankylosing of 
the spine and sacroiliac joints. Besides this ossification, osteoporosis is also a well recognized 
complication of AS.1,2  
The availability of tumor necrosis factor-alpha (TNF-α) blocking agents has significantly 
improved clinical outcome in AS.3-5 In daily clinical practice, starting and continuation of TNF-α 
blocking therapy in patients with AS is based mainly on subjective measures of disease activity 
such as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the global opinion of 
the physician, since more objective measures like erythrocyte sedimentation rate (ESR) and  
C-reactive protein (CRP) are, in contrast to patients with rheumatoid arthritis (RA), elevated 
only in a minority of patients with AS.6-8 Thus, better objective measures for evaluating 
response to TNF-α blocking therapy in AS are needed. 
Recently, Woo et al. suggested the potential usefulness of matrix metalloproteinase-3  
(MMP-3; stromelysin-1) as a biomarker for monitoring response to TNF-α blocking therapy in 
AS.9 MMP are produced in response to proinflammatory cytokines such as TNF-α and 
interleukin 1 (IL-1)10,11 and play an important role in degradation of extracellular matrix 
components.12 Studies in AS have shown that serum levels of MMP-3 are related to clinical 
and laboratory measures of disease activity,9,13-16 and that baseline serum MMP-3 is an 
independent predictor of 2-year radiographic progression of the spine.17 Various studies have 
reported that TNF-α blocking therapy significantly reduces serum MMP-3 levels in patients 
with AS.9,15,16,18-20 To date, knowledge of the predictive value of serum MMP-3 levels for 
response to TNF-α blocking therapy is limited. Identification of objective predictors of 
response to TNF-α blocking therapy seems important, especially in view of the costs and 
potential side effects of these agents. 
The aim of our study was to investigate whether serum MMP-3 levels can serve as a biomarker 





MATERIALS AND METHODS  
Patients 
Ninety-two consecutive AS outpatients with active disease who started treatment with 
etanercept at the Medical Center Leeuwarden (n=59) or the University Medical Center 
Groningen (n=33) were included in this longitudinal observational study. All patients were age 
≥18 years, fulfilled the modified New York criteria for AS,21 and started etanercept treatment 
because of active disease according to the Assessments in Ankylosing Spondylitis (ASAS) 
consensus statement.22 Patients were excluded if they had previously received TNF-α blocking 
therapy. Etanercept was administered as subcutaneous injection once (50 mg) or twice  
(25 mg) a week. Patients were allowed to receive concomitant medication as usual in daily 
clinical practice. The study was approved by the local ethics committees of the Medical Center 
Leeuwarden and University Medical Center Groningen and all patients provided written 
informed consent according to the Declaration of Helsinki. 
 
Clinical assessments 
Clinical data were collected prospectively at baseline and after 3 months (mean 3.4 mo, SD ± 
0.7) and 12 months (mean 12.5 mo, SD ± 1.8) of etanercept treatment. Disease activity was 
assessed using BASDAI (scale of 0-10),23 physician and patient global assessment of disease 
activity (GDA; scale of 0-10), ESR, CRP, and the Ankylosing Spondylitis Disease Activity Score 
(ASDAS), a composite score calculated from BASDAI questions 2, 3 and 6, patient GDA, and 
CRP.24,25 Physical function was assessed using the Bath Ankylosing Spondylitis Functional Index 
(BASFI; on a scale of 0-10).26 
Continuation of etanercept treatment was based on decrease in BASDAI of at least 50% or  
2 units compared with baseline, and/or expert opinion in favor of continuation of treatment. 
Response to etanercept treatment was defined using ASAS20 and ASAS40 response criteria. 
ASAS20 response was defined as an improvement of at least 20% and absolute improvement 
of at least 1 unit (scale of 0-10) compared with baseline in 3 or more of the 4 domains physical 
function (BASFI), pain, patient GDA, and inflammation (mean from BASDAI questions 5 and 
6), with no worsening by more than 20% in the remaining domain. ASAS40 response was 
defined as an improvement of at least 40% and absolute improvement of at least 2 units 
compared with baseline in 3 or more of the 4 domains, with no worsening at all in the 
remaining domain.27  
 
Laboratory assessments 
Serum MMP-3 levels were measured retrospectively at baseline and after 3 months (mean 3.4 
mo, SD ± 0.7) and 12 months (mean 12.5 mo, SD ± 1.8) of etanercept treatment. Samples 
were stored at -20°C until analysis. Serum MMP-3 levels were measured by enzyme-linked 
immunosorbent assay (ELISA; Invitrogen, Breda, The Netherlands) according to the 
manufacturer’s instructions. The assay measures total human MMP-3 including pro-MMP-3, 
active MMP-3, and MMP-3 in complex with tissue inhibitor of metalloproteinase (TIMP). 
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Statistical analysis 
All data were analyzed on an intention-to-treat basis using SPSS 16.0 (SPSS Inc., Chicago, IL, 
USA) and Analyse-It version 2.20 (Analyse-It Software, Ltd., Leeds, UK). Results were 
expressed as mean ± SD or median (range) for normally distributed and non-normally 
distributed data, respectively. Independent samples t test and Mann-Whitney U test were 
used to compare differences between groups. Chi-Square test and Fisher Exact test were used 
to compare differences in percentages between groups. Paired samples t test and Wilcoxon 
signed-rank test were used to compare differences within groups. Spearman’s correlation 
coefficients were used to analyze the relationship between serum MMP-3 levels and clinical 
measures of disease activity and physical function. Receiver operating characteristic (ROC) 
analysis was performed to determine the accuracy of baseline or change in serum MMP-3 
levels to predict ASAS20 or ASAS40 response after 3 or 12 months of etanercept treatment. 
Area under the curve (AUC) <0.70 was interpreted as poor accuracy, 0.70< AUC <0.90 as 
moderate accuracy, and AUC >0.90 as high accuracy.28 A sample size of 29 responders and 29 
nonresponders achieved 80% power to detect an AUC of 0.70 at a significance level of 0.05.  
ROC analysis was performed to compare the accuracy (AUC) of change in serum MMP-3 
levels to predict ASAS20 response after etanercept treatment with that of change in BASDAI, 





Mean age of the 92 patients with AS was 41.2 years (SD ± 9.9), median disease duration was 
16 years (range 2-41), and 74% were male. At baseline, male patients showed significantly 
higher serum MMP-3 levels (p<0.001) and lower BASDAI and patient GDA scores (p<0.05) 
compared to female patients. Both groups were comparable for age, disease duration,  
HLA-B27 status, concomitant presence of extraarticular manifestations or peripheral arthritis, 
comedication, and baseline ESR, CRP, ASDAS, physician GDA, and BASFI scores (Table 1). 
Since baseline serum MMP-3 levels were significantly different between male and female AS 
patients, further data analysis was split for gender. 
 
 
Table 1. Baseline characteristics of the ankylosing spondylitis (AS) study population. Values are mean ± 
SD or median (range) unless otherwise indicated.  
Characteristic Total Male Female p* 
No. 92 68 24 - 
Age (yrs) 41.2 ± 9.9 42.5 ± 10.4 37.9 ± 7.5 0.053 
Duration of symptoms (yrs) 16 (2-41) 16 (2-41) 14 (3-36) 0.690 
Time since diagnosis (yrs) 9 (0-37) 9 (0-37) 9 (0-26) 0.685 
HLA-B27+ (%) 76 (85) 55 (83) 21 (91) 0.501 
History of IBD (%) 4 (4) 3 (4) 1 (4) 1.000 
History of uveitis (%) 29 (32) 22 (32) 7 (29) 0.773 
History of psoriasis (%) 4 (4) 4 (6) 0 (0) 0.570 
Peripheral arthritis (%) 21 (23) 15 (22) 6 (25) 0.782 
Concomitant NSAID use (%) 81 (88) 59 (87) 22 (92) 0.722 
Concomitant DMARD use (%) 20 (22) 14 (21) 6 (25) 0.652 
BASDAI (range 0-10) 6.2 ± 1.8 6.0 ± 1.7 6.8 ± 1.8 0.048 
ESR (mm/h) 21 (2-101) 19 (2-101) 27 (5-67) 0.294 
CRP (mg/l) 15 (2-99) 15 (2-99) 12 (2-55) 0.800 
ASDAS 3.8 ± 0.8 3.8 ± 0.9 4.1 ± 0.5 0.174 
Physician GDA (range 0-10) 6 (1-9) 6 (1-9) 7 (1-8) 0.516 
Patient GDA (range 0-10) 7 (1-10) 7 (1-10) 8 (2-10) 0.034 
BASFI (range 0-10) 5.9 ± 2.0 6.0 ± 2.0 5.7 ± 2.2 0.567 
MMP-3 (ng/ml) 10.8 (1.8-47.5) 13.6 (4.3-47.5) 5.9 (1.8-26.2) 0.000 
* Male compared to female patients.  
IBD: inflammatory bowel disease; NSAID: non-steroidal anti-inflammatory drug; DMARD: disease-
modifying antirheumatic drug; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ESR: 
erythrocyte sedimentation rate; CRP: C-reactive protein; ASDAS: Ankylosing Spondylitis Disease 
Activity Score; GDA: global disease activity; BASFI: Bath Ankylosing Spondylitis Functional Index;  
MMP-3: matrix metalloproteinase 3. 
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As shown in Table 2, all clinical assessments of disease activity and physical function 
significantly improved after 3 and 12 months of etanercept treatment in both male and female 
patients (p<0.01). Further, etanercept treatment resulted in a significant reduction in serum 
MMP-3 levels in male patients after 3 months (p<0.05). The percentage of patients that 
achieved ASAS20 response after 3 and 12 months of etanercept treatment was 79% and 66% 
for male patients, respectively, and 50% and 46% for female patients. The percentage of 
patients that reached ASAS40 response after 3 and 12 months of etanercept treatment was 
50% and 47% for male patients, and 42% and 42% for female patients. The percentage of 
patients that discontinued etanercept treatment after 3 and 12 months was 10% and 19% for 
male patients, and 25% and 33% for female patients. 
 
 
Table 2. Clinical and laboratory assessments at baseline and after 3 and 12 months of etanercept 
treatment. Values are mean ± SD or median (range).  
Assessment Baseline 3 Months p* 12 Months p** 
Males (n=68)      
BASDAI (range 0-10) 6.0 ± 1.7 3.0 ± 2.0 0.000 3.1 ± 2.3 0.000 
ESR (mm/h) 19 (2-101) 4 (2-51) 0.000 5 (2-50) 0.000 
CRP (mg/l) 15 (2-99) 3 (2-56) 0.000 3 (2-56) 0.000 
ASDAS 3.8 ± 0.9 1.9 ± 0.8 0.000 2.1 ± 1.1 0.000 
Physician GDA (range 0-10) 6 (1-9) 2 (0-5) 0.000 1 (0-8) 0.000 
Patient GDA (range 0-10) 7 (1-10) 3 (0-9) 0.000 2 (0-10) 0.000 
BASFI (range 0-10) 6.0 ± 2.0 3.8 ± 2.4 0.000 3.6 ± 2.6 0.000 
MMP-3 (ng/ml) 13.6 (4.3-47.5) 13.1 (5.0-35.7) 0.016 12.7 (3.3-37.6) 0.053 
Females (n=24)      
BASDAI (range 0-10) 6.8 ± 1.8 3.8 ± 1.9 0.000 3.6 ± 2.0 0.000 
ESR (mm/h) 27 (5-67) 15 (2-40) 0.000 17 (3-46) 0.012 
CRP (mg/l) 12 (2-55) 4 (2-24) 0.001 6 (2-196) 0.019 
ASDAS 4.1 ± 0.5 2.5 ± 1.0 0.000 2.6 ± 1.1 0.000 
Physician GDA (range 0-10) 7 (1-8) 2 (0-7) 0.000 1 (0-9) 0.001 
Patient GDA (range 0-10) 8 (2-10) 4 (0-10) 0.002 4 (1-9) 0.004 
BASFI (range 0-10) 5.7 ± 2.2 3.2 ± 2.1 0.000 3.1 ± 2.3 0.001 
MMP-3 (ng/ml) 5.9 (1.8-26.2) 5.6 (2.4-11.0) 0.983 7.2 (3.3-14.6) 0.191 
See Table 1 for definitions.  





Concomitant peripheral arthritis 
At baseline, peripheral arthritis (defined as at least one swollen joint) was observed in 15 (22%) 
male and 6 (25%) female patients, respectively. After 3 and 12 months of etanercept 
treatment, serum MMP-3 levels decreased significantly in male patients with concomitant 




Table 3. Clinical and laboratory assessments at baseline and after 3 and 12 months of etanercept 
treatment in male AS patients with concomitant peripheral arthritis and with axial disease only. Values 
are mean ± SD or median (range).  
Assessment Baseline 3 Months p* 12 Months p** 
Males with concomitant peripheral arthritis (n=15) 
BASDAI (range 0-10) 6.7 ± 1.5† 3.0 ± 2.0 0.000 2.5 ± 1.8 0.000 
ESR (mm/h) 26 (2-101) 4 (2-26) 0.001 5 (2-50) 0.001 
CRP (mg/l) 24 (4-99)† 3 (2-14) 0.001 3 (2-15) 0.001 
ASDAS 4.3 ± 0.8 1.8 ± 0.7 0.000 1.7 ± 0.7 0.000 
MMP-3 (ng/ml) 17.0 (4.3-47.5) 14.7 (7.2-35.7) 0.016 10.9 (3.3-21.3) 0.004 
Males with axial disease only (n=53) 
BASDAI (range 0-10) 5.8 ± 1.8 3.0 ± 2.0 0.000 3.3 ± 2.4 0.000 
ESR (mm/h) 15 (2-80) 5 (2-51) 0.000 6 (2-43) 0.000 
CRP (mg/l) 12 (2-69) 2 (2-56) 0.000 3 (2-56) 0.000 
ASDAS 3.6 ± 0.9 2.0 ± 0.8 0.000 2.2 ± 1.1 0.000 
MMP-3 (ng/ml) 13.2 (4.9-37.2) 12.3 (5.0-29.6) 0.218 12.7 (4.6-37.6) 0.818 
See Table 1 for definitions.  
† Statistically significant difference (p<0.05) compared to values of males with axial disease only.  
* Values at baseline compared to 3 months. ** Values at baseline compared to 12 months. 
 
 
Correlations between serum MMP-3 levels and clinical assessments 
At baseline, no statistically significant correlations were found between serum MMP-3 levels 
and clinical assessments of disease activity or physical function in male patients. In female 
patients, baseline serum MMP-3 levels correlated positively with baseline CRP and ASDAS 
scores (p<0.05). After 3 and 12 months of etanercept treatment, changes in serum MMP-3 
levels positively correlated with changes in BASDAI, ESR, CRP, ASDAS, physician GDA, and 
patient GDA scores in male patients (p<0.05). In female patients, there were significant 
positive correlations between changes in serum MMP-3 levels and changes in physician GDA 
scores after 3 months as well as changes in BASDAI, CRP, ASDAS, and BASFI scores after 12 
months (p<0.05) (Table 4). 
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Table 4. Spearman correlations between baseline or change in serum MMP-3 levels and clinical 
assessments after 3 and 12 months of etanercept treatment 



































































































































Δ0-3: baseline to 3 months change; Δ0-12: baseline to 12 months change; PhyGDA: physician global 
disease activity; PatGDA: patient global disease activity. See Table 1 for other definitions. 
 
 
Accuracy of baseline serum MMP-3 levels in predicting response 
Since the number of female patients was relatively small (n = 24), ROC analysis was performed 
only in male patients. The accuracy of baseline serum MMP-3 levels to predict response after 3 
and 12 months of etanercept treatment was poor, with an AUC of 0.685 (95% CI: 0.551-0.819) 
and 0.655 (95% CI: 0.515-0.796), respectively, for ASAS20 response; and 0.568 (95% CI: 0.425-
0.710) and 0.607 (95% CI: 0.468-0.747), respectively, for ASAS40 response.  
 
Accuracy of change in serum MMP-3 levels in predicting response 
The accuracy of change in serum MMP-3 levels from baseline to 3 months to predict ASAS20 
response after 3 and 12 months of etanercept treatment was moderate, with an AUC of 0.752 
(95% CI: 0.618-0.886) and 0.744 (95% CI: 0.607-0.882), respectively. The best cutoff value of 
change in serum MMP-3 levels from baseline to 3 months to discriminate between ASAS20 
responders and nonresponders had a sensitivity of 72% and specificity of 75% after 3 months, 
and of 73% and 72% after 12 months. When AUC values were compared, the AUC value of 
baseline to 3 months change in serum MMP-3 levels to predict ASAS20 response after 3 
months was significantly lower than that of baseline to 3 months change in BASDAI (p<0.001). 
Further, no significant differences were found between AUC values of baseline to 3 months 
change in serum MMP-3 levels to predict ASAS20 response after 3 or 12 months and those of 
baseline to 3 months change in ESR or CRP levels.  
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The accuracy of change in serum MMP-3 levels from baseline to 3 months to predict ASAS40 
response after 3 and 12 months of etanercept treatment was poor, with an AUC of 0.610 (95% 
CI: 0.458-0.762) and 0.670 (95% CI: 0.528-0.813), respectively (Table 5). 
 
 
Table 5. Receiver operating characterisic analysis of baseline to 3 months change in clinical and 
laboratory assessments predicting response after 3 and 12 months of etanercept treatment in male 
patients with AS (n = 68) 
 AUC (95% CI) p* Optimal cutoff Sensitivity, % Specificity, % 
ASAS20 response after 3 months 
Δ0-3 MMP-3 0.752 (0.618-0.886) - 0.0 72 75 
Δ0-3 ESR 0.708 (0.544-0.872) 0.556 6.5 77 64 
Δ0-3 CRP 0.609 (0.436-0.781) 0.120 6.5 69 57 
Δ0-3 BASDAI 0.953 (0.898-1.000) 0.000 1.9 90 86 
Δ0-3 ASDAS 0.864 (0.744-0.984) 0.107 1.3 89 79 
ASAS40 response after 3 months 
Δ0-3 MMP-3 0.610 (0.458-0.762) - 0.1 76 55 
Δ0-3 ESR 0.679 (0.546-0.811) 0.387 6.5 88 53 
Δ0-3 CRP 0.584 (0.442-0.726) 0.761 10.5 64 67 
Δ0-3 BASDAI 0.831 (0.731-0.932) 0.001 2.5 91 67 
Δ0-3 ASDAS 0.777 (0.663-0.891) 0.007 1.3 97 52 
ASAS20 response after 12 months 
Δ0-3 MMP-3 0.744 (0.607-0.882) - 0.2 73 72 
Δ0-3 ESR 0.779 (0.659-0.899) 0.662 6.5 88 70 
Δ0-3 CRP 0.616 (0.472-0.761) 0.161 9.5 63 74 
Δ0-3 BASDAI 0.816 (0.699-0.934) 0.395 2.6 81 83 
Δ0-3 ASDAS 0.810 (0.694-0.926) 0.356 1.3 91 61 
ASAS40 response after 12 months 
Δ0-3 MMP-3 0.670 (0.528-0.813) - 0.5 74 61 
Δ0-3 ESR 0.683 (0.552-0.814) 0.882 6.5 90 51 
Δ0-3 CRP 0.578 (0.437-0.719) 0.268 9.5 63 61 
Δ0-3 BASDAI 0.790 (0.680-0.900) 0.137 2.7 83 69 
Δ0-3 ASDAS 0.739 (0.618-0.860) 0.325 1.9 70 72 
* Compared to AUC of Δ0-3 MMP-3.  
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DISCUSSION 
This longitudinal observational study in daily clinical practice did not confirm the potential 
usefulness of serum MMP-3 levels as a biomarker for monitoring response to TNF-α-blocking 
therapy in AS, as suggested.9 At baseline, serum MMP-3 levels correlated positively with CRP 
and ASDAS scores in female patients with AS. However, no statistically significant correlations 
were found between baseline serum MMP-3 levels and clinical assessments of disease activity 
or physical function in male AS patients. Changes in serum MMP-3 levels after 3 or 12 months 
of etanercept treatment correlated positively with changes in clinical assessments of disease 
activity and physical function in both male and female patients. However, ROC analysis in male 
patients showed that baseline to 3 months change in serum MMP-3 levels had poor accuracy 
to discriminate between ASAS40 responders and nonresponders after 3 months of etanercept 
treatment. The accuracy of baseline to 3 months change in serum MMP-3 levels to predict 
ASAS20 response after 3 months was moderate, but not superior to the accuracy of change in 
the objective biomarkers ESR and CRP that are currently used. 
The second aim of our study was to investigate whether serum MMP-3 levels can predict 
response to etanercept treatment in AS. Our ROC analysis in male patients showed that 
baseline serum MMP-3 level had poor accuracy to discriminate between ASAS20 or ASAS40 
responders and nonresponders after 3 or 12 months of etanercept treatment in daily clinical 
practice. This finding is in accord with results from Romero-Sanchez et al., who also reported 
that serum MMP-3 levels did not predict ASAS20 or ASAS40 response at the same timepoint 
or at later timepoints.19 Further, in our study, the accuracy of change in serum MMP-3 levels 
from baseline to 3 months to predict ASAS20 or ASAS40 response after 12 months was 
moderate and poor, respectively, and not superior to the accuracy of change in ESR or CRP 
levels from baseline to 3 months.  
A possible explanation for our results may be that serum MMP-3 levels primarily reflect 
peripheral joint inflammation, which occurs in only a relatively small proportion of AS patients. 
In our study, baseline serum MMP-3 levels seemed somewhat higher in male patients with 
concomitant peripheral arthritis compared to male patients with only axial disease. In addition, 
etanercept treatment significantly decreased serum MMP-3 levels only in male patients with 
concomitant peripheral arthritis. Previous studies also reported differences in serum MMP-3 
levels between patients with and those without concomitant peripheral arthritis.13,15,29 
Moreover, serum MMP-3 levels were found to be markedly elevated in patients with RA, a 
disease characterized by chronic inflammation of the joints.30-32 Unfortunately, the number of 
AS patients with concomitant peripheral arthritis included in our study was too small to 
investigate the usefulness of serum MMP-3 levels as a biomarker for monitoring and 
predicting response to etanercept treatment in this particular group of AS patients.  
Since baseline serum MMP-3 levels were significantly higher in male compared to female AS 
patients, we decided to split further data analysis for gender. Our finding that male sex is 
associated with higher serum MMP-3 levels is in accord with other findings in AS33 and in 
healthy controls.30-32 In addition, Natoli et al. showed that the male sex steroid testosterone 
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increased both gene and protein expression of MMP-3.34 A drawback of splitting our analysis 
for gender was that analyses in female patients were limited by the relatively small number.  
Although significant changes in serum MMP-3 levels after etanercept treatment were found, 
especially in male AS patients with concomitant peripheral arthritis, further data analysis 
indicated that measuring serum MMP-3 levels was not very useful for monitoring and 
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Introduction: Identifying ankylosing spondylitis (AS) patients who are likely to benefit from 
tumor necrosis factor-alpha (TNF-α) blocking therapy is important, especially in view of the 
costs and potential side effects of these agents. Recently, the AS Disease Activity Score 
(ASDAS) has been developed to assess both subjective and objective aspects of AS disease 
activity. However, data about the predictive value of the ASDAS with respect to clinical 
response to TNF-α blocking therapy are lacking. The aim of the present study was to identify 
baseline predictors of response and discontinuation of TNF-α blocking therapy in AS patients 
in daily clinical practice.  
Methods: AS outpatients who started TNF-α blocking therapy were included in the 
Groningen Leeuwarden Ankylosing Spondylitis (GLAS) study, an ongoing prospective 
longitudinal observational cohort study with follow-up visits according to a fixed protocol. For 
the present analysis, patients were excluded if they had previously received anti-TNF-α 
treatment. Predictor analyses of response and treatment discontinuation were performed 
using logistic and Cox regression models, respectively. 
Results: Between November 2004 and April 2010, 220 patients started treatment with 
infliximab (n=32), etanercept (n=137), or adalimumab (n=51). At 3 and 6 months, 68% and 
63% of patients were Assessments in Ankylosing Spondylitis (ASAS)20 responders, 49% and 
46% ASAS40 responders, and 49% and 50% Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI)50 responders, respectively. Baseline predictors of response were younger age, male 
gender, higher ASDAS score, higher erythrocyte sedimentation rate (ESR) level, higher  
C-reactive protein (CRP) level, presence of peripheral arthritis, higher patient’s global 
assessment of disease activity, and lower modified Schober test. In August 2010, 64% of 
patients were still using their TNF-α blocking agent with a median follow-up of 33.1 months 
(range 2.4 to 68.2). Baseline predictors of discontinuation of TNF-α blocking therapy were 
female gender, absence of peripheral arthritis, higher BASDAI, lower ESR level, and lower CRP 
level. 
Conclusions: Besides younger age and male gender, objective variables such as higher 
inflammatory markers or ASDAS score were identified as independent baseline predictors of 
response and/or continuation of TNF-α blocking therapy. In contrast, higher baseline BASDAI 
score was independently associated with treatment discontinuation. Based on these results, it 
seems clinically relevant to include more objective variables in the evaluation of anti-TNF-α 
treatment.  
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INTRODUCTION 
Randomized controlled trials (RCTs) have demonstrated that the tumor necrosis factor alpha 
(TNF-α) blocking agents infliximab, etanercept, and adalimumab are effective in the treatment 
of Ankylosing Spondylitis (AS). However, a significant proportion of patients has to withdraw 
from TNF-α blocking therapy due to inefficacy or adverse events.1-3 Identifying patients who 
are likely to benefit from TNF-α blocking therapy is important, especially in view of the costs 
and potential side effects of these agents. 
Several studies using clinical data from RCTs have focused on the identification of predictors of 
response to anti-TNF-α treatment in AS.4-6 However, many patients who are treated with  
TNF-α blocking therapy in daily clinical practice would have been excluded in RCTs. Until now, 
three population based registries have investigated predictors of response and/or continuation 
of TNF-α blocking therapy. These registries showed that raised inflammatory markers, lower 
Bath Ankylosing Spondylitis Functional Index (BASFI), and younger age at baseline were 
associated with clinical response,7,8 whereas male gender, raised inflammatory markers, low 
visual analogue scale (VAS) fatigue, and presence of peripheral arthritis were baseline 
predictors of longer drug survival.7,9  
Disease activity in AS encompasses a wide range of concepts and is therefore difficult to 
measure. Recently, the Ankylosing Spondylitis Disease Activity Score (ASDAS) has been 
developed.10,11 This new index is a composite score of patient-reported measures and acute 
phase reactants developed in order to capture both subjective and objective aspects of AS 
disease activity. Currently, information about the predictive value of the ASDAS with respect 
to response to TNF-α blocking therapy or drug survival is lacking due to absence of ASDAS 
data in previous studies. The aim of the present study was to identify baseline predictors of 
response and discontinuation of TNF-α blocking therapy in AS patients in daily clinical practice. 
 
MATERIALS AND METHODS 
Patients 
Since 2004 AS outpatients with active disease, who started treatment with the TNF-α blocking 
agents infliximab, etanercept, or adalimumab at the Medical Center Leeuwarden (MCL) and 
the University Medical Center Groningen (UMCG), were included in the Groningen 
Leeuwarden Ankylosing Spondylitis (GLAS) study, an ongoing prospective longitudinal 
observational cohort study with follow-up visits according to a fixed protocol. All patients 
were over 18 years of age, fulfilled the modified New York criteria for AS or the  Assessments 
in Ankylosing Spondylitis (ASAS) criteria for axial spondyloarthritis including MRI,12 and 
started anti-TNF-α treatment because of active disease according to the ASAS consensus 
statement.13 For the present analysis, patients were excluded if they had previously received 
anti-TNF-α treatment. Infliximab (5mg/kg) was given intravenously at 0, 2, and 6 weeks and 
then every 8 weeks. In case of inadequate response, the frequency of infliximab treatment was 
raised to every 6 weeks. Etanercept was administered as a subcutaneous injection once  
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(50 mg) or twice (25 mg) a week. Adalimumab (40 mg) was administered as a subcutaneous 
injection on alternate weeks. In the first years of this study, patients were treated with either 
infliximab or etanercept since adalimumab was only registered in the Netherlands since 2006. 
The choice of the TNF-α blocking agent was based on the judgment of the treating 
rheumatologist (chiefly) and/or the specific preference of the patient. Patients were allowed to 
receive concomitant medication as usual in daily clinical practice. The study was approved by 
the local ethics committees of the UMCG and MCL and all patients provided written informed 
consent according to the Declaration of Helsinki to participate in this study. 
 
Clinical assessments 
Patients were evaluated at baseline, after 3 and 6 months of anti-TNF-α treatment, and then 
every 6 months. Disease activity was assessed using the Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI; on a scale of 0-10),14 physician’s and patient’s global assessment of 
disease activity (GDA; on a scale of 0-10), erythrocyte sedimentation rate (ESR), C-reactive 
protein (CRP), and ASDAS calculated from BASDAI questions 2, 3, and 6, patient’s GDA, and 
CRP.10,11 Physical function was assessed using BASFI (on a scale of 0-10).15 Spinal mobility 
assessments included chest expansion, modified Schober test, occiput to wall distance, and 
lateral lumbar flexion (left and right). Peripheral arthritis was defined as at least one swollen 
joint (excluding the hip) at baseline. 
 
Response 
At every visit, continuation of treatment was based on decrease in BASDAI, amounting at least 
50% (BASDAI50 response) or 2 units compared with baseline, and/or expert opinion in favor 
of treatment continuation. The ASAS20 and ASAS40 response criteria have been developed 
for defining treatment response in clinical trials. ASAS20 response was defined as an 
improvement of at least 20% and absolute improvement of at least 1 unit (on a scale of 0-10) 
compared with baseline in 3 or more of the 4 domains: physical function (BASFI), pain (VAS), 
patient’s GDA (VAS), and inflammation (mean from BASDAI questions 5 and 6), with no 
worsening by more than 20% in the remaining domain. ASAS40 response was defined as an 
improvement of at least 40% and an absolute improvement of at least 2 units compared with 
baseline in 3 or more of the 4 domains, with no worsening at all in the remaining domain.12,16  
In the present analysis, the ASAS20, ASAS40, and BASDAI50 response criteria were used to 
define treatment response. Patients who did not respond to TNF-α blocking therapy in the first 
3 months were classified as primary non-responders and patients who lost their initial clinical 
response as secondary non-responders. 
 
Antibody assessment 
Antibodies to TNF-α blocking agents were measured in patients who discontinued infliximab 
or adalimumab treatment due to inefficacy. Antibodies were detected by radioimmunoassay 
(RIA) as described in detail previously.17,18 The assay measures specific high-avidity IgG 
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antibodies to infliximab or adalimumab by an antigen-binding test. In short, serum (1 μl/test) 
was pre-incubated with Sepharose-immobilized protein A (1 mg/test; Pharmacia, Uppsala, 
Sweden) in Freeze buffer (Sanquin, Amsterdam, the Netherlands). Non-bound serum 
components were removed by washing before 50 μl 125I-radiolabeled F(ab)’2 fragment of 
infliximab or adalimumab was added. After overnight incubation, non-bound radiolabel was 
washed away and Sepharose-bound radioactivity was measured. Test results were converted 
into arbitrary units per milliliter (AU/ml) by comparison with dilutions of a reference serum. 
The reference value was set at 12 AU/ml, as derived from 100 healthy donors. 
 
Statistical analysis 
Statistical analysis was performed with SPSS 16.0 software (SPSS, Chicago, IL, USA). Results 
were expressed as mean ± SD or median (range) for normally and non-normally distributed 
data, respectively. The Independent Samples T test and Mann-Whitney U test were used to 
compare differences between groups. The Chi-Square test and Fisher Exact test were used to 
compare percentages between groups. Predictor analyses of ASAS20, ASAS40, and BASDAI50 
response (yes/no) were performed using binary logistic regression. Predictor analysis of time 
to discontinuation of TNF-α blocking therapy (yes/no) was performed using Cox regression. 
Multivariate analysis was performed with conditional stepwise forward inclusion of predictors 




Between November 2004 and April 2010, a total of 220 patients (MCL: n=163; UMCG: n=57) 
started treatment with a first TNF-α blocking agent; 32 receiving infliximab, 137 etanercept, 
and 51 adalimumab. Mean age of all patients was 42.9 years (SD ± 11.9), median disease 
duration was 15 years (range 1-53), and 69% were male. The three treatment groups were 
comparable for age, gender, HLA-B27 status, BASDAI, ASDAS, patient’s GDA, CRP, ESR, 
concomitant medication, and presence of peripheral arthritis at baseline. In the infliximab 
group, time since diagnosis was significantly longer, the percentage of patients with a history 
of inflammatory bowel disease (IBD) was significantly higher, and occiput to wall distance was 
significantly larger compared to the etanercept and adalimumab groups. In the adalimumab 
group, the percentage of patients with a history of uveitis and physician’s GDA were 
significantly lower and chest expansion was significantly higher compared to the infliximab 




Table 1. Baseline characteristics of the AS study population 
 Total IFX ETA ADA 
Number of patients 220 32 137 51 
Age (yrs) 42.9 ± 11.9 45.8 ± 10.1 41.9 ± 11.6 43.7 ± 13.3 
Gender (male) (n, %) 152 (69) 20 (63) 96 (70) 36 (71) 
Duration of symptoms (yrs) 15 (1-53) 21 (2-49) 15 (1-47) 11 (1-53) 
Time since diagnosis (yrs) 7 (0-45) 16 (0-35)* 7 (0-44) 6 (0-45) 
HLA-B27+ (n, %) 174 (81) 24 (75) 108 (82) 42 (82) 
History of IBD (n, %) 20 (9) 8 (26)† 7 (5) 4 (8) 
History of uveitis (n, %) 64 (29) 13 (40) 44 (32) 7 (14)‡ 
History of psoriasis (n, %) 13 (6) 3 (9) 8 (6) 13 (6) 
Peripheral arthritis (n, %) 37 (17) 5 (16) 27 (20) 5 (10) 
Current NSAID use (n, %) 158 (72) 24 (75) 102 (75) 32 (63) 
Current DMARD use (n, %) 45 (21) 10 (31) 28 (20) 7 (14) 
BASDAI (range 0-10) 6.1 ± 1.7 6.1 ± 1.4 6.2 ± 1.7 5.9 ± 1.7 
ASDAS 3.8 ± 0.8 3.8 ± 0.6 3.8 ± 0.8 3.7 ± 0.9 
Physician’s GDA (range 0-10) 5 (0-9) 5 (0-8) 5 (0-9) 3 (0-9)‡ 
Patient’s GDA (range 0-10) 7 (1-10) 6 (1-9) 7 (1-10) 6 (1-10) 
ESR (mm/h) 21 (2-101) 24 (2-90) 20 (2-101) 23 (2-74) 
CRP (mg/l) 13 (2-99) 15 (2-74) 12 (2-99) 14 (2-92) 
BASFI (range 0-10) 6.1 (0.3-9.7) 6.3 (1.9-9.6) 5.9 (0.3-9.7) 6.3 (0.4-9.5) 
Chest expansion (cm) 3.0 (0.5-43.0) 2.5 (0.5-7.0) 3.0 (0.5-22.0) 3.5 (0.0-43.0)§ 
Modified Schober test (cm) 2.9 (0.0-7.0) 2.4 (0.5-6.0) 2.8 (0.1-7.0) 3.2 (0.0-5.5) 
Occiput to wall distance (cm) 4.9 (0.0-34.5) 9.0 (0.0-26.0)^ 4.5 (0.0-34.5) 3.5 (0.0-30.0) 
Lateral lumbar flexion L (cm) 8.0 (0.0-30.0) 7.0 (2.0-15.0) 9.0 (0.0-30.0) 8.0 (1.0-20.5) 
Lateral lumbar flexion R (cm) 8.0 (0.0-29.0) 8.0 (0.5-17.0) 8.0 (0.0-29.0) 7.5 (1.0-20.0) 
Values are mean ± SD or median (range) unless otherwise indicated.  
AS: Ankylosing Spondylitis; IFX: infliximab; ETA: etanercept; ADA: adalimumab; HLA-B27+: human 
leukocyte antigen B27 positive; IBD: inflammatory bowel disease; NSAID: non-steroidal anti-
inflammatory drug; DMARD: disease-modifying antirheumatic drug; BASDAI: Bath Ankylosing 
Spondylitis Disease Activity Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; GDA: global 
disease activity; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; BASFI: Bath Ankylosing 
Spondylitis Functional Index; L: left; R: right.  
* p<0.05 compared to ETA group and p=0.052 compared to ADA group.  
† p<0.05 compared to ETA group and p=0.050 compared to ADA group.  
‡ p<0.05 compared to IFX and ETA groups.  
§ p<0.05 compared to ETA group.  
^ p<0.05 compared to ETA and ADA groups. 
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Table 2. Response and drug survival rate in AS patients treated with TNF-α blocking therapy 
 Total IFX ETA ADA 
Number of patients 220 32 137 51 
ASAS20 responders at 3 months 
(number of patients) 
68% 
(145 of 214) 
80% 
(24 of 30) 
66% 
(88 of 133) 
65% 
(33 of 51) 
ASAS20 responders at 6 months 
(number of patients) 
63% 
(132 of 209) 
71% 
(22 of 31) 
66% 
(86 of 131) 
51% 
(24 of 47) 
ASAS40 responders at 3 months 
(number of patients) 
49% 
(104 of 214) 
63% 
(19 of 30) 
47% 
(62 of 133) 
45% 
(23 of 51) 
ASAS40 responders at 6 months 
(number of patients) 
46% 
(97 of 209) 
52% 
(16 of 31) 
48% 
(63 of 131) 
38% 
(18 of 47) 
BASDAI50 responders at 3 months 
(number of patients) 
49% 
(105 of 214) 
60% 
(18 of 30) 
46% 
(61 of 133) 
51% 
(26 of 51) 
BASDAI50 responders at 6 months 
(number of patients) 
50% 
(104 of 209) 
48% 
(15 of 31) 
51% 
(67 of 131) 
47% 
(22 of 47) 
1-year drug survival 
(number of patients) 
71% 
(136 of 192) 
76% 
(22 of 29) 
72% 
(88 of 123) 
65% 
(26 of 40) 
2-year drug survival 
(number of patients) 
66% 
(97 of 148) 
70% 
(19 of 27) 
69% 
(66 of 96) 
48% 
(12 of 25) 
See Table 1 for definitions. 
No statistical differences were found between treatment groups (p≥0.05). 
 
ASAS20 response 
The percentage of ASAS20 responders to TNF-α blocking therapy was 68% and 63% at 3 and 6 
months, respectively. No significant differences were found in the percentage of ASAS20 
responders between the three TNF-α blocking agents at 3 or 6 months (p=0.297 and p=0.128, 
respectively) (Table 2). 
Results of univariate and multivariate logistic regression analysis for ASAS20 response at 3 and 
6 months of anti-TNF-α treatment are presented in Tables 3 and 4, respectively. Male gender 
(OR: 2.166) was identified as a significant baseline predictor of ASAS20 response in univariate 
logistic regression analysis. Therefore, variables that significantly differed between men and 
women at baseline were included in multivariate analysis: age, patient’s GDA, ESR, chest 
expansion, and occiput to wall distance. Multivariate logistic regression analysis showed that 
younger age (OR: 0.972), male gender (OR: 3.151), and higher ESR level (OR: 1.023) or 
alternatively, higher CRP level (OR: 1.024) or higher ASDAS score (OR: 1.728) were 
independent baseline predictors of ASAS20 response at 3 months of anti-TNF-α treatment 
(Table 3). 
At 6 months of anti-TNF-α treatment, younger age (OR: 0.960), male gender (OR: 2.991), and 
higher ASDAS score (OR: 1.573) or alternatively, presence of peripheral arthritis (OR: 2.518) 
and higher patient’s GDA (OR: 1.173), were independent baseline predictors of ASAS20 
response (Table 4). 
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Table 3. Baseline predictors of ASAS20 response at 3 months of anti-TNF-α treatment 
  Univariate analysis Multivariate analysis 
  OR (95% CI) p-value OR (95% CI) p-value 
Age (yr)†a  0.982 (0.959-1.006) 0.150 0.972 (0.947-0.998) 0.035 
Gender Female 1 -  - 
 Male 2.166 (1.185-3.958) 0.012 3.151 (1.580-6.285) 0.001 
Duration of symptoms (yr)†  1.001 (0.976-1.028) 0.914  *** 
HLA-B27 Neg. 1 -  - 
 Pos. 0.779 (0.363-1.675) 0.523  *** 
Peripheral arthritis Absent 1 -  - 
 Present 2.120 (0.876-5.129) 0.096  ** 
BASDAI (range 0-10)‡  0.946 (0.793-1.129) 0.538  *** 
ASDAS‡  1.458 (0.992-2.144) 0.055  * 
Physician’s GDA (range 0-10)‡  1.122 (0.983-1.282) 0.089  ** 
Patient’s GDA (range 0-10)‡a  1.029 (0.882-1.201) 0.714  ** 
ESR (mm/h)‡a  1.016 (1.000-1.032) 0.049 1.023 (1.005-1.041) 0.014 
CRP (mg/l)‡  1.021 (1.003-1.040) 0.025  * 
BASFI (range 0-10)‡  0.939 (0.816-1.081) 0.382  *** 
Chest expansion (cm)‡a  1.081 (0.948-1.233) 0.243  ** 
Modified Schober test (cm)‡  1.026 (0.861-1.224) 0.773  *** 
Occiput to wall distance (cm)‡a  0.981 (0.942-1.022) 0.364  ** 
Lateral lumbar flexion L (cm)‡  1.027 (0.965-1.092) 0.402  *** 
Lateral lumbar flexion R (cm)‡  1.029 (0.968-1.094) 0.352  *** 
TNF-α blocking agent ETA 1 -  - 
 IFX 2.045 (0.780-5.364) 0.146  ** 
 ADA 0.938 (0.476-1.846) 0.852  ** 
See Table 1 for definitions. 
OR refers to the risk of achieving ASAS20 response: † per year; ‡ per 1 grade or 1 point. 
a Significant difference (p<0.05) between men and women at baseline. 
* CRP and ASDAS were not selected during forward conditional logistic regression due to the strong correlation 
with ESR (ESR and CRP: ρ=0.669, p=0.000; ESR and ASDAS: ρ=0.412, p=0.000). Although, higher CRP level  
(OR: 1.024, 95% CI: 1.004-1.044) and higher ASDAS level (OR: 1.728, 95% CI: 1.126-2.652) were also significant 
predictors of ASAS20 response at 3 months in the presence of age and gender. 
** The variable was not selected during multivariate regression analysis (p≥0.05).  
*** The variable was not tested in multivariate regression analysis because of a p-value >0.3 in univariate 
regression analysis and no significant difference between men and women at baseline. 
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Table 4. Baseline predictors of ASAS20 response at 6 months of anti-TNF-α treatment 
  Univariate analysis Multivariate analysis 
  OR (95% CI) p-value OR (95% CI) p-value 
Age (yr)†a  0.977 (0.954-1.002) 0.069 0.960 (0.934-0.987) 0.004 
Gender Female 1 -  - 
 Male 1.995 (1.087-3.659) 0.026 2.991 (1.519-5.890) 0.002 
Duration of symptoms (yr)†  0.997 (0.972-1.023) 0.821  *** 
HLA-B27 Neg. 1 -  - 
 Pos. 1.086 (0.520-2.266) 0.827  *** 
Peripheral arthritis Absent 1 -  - 
 Present 2.218 (0.952-5.165) 0.065  * 
BASDAI (range 0-10)‡  1.031 (0.873-1.219) 0.717  *** 
ASDAS‡  1.356 (0.945-1.946) 0.099 1.573 (1.051-2.354) 0.028 
Physician’s GDA (range 0-10)‡  1.087 (0.955-1.239) 0.207  ** 
Patient’s GDA (range 0-10)‡a  1.124 (0.973-1.300) 0.113  * 
ESR (mm/h)‡a  1.005 (0.991-1.019) 0.499  ** 
CRP (mg/l)‡  1.009 (0.993-1.024) 0.281  ** 
BASFI (range 0-10)‡  0.989 (0.861-1.135) 0.872  *** 
Chest expansion (cm)‡a  1.108 (0.953-1.289) 0.183  ** 
Modified Schober test (cm)‡  0.900 (0.755-1.074) 0.243  ** 
Occiput to wall distance (cm)‡a  0.989 (0.950-1.030) 0.591  ** 
Lateral lumbar flexion L (cm)‡  0.985 (0.928-1.044) 0.606  *** 
Lateral lumbar flexion R (cm)‡  1.018 (0.960-1.079) 0.557  *** 
TNF-α blocking agent ETA 1 -  - 
 IFX 1.279 (0.544-3.008) 0.573  ** 
 ADA 0.546 (0.278-1.076) 0.079  ** 
See Table 1 for definitions. 
OR refers to the risk of achieving ASAS20 response: † per year; ‡ per 1 grade or 1 point. 
a Significant difference (p<0.05) between men and women at baseline. 
* Presence of peripheral arthritis and patient’s GDA were not selected during forward conditional logistic 
regression due to the significant difference in ASDAS score between patients with and without peripheral arthritis 
(mean 4.2 vs. 3.7, p=0.001) and the strong correlation between ASDAS and patient’s GDA (ρ=0.508, p=0.000).  
Although, presence of peripheral arthritis (OR: 2.518, 95% CI: 1.053-6.025) and higher patient’s GDA (OR: 1.173, 
95% CI: 1.003-1.372) were also significant predictors of ASAS20 response at 6 months in the presence of age and 
gender. 
** The variable was not selected during multivariate regression analysis (p≥0.05).  
*** The variable was not tested in multivariate regression analysis because of a p-value >0.3 in univariate 





The percentage of ASAS40 responders to TNF-α blocking therapy was 49% and 46% at 3 and 6 
months, respectively. No significant differences were found in the percentage of responders 
between the three TNF-α blocking agents at 3 or 6 months (p=0.216 and p=0.421, 
respectively) (Table 2). 
Multivariate logistic regression analysis showed that younger age (OR: 0.970, 95% CI: 0.946-
0.994) was the only independent baseline predictors of ASAS40 response at 3 months of  
anti-TNF-α treatment. 
At 6 months of anti-TNF-α treatment, younger age (OR: 0.961, 95% CI: 0.935-0.987), male 
gender (OR: 2.488, 95% CI: 1.235-5.014), and higher patient’s GDA (OR: 1.258, 95% CI: 1.067-
1.483) or alternatively, higher ASDAS score (OR: 1.721, 95% CI: 1.159-2.555) were 
independent baseline predictors of ASAS40 response. 
 
BASDAI50 response 
The percentage of BASDAI50 responders to TNF-α blocking therapy was 49% and 50% at 3 and 
6 months, respectively. No significant differences were found in the percentage of responders 
between the three TNF-α blocking agents at 3 or 6 months (p=0.358 and p=0.866, 
respectively) (Table 2). 
Multivariate logistic regression analysis showed that younger age (OR: 0.975, 95% CI: 0.951-
0.999), male gender (OR: 2.572, 95% CI: 1.346-4.913), and higher CRP level (OR: 1.025, 95% CI: 
1.008-1.042) or alternatively, higher ESR level (OR: 1.026, 95% CI: 1.009-1.042) were 
independent baseline predictors of BASDAI50 response at 3 months of anti-TNF-α treatment. 
At 6 months of anti-TNF-α treatment, younger age (OR: 0.957, 95% CI: 0.929-0.985), male 
gender (OR: 2.598, 95% CI: 1.302-5.186), presence of peripheral arthritis (OR: 4.991, 95% CI: 
2.054-12.124), and lower modified Schober test (OR: 0.751, 95% CI: 0.610-0.924) were 
independent baseline predictors of BASDAI50 response.  
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Treatment discontinuation 
In August 2010, 141 (64%) patients were still using their TNF-α blocking agent with a median 
follow-up of 33.1 months (range 2.4-68.2). The remaining 79 (36%) patients discontinued  
TNF-α blocking therapy after median treatment duration of 7.0 months (range 0.2-55.6). 
Reasons for discontinuation of TNF-α blocking therapy were inefficacy (n=40; 51%), adverse 
events (n=21, 27%: infection (n=8); allergic reaction (n=4); diarrhea or IBD (n=5);  
cardio-vascular disease (n=2); demyelization problems (n=1); bladder cancer (n=1)), both 
inefficacy and adverse events (n=8, 10%: recurrent infections (n=3); allergic reaction (n=1); 
diarrhea or IBD (n=2); uveitis (n=1); malaise (n=1)), or other reasons (n=10, 13%: good initial 
response, own choice (n=3); pregnancy wish (n=5); lost to follow up (n=2)).  
Antibodies to TNF-α blocking agents were measured in patients who discontinued infliximab 
(n=7) or adalimumab (n=14) treatment due to inefficacy. Antibody data were missing for one 
adalimumab patient. Antibodies against infliximab and adalimumab were detected in 5 of 7 
(71%) and in 8 of 13 (62%) patients who discontinued treatment due to inefficacy, respectively. 
In total, 5 of 13 (38%) patients with antibodies to TNF-α blocking agents were primary  
non-responders and 8 of 13 (62%) patients were secondary non-responders.  
The 1-year and 2-year TNF-α blocking therapy survival rates were 71% and 66%, respectively. 
No significant differences were found in 1-year or 2-year survival rates between the three  
TNF-α blocking agents (p=0.593 and p=0.127, respectively) (Table 2). 
Results of univariate and multivariate Cox regression analysis for discontinuation of anti-TNF-α 
treatment are presented in Table 5. Since female gender (HR: 0.503) and absence of peripheral 
arthritis (HR: 0.382) were significantly associated with treatment discontinuation in univariate 
Cox regression analysis, baseline variables that significantly differed between men and women 
(age, patient’s GDA, ESR, chest expansion, and occiput to wall distance) or between patients 
with and without peripheral arthritis (BASDAI, ASDAS, physician’s GDA, and CRP) were 
included in multivariate analysis. Multivariate Cox regression analysis showed that female 
gender (HR: 0.406), absence of peripheral arthritis (HR: 0.320), higher BASDAI score  
(HR: 1.225), and lower ESR level (HR: 0.983) or alternatively, lower CRP level (HR: 0.984) were 




Table 5. Baseline predictors of anti-TNF-α treatment discontinuation 
  Univariate analysis Multivariate analysis 
  HR (95% CI) p-value HR (95% CI) p-value 
Age (yr)†a  0.994 (0.975-1.014) 0.561  ** 
Gender Female 1 -  - 
 Male 0.503 (0.321-0.787) 0.003 0.406 (0.251-0.657) 0.000 
Duration of symptoms (yr)†  0.981 (0.959-1.002) 0.082  ** 
HLA-B27 Neg. 1 -  - 
 Pos. 0.823 (0.468-1.448) 0.500  *** 
Peripheral arthritis Absent 1 -  - 
 Present 0.382 (0.176-0.830) 0.015 0.320 (0.144-0.712) 0.005 
BASDAI (range 0-10)‡b  1.162 (1.016-1.329) 0.028 1.225 (1.053-1.424) 0.008 
ASDAS‡b  1.005 (0.759-1.330) 0.974  ** 
Physician’s GDA (range 0-10)‡b  0.907 (0.816-1.008) 0.070  ** 
Patient’s GDA (range 0-10)‡a  1.075 (0.958-1.208) 0.219  ** 
ESR (mm/h)‡a  0.987 (0.974-0.999) 0.039 0.983 (0.969-0.997) 0.018 
CRP (mg/l)‡b  0.986 (0.972-1.000) 0.049  * 
BASFI (range 0-10)‡  1.045 (0.935-1.168) 0.438  *** 
Chest expansion (cm)‡a  0.986 (0.903-1.076) 0.753  ** 
Modified Schober test (cm)‡  1.189 (1.036-1.365) 0.014  ** 
Occiput to wall distance (cm)‡a  0.971 (0.938-1.006) 0.971  ** 
Lateral lumbar flexion L (cm)‡  1.018 (0.973-1.066) 0.434  *** 
Lateral lumbar flexion R (cm)‡  1.016 (0.971-1.062) 0.498  *** 
TNF-α blocking agent ETA 1 -  - 
 IFX 0.847 (0.441-1.627) 0.618  *** 
 ADA 1.334 (0.769-2.314) 0.305  *** 
See Table 1 for definitions. 
HR refers to the risk of anti-TNF-α treatment discontinuation: † per year; ‡ per 1 grade or 1 point. 
a Significant difference (p<0.05) between men and women at baseline. 
b Significant difference (p<0.05) between patients with peripheral arthritis (defined as at least one swollen joint) 
and only axial disease at baseline. 
* CRP was not selected during forward conditional logistic regression due to the strong correlation with ESR 
(ρ=0.669, p=0.000) and the significant difference in CRP level between patients with and without peripheral 
arthritis (median 17 vs. 12, p=0.014). Although, lower CRP level (HR: 0.984, 95% CI: 0.969-0.999) was also a 
significant predictor of treatment discontinuation in the presence of gender and BASDAI. 
** The variable was not selected during multivariate regression analysis (p≥0.05).  
*** The variable was not tested in multivariate regression analysis because of a p-value >0.3 in univariate regression 
analysis and no significant difference between men and women at baseline. 
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DISCUSSION 
In this prospective longitudinal observational cohort study, ASAS20 and ASAS40 response was 
reached by 51% to 80% and 38% to 63% of AS patients at 3 to 6 months of anti-TNF-α 
treatment, respectively. These results from daily practice are in line with the findings in RCTs.1-3 
Although TNF-α blocking therapy is effective in the majority of AS patients, identifying patients 
who are likely to benefit from TNF-α blocking therapy is important, especially in view of the 
potential side effects and financial burden of these agents. Data from observational studies are 
necessary, since inclusion criteria of RCTs are very strict and therefore not completely 
comparable to the criteria for starting TNF-α blocking therapy in daily clinical practice. Our 
finding that younger AS patients respond significantly better to anti-TNF-α treatment is in line 
with previous studies using data from RCTs and population based registries.5-7 Previous studies 
in rheumatoid arthritis (RA) also found that females were less likely to achieve remission on 
anti-TNF-α treatment.19,20 Furthermore, female gender was significantly associated with 
discontinuation of TNF-α blocking therapy in registries of arthritic rheumatic diseases.21,22 and 
AS.7,9 Unfortunately, it is still unclear why male patients respond better to TNF-α blocking 
therapy. 
Multiple studies have shown the importance of raised inflammatory markers with regard to 
achieving clinical response 4-7 or treatment continuation.7 This study also confirms the 
predictive value of high ESR or CRP levels. Our finding that absence of peripheral arthritis is 
associated with treatment discontinuation is in accordance with Kristensen et al., who 
reported that patients with peripheral arthritis are more likely to continue TNF-α blocking 
therapy.9 In the present study, presence of peripheral arthritis was also independently related 
to ASAS20 and BASDAI50 response at 6 months in the presence of age and gender, indicating 
that concomitant peripheral arthritis is a predictor of both response and continuation of  
anti-TNF-α treatment. 
Recently, the ASDAS has been developed to assess a broader spectrum of disease activity.10,11 
A new and interesting finding is that higher ASDAS score was identified as a significant 
baseline predictor of ASAS20 and ASAS40 response to TNF-α blocking therapy in this study. 
Until now, in clinical practice, starting and continuation TNF-α blocking therapy is mainly based 
on BASDAI response, which is solely based on the opinion of the patient. In this study, more 
objective variables such as higher inflammatory markers and higher ASDAS score were 
identified as independent baseline predictors of response and/or continuation of anti-TNF-α 
treatment. In contrast, a higher baseline BASDAI score was independently associated with 
treatment discontinuation. Based on these results, it seems clinically relevant to include more 
objective variables in the evaluation of anti-TNF-α treatment. 
Our finding that the majority of AS patients discontinued TNF-α blocking therapy because of 
inefficacy is in accordance with Glintborg et al.,7 but other registries found an almost equal 
distribution between treatment withdrawal due to adverse events and inefficacy9,23 or even a 
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higher discontinuation rate because of adverse events.21,22 These differences may be explained 
by variation in the classification of reasons for stopping TNF-α blocking therapy. 
Since previous studies in AS patients treated with etanercept have reported that no antibodies 
against etanercept could be detected,24,25 antibodies were only measured in patients who 
discontinued infliximab and adalimumab due to inefficacy in this study. Antibody formation 
seems to be related to inefficacy of infliximab and adalimumab since these antibodies were 
detected in almost two third of patients (13 out of 20) who discontinued infliximab or 
adalimumab treatment due to inefficacy. This is in line with our previous findings in a smaller 
group of AS patients. In this study, patients with antibodies had significantly lower serum  
TNF-α blocker levels compared to patients without antibodies and significant negative 
correlations between serum levels of TNF-α blocking agents and assessments of disease 
activity were found.24 Based on these results, it seems useful to determine antibody formation 
to TNF-α blocking agents in non-responsive AS patients. 
In the present study, we did not find significant differences in the percentage of ASAS20, 
ASAS40, or BASDAI50 responders at 3 and 6 months or in 1-year and 2-year drug survival 
rates between the three TNF-α blocking agents. Furthermore, the type of anti-TNF-α treatment 
(infliximab, etanercept, or adalimumab) was not significantly associated with achieving 
response or discontinuation of treatment. However, these findings should be interpreted with 
caution since there were differences in disease duration, the percentage of patients with  
extra-articular manifestations, physician’s GDA, and spinal mobility measures at baseline and 
there was an uneven distribution of patients among the different treatment groups. 
 
CONCLUSIONS  
This prospective longitudinal observational cohort study identified higher ASDAS score, 
higher ESR or CRP level, presence of peripheral arthritis, younger age, male gender, lower 
modified Schober test, higher patient’s GDA, and lower BASDAI as independent baseline 
predictors of response and/or continuation of TNF-α blocking therapy in AS patients. These 
findings may help clinicians to identify AS patients who are more likely to benefit from TNF-α 
blocking therapy in daily clinical practice. 
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Purpose of review: Identifying the characteristics of patients with ankylosing spondylitis (AS) 
before start of treatment which are able to predict a beneficial response to tumor necrosis 
factor-alpha (TNF-α) blocking therapy is relevant, especially in view of the high costs and 
potential side effects of these agents. This review provides an overview of clinical trials and 
observational studies investigating baseline predictors of response after 3-6 months of TNF-α 
blocking therapy and baseline predictors of long-term anti-TNF-α treatment continuation in 
AS. 
Recent findings: In multiple studies, increased acute phase reactants, higher disease activity, 
higher functional status, younger age, and HLA-B27 positivity were identified as independent 
baseline predictors of achieving clinical response to TNF-α blocking therapy. Increased acute 
phase reactants, presence of peripheral arthritis, and male sex were repeatedly identified as 
independent baseline predictors of anti-TNF-α treatment continuation.  
Summary: Several studies using multivariate analyses identified comparable baseline 
predictors of response and/or continuation of TNF-α blocking therapy. The single predictors 
identified have, at best, moderate capacity to predict treatment response in the individual 
patient. The development of a prediction model may lead to a more robust instrument to 
support physicians in decision-making on TNF-α blocking therapy in AS in daily clinical 
practice. 
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INTRODUCTION 
Randomized controlled trials (RCTs) have demonstrated that tumor necrosis factor-alpha 
(TNF-α) blocking agents are effective in controlling inflammation and improving clinical 
assessments in ankylosing spondylitis (AS).1-4 According to the recently published 2010 update 
of the Assessment in SpondyloArthritis international Society (ASAS) recommendations, 
patients who start TNF-α blocking therapy should fulfill the modified New York criteria for 
definitive AS or the ASAS criteria for axial spondyloarthritis (SpA), have active disease [Bath 
AS Disease Activity Index (BASDAI) ≥4 and a positive expert opinion] for at least 4 weeks, and 
have tried at least two nonsteroidal anti-inflammatory drugs (NSAIDs) for a minimum of 4 
weeks in total.5 It is relevant to identify patient characteristics before start of treatment which 
are able to predict a beneficial response to TNF-α blocking therapy, especially considering the 
economic burden and potential side effects of these agents. The purpose of this review is to 
provide an overview of the RCTs and observational studies that investigated baseline 
predictors of achieving response after 3-6 months of TNF-α blocking therapy and baseline 
predictors of long-term anti-TNF-α treatment continuation in AS. 
 
Ankylosing spondylitis 
AS is a chronic inflammatory rheumatic disease that primarily affects the axial skeleton. The 
disease is characterized by new bone formation, which can lead to the formation of 
syndesmophytes, ankylosis of the spine and sacroiliac joints, and bony formations on enthesal 
sites.6,7 In addition to bone formation, AS is also characterized by bone loss. Osteoporosis of 
the spine can already be observed at early stages of the disease. Vertebral bone loss can be 
associated with severe complications, particularly vertebral fractures and increased spinal 
deformity.8-10 Other frequently occurring symptoms in patients with AS are peripheral arthritis, 
enthesitis, and extra-articular manifestations such as acute anterior uveitis, psoriasis, and 
inflammatory bowel disease.11  
AS has an estimated prevalence of 0.3-0.5% (mid-Europe), starts usually in the third decade of 
life, and manifests more often in males than in females (ratio 2:1). The cause of AS is suggested 
to be multifactorial, including both endogenous factors, such as genetic factors, in particular 
expression of the major histocompatibility complex (MHC) class I  antigen HLA-B27, and 
exogenous factors, such as bacterial antigens.11 
 
Treatment of ankylosing spondylitis 
The standard treatment for axial symptoms of patients with AS consists of NSAIDs and 
physical therapy. The use of classic disease-modifying antirheumatic drugs (DMARDs), such as 
sulfasalazine or methotrexate, can be considered in case of peripheral arthritis. There is no 
evidence that DMARDs are effective for the axial manifestations in AS. Treatment with TNF-α 
blocking agents is available for AS patients with persistently active disease (BASDAI ≥4 and 
expert opinion), who do not respond to conventional treatment.12 The ASAS working group 
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made recommendations for decision-making on TNF-α blocking therapy in AS in daily clinical 
practice.5  
Currently, there are four TNF-α blocking agents approved for AS: infliximab, a monoclonal 
chimeric antibody which is given intravenously at a dose of 5 mg/kg every 6-8 weeks;1 
etanercept, a human TNF receptor fusion protein which is administered as subcutaneous 
injection at a dose of 50 mg once a week or 25 mg twice a week;2 adalimumab, a humanized 
monoclonal antibody which is administered as subcutaneous injection at a dose of 40 mg on 
alternate weeks;3 and golimumab, a fully human monoclonal antibody which is administered as 
subcutaneous injection at a dose of 50 mg once a month.4  
 
Efficacy of TNF-α blocking therapy 
TNF-α blocking therapy has been shown to significantly improve clinical outcome and disease-
related quality of life in AS. Continuation of treatment is based on a decrease in BASDAI, 
amounting to at least 50% (BASDAI50 response) or two units compared with baseline, and 
expert opinion in favor of treatment continuation.5 RCTs have demonstrated that BASDAI50 
response is achieved by 45-60% of AS patients after 3-6 months of TNF-α blocking therapy.13-15  
The ASAS20 and ASAS40 response criteria have been developed for defining treatment 
response in RCTs. ASAS20 response is defined as an improvement of at least 20% and absolute 
improvement of at least 1 unit (on a scale of 0 to 10) compared with baseline in three or more 
of the following four domains, physical function, back pain, patient’s global assessment of 
disease activity (GDA), and inflammation, with no worsening of more than 20% and more than 
1 unit in the remaining domain. ASAS40 response is defined as an improvement of at least 
40% and at least 2 units compared with baseline in three or more of the four domains, with no 
worsening at all in the remaining domain.16,17 RCTs have demonstrated that ASAS20 and 
ASAS40 response are achieved by 55-65% and 40-50% of AS patients after 3-6 months of  
TNF-α blocking therapy, respectively.13,14,18,19  
Data from observational studies are of additional value, as inclusion criteria of RCTs are very 
strict and, therefore, not completely comparable to criteria for starting anti-TNF-α treatment in 
daily clinical practice. Cohort studies and national registries have reported BASDAI50, ASAS20, 
and ASAS40 response rates of 50-70%, 60-70%, and 45-50% after 3-6 months of TNF-α 
blocking therapy, respectively.20,21*-23*,24** 
Although the majority of AS patients respond very well to TNF-a blocking therapy, a significant 
proportion of patients have to withdraw from treatment due to inefficacy or adverse events. In 
clinical practice, the reported one-year and two-year treatment survival rates are 70-85% and 
60-75%, respectively.22*,24**,25,26* The high costs involved27 and the potential side effects28 
indicate that there is a clear need to identify characteristics of AS patients which are able to 
predict treatment response and/or continuation of TNF-a blocking therapy. 
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BASELINE PREDICTORS OF RESPONSE TO TNF-α BLOCKING THERAPY 
Especially in the last 2 years, several studies using data from RCTs, cohort studies, or 
population-based registries have investigated whether patient characteristics before start of 
treatment can predict a beneficial response to TNF-α blocking therapy in AS.  
 
Independent predictors 
Large sample sizes and multivariate analyses are required to determine to what degree a 
parameter contributes independently to the prediction of clinical response after 3-6 months 
and to the prediction of long-term treatment continuation. An overview of the results from all 
trials, cohort studies, and registries using multivariate analyses is given in Table 1. The clinical 
assessments and response criteria used in these studies are described in Table 2. 
The presence of inflammation at baseline was found to be an important independent predictor 
of achieving response to TNF-α blocking therapy in almost all studies. Increased levels of  
C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) were predictive for 
BASDAI50, ASAS20, ASAS40, ASAS partial remission, and AS Disease Activity Score (ASDAS) 
major improvement,15,20,22*,23*,24**,29,31**,33,35,36 as well as for continuation of TNF-α blocking 
therapy.22*,24**,25,34 The presence of peripheral arthritis was also identified as a predictor of both 
response (BASDAI50 and ASAS20) and treatment continuation.22*,26* Higher Berlin MRI spine 
score (reflecting the extent of bone marrow edema) was shown to be predictive for BASDAI50 
response.35 These results clearly indicate that AS patients with active inflammatory disease are 
more likely to benefit from TNF-α blocking therapy than patients with chronic, less 
inflammatory disease. Kristensen et al. suggested that the predictive value of peripheral 
arthritis for achieving response and treatment continuation may be related to the fact that it is 
clinically easier to distinguish active inflammation from irreversible damage in the peripheral 
joints than in the spine.26* 
Recently, the ASDAS, a composite score of patient-reported measures and acute phase 
reactants, has been developed to capture both subjective and objective aspects of AS disease 
activity.37,38 Interestingly, the ASDAS was found to be an independent predictor of ASAS20 
and ASAS40 response.22* Furthermore, clinical responders had significantly higher ASDAS 
scores at baseline than non-responders.21* The results for the completely subjective measures 
of disease activity were somewhat less clear. Identified predictors of response were higher 
patient’s GDA (ASAS20 and ASAS40),22*,29,33 higher BASDAI (BASDAI50 and ASAS20),15,23*,29 
higher score for back pain (ASAS20),29 and higher score for morning stiffness (ASAS40).33 On 
the other hand, lower score for back pain and lower physician’s GDA were found to be 
predictive for BASDAI50 and ASAS40 response, respectively.33 Lower BASDAI22* and low 
visual analogue scale (VAS) fatigue24** were related to continuation of TNF-α blocking therapy. 
These discrepancies may partly be explained by the fact that some predictors are components 
of the BASDAI or ASAS response criteria and are therefore not independent variables.29 
Furthermore, a subjectively generated score, such as BASDAI, is not able to differentiate 
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between back pain caused by inflammation or structural damage (ankylosis or joint 
destruction), or myalgia.26*,30  
Multiple studies have identified higher functional status as an independent baseline predictor 
of clinical response to anti-TNF-α treatment. Lower Bath AS Functional Index (BASFI) score 
(indicating better physical function) was found to be related to BASDAI50, ASAS20, ASAS40, 
and ASAS partial remission.15,23*,24**,29,31**,33 In addition, lower Bath AS Metrology Index 
(BASMI)33 and lower modified Schober test22* (reflecting mobility of the spine) were 
predictive for ASAS partial remission and BASDAI50 response, respectively. Younger age was 
identified as a predictor of BASDAI50, ASAS20, ASAS40, and ASAS partial 
remission,22*,24**,31**,33 and shorter disease duration was related to BASDAI50 and ASAS40 
response.15 The fact that younger AS patients with shorter disease duration and higher 
functional status respond better to TNF-α blocking therapy indicates that less structural 
damage has occurred and more acute inflammation is present in these patients.15 
Male sex was found to be predictive for both response (BASDAI50 ASAS20, and ASAS40)22* 
and treatment continuation.22*,24**,25,26* It is still unclear why male AS patients respond better to 
TNF-α blocking therapy. Female patients were found to have lower CRP or ESR levels and 
higher subjective scores of disease activity compared to male patients.22*,26* It may be 
hypothesized that female patients score higher on subjective measures of disease activity 
because of different musculoskeletal performance or a general tendency towards reporting 
poorer scores in questionnaires.24** Furthermore, the lower objective and higher subjective 
disease activity scores may indicate a higher level of comorbidity with chronic pain syndromes 
such as fibromyalgia in female patients, which may affect subjectively perceived treatment 
efficacy.26* 
Two studies that included a very large number of patients in their analyses identified HLA-B27 
positivity as a predictor of BASDAI50, ASAS40, and ASAS partial remission.31**,33 It is unclear 
whether this predictive value can be explained by the fact that HLA-B27 positivity results in 
earlier diagnosis or that the disease biology differs between HLA-B27 positive and negative 
patients.31** 
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Table 1. Overview of studies investigating baseline predictors of response and treatment continuation in AS 
using multivariate analyses 
Authors Sample size 
predictor 
analysis 
Study design Identified predictors before start of treatment 
that are independently associated with achieving 
clinical response or continuation of TNF-α 
blocking therapy 






ASAS20 (over time, 6m): higher CRP, lower 
BASFI, higher score for back pain / patient’s GDA / 
BASDAI / inflammation (BASDAI Q5-Q6) 







BASDAI50 (3m): shorter disease duration, lower 
BASFI, higher CRP, higher BASDAI 
ASAS40 (3m): shorter disease duration, lower 
BASFI, higher CRP 








BASDAI50 (3m): higher Berlin MRI spine score 








BASDAI50 and ASAS partial remission (6m): 
young age, low BASFI, absence of enthesitis, high 
CRP, HLA-B27 positivity, anti-TNF-α treatment 







BASDAI50 (3m): lower leptin levels, higher 
immunoglobulin M, higher VEGF 
ASAS20 (3m): lower PINP, lower insulin levels 




Open-label trial BASDAI50 (3m): younger age, higher CRP, HLA-
B27 positivity, TNF antagonist naivety, lower 
BASFI, lower score for total back pain 
ASAS40 (3m): younger age, higher CRP, HLA-B27 
positivity, TNF antagonist naivety, higher score for 
morning stiffness, lower physician’s GDA, higher 
patient’s GDA, use of glucocorticoids 
ASAS partial remission (3m): younger age, higher 
CRP, HLA-B27 positivity, TNF antagonist naivety, 
lower BASFI, lower BASMI  
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Table 1. (Continued) 
Authors Sample size 
predictor 
analysis 
Study design Identified predictors before start of treatment 
that are independently associated with achieving 
clinical response or continuation of TNF-α 
blocking therapy 









BASDAI50 (3m): younger age, male gender, 
higher CRP / ESR 
BASDAI50 (6m): younger age, male gender, 
presence of peripheral arthritis, lower modified 
Schober test  
ASAS20 (3m): younger age, male gender, higher 
ESR / CRP /  ASDAS 
ASAS20 (6m): younger age, male gender, higher 
ASDAS / patient’s GDA / presence of peripheral 
arthritis 
ASAS40 (3m): younger age 
ASAS40 (6m): younger age, male gender, higher 
patient’s GDA / ASDAS 
Treatment continuation (up to 5.7y follow-up): 
male gender, presence of peripheral arthritis, 
lower BASDAI, higher ESR / CRP 









Treatment continuation (2y follow-up): male 
gender, presence of peripheral arthritis 








BASDAI50 (6m): high CRP, lower BASFI, younger 
age 
Treatment continuation (up to 8y follow-up): 
male gender, low VAS fatigue, high CRP 








BASDAI50 (6m): higher BASDAI, lower BASFI, 
raised inflammatory markers, concomitant 
DMARD treatment 








Treatment continuation (2y follow-up): increased 
CRP 
AS: ankylosing spondylitis; ASAS: assessment in spondyloarthritis international society; ASDAS: ankylosing 
spondylitis disease activity index; BASDAI: Bath ankylosing spondylitis disease activity index; BASFI: Bath 
ankylosing spondylitis functional index; BASMI: Bath ankylosing spondylitis metrology index; CRP: C-reactive 
protein; ESR: erythrocyte sedimentation rate; GDA: global assessment of disease activity; HLA: human 
leukocyte antigen; m: months; PINP: procollagen type I N-terminal peptide; TNF: tumor necrosis factor; VAS: 
visual analogue scale; VEGF: vascular endothelial growth factor; y: years 
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Table 2. Explanation of clinical assessments and response criteria 
Assessment Abbreviation Description 
Disease activity 
BASDAI Bath ankylosing spondylitis 
disease activity index 
Combined assessment of fatigue, spinal pain, 
peripheral arthritis, enthesitis, and morning stiffness 
(mean from intensity and duration) during last week 
ASDAS Ankylosing spondylitis disease 
activity score 
Calculated from BASDAI questions on spinal pain 
(Q2), peripheral arthritis (Q3) and duration of 
morning stiffness (Q6), patient’s GDA, and CRP 
(preferred) or ESR 
Patient’s GDA Patient’s global assessment of 
disease activity 
Global disease activity during last week as assessed by 
the patient 
Physician’s GDA Physician’s global assessment of 
disease activity 
Global disease activity during last week  as assessed 
by the physician 
Berlin MRI spine 
score 
Berlin magnetic resonance 
imaging spine score 
Extent of bone marrow edema (grade 0-3) for 23 
vertebral units from C2/C3 to L5/S1 
Physical function 
BASFI Bath ankylosing spondylitis 
functional index 
Includes 8 questions relating to the patient’s function 
and 2 questions relating to the patient’s ability to 
cope with everyday life 
Spinal mobility 
BASMI Bath ankylosing spondylitis 
metrology index 
Combination assessment of tragus to wall distance, 
lumbar flexion (modified Schober test), cervical 
rotation, lateral lumbar flexion, and maximal 
intermalleolar distance 
Response criteria 
BASDAI50 Bath ankylosing spondylitis 
disease activity index 50% 
improvement 
≥50% improvement in BASDAI 
ASAS20 Assessments in ankylosing 
spondylitis 20% improvement 
≥20% improvement and ≥1 unit absolute 
improvement (range 0-10) in 3 of the following 4 
domains, physical function (BASFI), back pain, 
patient’s GDA, and inflammation (mean BASDAI Q5-
6), with no worsening of ≥20% and ≥1 unit in the 
remaining domain 
ASAS40 Assessments in ankylosing 
spondylitis 40% improvement 
≥40% improvement and ≥2 units absolute 
improvement (range 0-10) in 3 of the following 4 
domains, physical function (BASFI), back pain, 
patient’s GDA, and inflammation (mean BASDAI Q5-
6), with no worsening at all in the remaining domain 
ASAS partial 
remission 
Assessments in ankylosing 
spondylitis partial remission 
A value ≤2 in each of the following 4 domains (range 
0-10), physical function (BASFI), back pain, patient’s 
GDA, and inflammation (BASDAI Q5-6) 
ASDAS major 
improvement 
Ankylosing spondylitis disease 
activity score major 
improvement 




Biomarkers as potential predictors  
Several studies reported promising data regarding the potential value of biomarkers, for 
example markers of inflammation or bone and cartilage metabolism, as baseline predictors of 
response to TNF-α blocking therapy. Romero-Sanchez et al.39 tested 22 cytokines and found 
that only serum levels of IL-1α before start of treatment were able to distinguish ASAS40 
responders from non-responders. However, in receiver operating characteristics analysis, the 
accuracy to predict treatment response was moderate (area under the curve: 0.71) and the 
best cutoff value had a sensitivity of 84.9% and a specificity of 53.8%.  
De Vries et al.20 reported that elevated baseline levels of serum amyloid A (SAA), an acute 
phase reactant, were related to BASDAI50 response in univariate analysis. In addition, they 
showed that the combination of elevated CRP and SAA levels was the strongest predictor of 
BASDAI50 response. 
Woo et al.40 suggested the potential usefulness of matrix metalloproteinase-3 (MMP-3), an 
enzyme involved in degradation of extracellular matrix components, as a biomarker to 
monitor response to TNF-α blocking therapy. A recent study found that axial SpA patients with 
major improvement in ASDAS after anti-TNF-α treatment had significantly higher baseline 
MMP-3 levels compared to patients without major improvement.35 However, two other 
studies showed that serum MMP-3 levels at baseline could not predict ASAS20 or ASAS40 
response after TNF-α blocking therapy.39,41  
Pedersen et al.35 found that baseline levels of vascular endothelial growth factor (VEGF), a 
biomarker of angiogenesis, were higher and that baseline levels of the cartilage glycoprotein 
YKL-40, a biomarker of chronic inflammation, were lower in patients achieving BASDAI 
response and ASDAS major improvement. Furthermore, ASDAS responders had higher 
baseline levels of interleukin 6 (IL-6) and C-terminal crosslinking telopeptide of type II collagen 
(CTX-II), a biomarker of cartilage degradation. The results regarding IL-6 are in line with 
Visvanathan et al.,36 who reported that a greater percentage of AS patients with elevated IL-6 
before start of treatment achieved BASDAI50 and ASAS20 responses compared to those with 
low IL-6.  
Finally, Wagner et al.32* tested 92 serum proteins and identified lower baseline levels of leptin, 
a hormone that plays a central role in fat metabolism, and higher baseline levels of 
immunoglobulin M and VEGF as the strongest predictors of BASDAI50 response after TNF-α 
blocking therapy. Furthermore, they showed that lower baseline levels of insulin, a hormone 
regulating carbohydrate and fat metabolism, and procollagen type 1 N-terminal peptide 
(PINP), a marker of bone formation, were most predictive for ASAS20 response.  
Until now, the results of these studies are either not confirmed by other study groups or 
confirmed in studies that used less robust techniques of data analysis. Further studies using 
multivariate analyses are needed to confirm the predictive value of these biomarkers,  
in addition to the currently known predictors. 
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FUTURE PERSPECTIVES 
Several studies tested a large group of serum proteins instead of following a hypothesis-driven 
approach.32*,39 These analyses can contribute to the identification of potentially valuable 
predictors. The pathogenetic relevance of such predictive proteins still has to be proven. 
For evaluating TNF-α blocking therapy, not only the response regarding disease activity is 
important, but also the effect on disease-related quality of life and radiographic outcome. 
Therefore, it may also be interesting to use these parameters as endpoints in studies 
investigating whether patient characteristics before start of treatment are able to predict a 
beneficial effect of TNF-α blocking therapy. A drawback of using radiographic progression as 
an endpoint is the need for long-term observation in order to be able to see any effect of  
TNF-α blocking therapy.  
The currently identified single predictors have, at best, moderate capacity to predict treatment 
response in the individual patient and, therefore, they should not be mandatory for allowing 
AS patients to be treated with TNF-α blocking agents. Recently, Vastesaeger et al.31** took the 
first step to create a model that provides a potential basis for patient selection for TNF-α 
blocking therapy. The development of such a prediction model may lead to a more robust 
instrument to support physicians to make evidence-based decisions to start anti-TNF-α 
treatment in daily clinical practice. 
 
CONCLUSION 
Although TNF-α blocking therapy is effective in the majority of patients with AS, identifying 
patients who are most likely to benefit from TNF-α blocking therapy is important, especially 
considering the high costs and potential side effects of these agents. Currently, 
recommendations for starting TNF-α blocking therapy in AS are primarily based on inadequate 
response to conventional treatment and less on the expectation that anti-TNF-α treatment will 
be effective in a particular patient. Multiple studies using data from clinical trials and 
observational studies in AS have identified increased acute phase reactants, presence of 
peripheral arthritis, higher disease activity, higher functional status, younger age, male sex, and 
HLA-B27 positivity as independent baseline predictors for achieving clinical response after 3-6 
months and/or for long-term continuation of TNF-α blocking therapy in multivariate analyses 
(Figure 1). Currently, the predictive value of single parameters is not strong enough to predict 
treatment response in the individual AS patient. The development of a prediction model may 
lead to a better predictive instrument to support physicians when deciding on TNF-α blocker 






Figure 1. Repeatedly identified as independent baseline predictors for achieving clinical response after 3 




 Identifying AS patients who are most likely to benefit from TNF-α blocking therapy is 
relevant, especially in view of the high costs and potential side effects of these agents. 
 Increased acute phase reactants, presence of peripheral arthritis, higher disease activity, 
higher functional status, younger age, male sex, and HLA-B27 positivity are identified as 
independent predictors for achieving clinical response and/or for continuation of TNF-α 
blocking therapy in multivariate analyses. 
 The predictive value of single parameters is not strong enough to predict treatment 
response in the individual patient, but the development of a prediction model may 
support physicians in decision-making on TNF-α blocking therapy in AS in daily clinical 
practice. 
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Objective: To investigate the influence of antibody formation to TNF-α blocking agents on 
the clinical response in AS patients treated with infliximab (IFX), etanercept (ETA), or 
adalimumab (ADA), and to investigate the development of ANA, ANCA, and anti-dsDNA 
antibodies in association with the formation of antibodies to TNF-α blocking agents. 
Methods: Consecutive AS outpatients with active disease who started treatment with IFX 
(n=20), ETA (n=20), or ADA (n=20) were included in this longitudinal observational study. 
Clinical data were collected prospectively at baseline and after 3, 6, and 12 months of  
anti-TNF-α treatment. At the same time points, serum samples were collected. In these 
samples, antibodies to TNF-α blocking agents, serum TNF-α blocker levels, and ANA, ANCA, 
and anti-dsDNA antibodies were measured retrospectively. 
Results: Anti-IFX, anti-ETA, and anti-ADA antibodies were induced in 20%, 0%, and 30% of 
patients, respectively. Although ANA, ANCA, and anti-dsDNA antibodies were detected 
during anti-TNF-α treatment, no significant association was found between the presence of 
these autoantibodies and the formation of antibodies to TNF-α blocking agents. Patients with 
anti-IFX or anti-ADA antibodies had significantly lower serum TNF-α blocker levels compared 
to patients without these antibodies. Furthermore, significant negative correlations were 
found between serum TNF-α blocker levels and assessments of disease activity. 
Conclusion: This study indicates that antibody formation to IFX or ADA is related to a 
decrease in efficacy and early discontinuation of anti-TNF-α treatment in AS patients. 
Furthermore, autoantibody formation seems not to be associated with antibody formation to 
TNF-α blocking agents. 
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INTRODUCTION 
Ankylosing Spondylitis (AS) is a chronic inflammatory rheumatic disease that primarily affects 
the axial skeleton. Peripheral joints and extra-articular structures may also be involved. The 
availability of the tumor necrosis factor alpha (TNF-α) blocking agents infliximab (IFX), 
etanercept (ETA), and adalimumab (ADA) has significantly improved outcome in AS.1 
Although the majority of patients respond very well to these TNF-α blocking agents, 
approximately 30% fail to reach efficacy.2-4 One possible explanation for this failure could be 
that the formation of antibodies to TNF-α blocking agents may decrease serum TNF-α blocker 
levels. Previous studies in rheumatoid arthritis (RA) have shown that the development of 
neutralizing antibodies is associated with allergic reactions and reduced response to 
treatment.5-7 Recently, de Vries et al. published 3 studies on antibody formation to TNF-α 
blocking agents in different AS cohorts. They detected antibodies in 29% and 31% of the 
patients treated with IFX and ADA, respectively, and no antibodies in patients treated with 
ETA.8-10 
Unlike several other inflammatory auto-immune diseases, there are no disease specific 
autoantibodies found in AS.  However, the presence of well-known autoantibodies such as 
antinuclear antibodies (ANA), anti-neutrophil cytoplasmatic antibodies (ANCA), and  
anti-double-stranded DNA (anti-dsDNA) antibodies has been described in AS patients.11,12 
Furthermore, previous studies have shown that ANA and anti-dsDNA antibodies can be 
induced during anti-TNF-α treatment.12-15 Since patients who produce autoantibodies have a 
more activated immune system, it may be suggested that these patients are more prone to the 
production of antibodies to TNF-α blocking agents. 
The objective of the present study was to investigate the influence of antibody formation to 
TNF-α blocking agents on the clinical response in AS patients treated with IFX, ETA, or ADA in 
daily clinical practice. The second goal was to investigate the development of ANA, ANCA, and 
anti-dsDNA antibodies in association with the formation of antibodies to TNF-α blocking 
agents. 
 
PATIENTS AND METHODS 
Patients 
Consecutive AS outpatients with active disease who started treatment with infliximab (IFX, 
n=20), etanercept (ETA, n=20), or adalimumab (ADA, n=20) at the Medical Center 
Leeuwarden (MCL) or the University Medical Center Groningen (UMCG) were included in 
this longitudinal observational study. All patients were aged ≥18 years, fulfilled the modified 
New York criteria for AS,16 and started anti-TNF-α treatment because of active disease 
according to the Assessments in Ankylosing Spondylitis (ASAS) consensus statement.17 
Patients were excluded if they had previously received anti-TNF-α treatment. IFX (5mg/kg) was 
given intravenously at 0, 2 and 6 weeks and then every 8 weeks. ETA was administered as a 
subcutaneous injection once (50 mg) or twice (25 mg) a week. ADA (40 mg) was administered 
as a subcutaneous injection every 2 weeks. The choice of the TNF-α blocking agent was based 
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on the judgment of the treating rheumatologist and/or the specific preference of the patient. 
Patients were allowed to receive concomitant medication as usual in daily clinical practice. The 
study was approved by the local ethics committees of the MCL and UMCG and all patients 
provided written informed consent to participate in this study. 
 
Clinical assessments 
Clinical data were collected prospectively at baseline and after 3, 6, and 12 months of  
anti-TNF-α treatment. Continuation of anti-TNF-α treatment was based on decrease in Bath 
Ankylosing Spondylitis Disease Activity Index (BASDAI), amounting 50% or 2 units compared 
with baseline, and/or expert opinion in favor of treatment continuation. Response to  
anti-TNF-α treatment was defined using BASDAI and ASAS20 response criteria. ASAS20 
response was defined as an improvement of at least 20% and absolute improvement of at least 
1 unit (on a scale of 0-10) compared with baseline in 3 or more of the 4 domains: physical 
function (Bath Ankylosing Spondylitis Functional Index (BASFI)), pain, patient’s global 
assessment of disease activity, and inflammation (mean from BASDAI questions 5 and 6), with 
no worsening by more than 20% in the remaining domain.18 Disease activity was assessed 
using BASDAI, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and the 
Ankylosing Spondylitis disease activity score (ASDAS) calculated from BASDAI questions 2, 3 
and 6, patient’s global assessment of disease activity, and CRP.19,20 
 
Laboratory assessments 
Antibodies to TNF-α blocking agents, serum TNF-α blocker levels, and ANA, ANCA, and  
anti-dsDNA antibodies were measured retrospectively at baseline and after 3, 6, and 12 
months of anti-TNF-α treatment. Analyses in samples from one patient were always performed 
in one assay to avoid inter-assay variability. Samples were stored at -20°C until analysis. 
Anti-IFX and anti-ADA antibodies were detected by radioimmunoassay (RIA) as described in 
detail previously.5,6 The assay measures specific high-avidity IgG antibodies to IFX or ADA by an 
antigen-binding test. In short, serum (1 μl/test) was pre-incubated with Sepharose-
immobilized protein A (1 mg/test; Pharmacia, Uppsala, Sweden) in Freeze buffer (Sanquin, 
Amsterdam, The Netherlands). Non-bound serum components were removed by washing 
before 50 μl 125I-radiolabeled F(ab)’2 fragment of IFX or ADA was added. After overnight 
incubation, non-bound radiolabel was washed away and Sepharose-bound radioactivity was 
measured. Test results were converted into arbitrary units per milliliter (AU/ml) by 
comparison with dilutions of a reference serum. The reference value was set at 12 AU/ml, as 
derived from 100 healthy donors. Anti-ETA antibodies were detected using a two-site assay 
RIA using Sepharose-immobilized ETA as solid phase for capturing ETA-specific antibody and 
125I-radiolabeled ETA for detection.9 It should be noted that antibodies to the TNF-α blocking 
agent may be underestimated or undetectable in patients with high serum concentrations of 
TNF-α blocker since the presence of TNF-α blocking agent interferes with the assay. 
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Serum IFX, ETA, and ADA levels were measured by enzyme-linked immunosorbent assay 
(ELISA; Sanquin, Amsterdam, The Netherlands) as described previously.8,9 The ELISA is based 
on the principle that the TNF-α blocking agent is captured through its ability to bind TNF-α. 
The sensitivity of detection for IFX, ETA and ADA was 0.0003 μg/ml, 0.001 μg/ml, and 0.001 
μg/ml, respectively. 
Serum samples were tested for ANA by indirect immunofluorescence using fixed Hep-2000 
cells (ImmunoConcepts, Biomedical Diagnostics, Antwerp, Belgium) as recommended by the 
manufacturer. ANA titer and pattern were reported. An ANA titer ≥1:40 was considered 
positive. Detection of ANCA by indirect immunofluorescence was performed on ethanol-fixed 
granulocytes as described before21,22 with minor modifications.23 An ANCA titer ≥1:40 was 
considered positive. Anti-dsDNA antibodies were measured by Farr RIA (Siemens Healthcare 
Diagnostics, Breda, The Netherlands) and by anti-dsDNA IgG and IgM ELISA on the Alegria 
(ORGENTEC, supplied by Siemens Healthcare Diagnositics). The Farr assay detects both IgG 
and IgM antibodies against dsDNA using 125I-labeled recombinant dsDNA as a substrate.  
A result ≥10 IU/ml was considered positive. To be able to distinguish between IgG and IgM 
responses, all samples positive for anti-dsDNA in the Farr assay were also measured in the 
separate IgG and IgM assays on the Alegria. A result ≥20 IU/ml was considered positive. 
 
Statistical analysis 
Statistical analysis was performed with SPSS 16.0 software (SPSS, Chicago, IL, USA). Results 
were expressed as mean ± SD or median (range) for parametric and nonparametric data, 
respectively. The Independent Samples T test and Mann-Whitney U test were used to 
compare differences between groups. The Chi-Square test and Fisher Exact test were used to 
compare percentages between groups. The Paired Samples T test and Wilcoxon Signed Rank 
test were used to compare differences within groups. The Fisher Exact test was used to 
analyze the relationship between the presence or absence of antibodies to TNF-α blocking 
agent and the presence or absence of ANA, ANCA, and anti-dsDNA antibodies. The 
Spearman’s correlation coefficient was used to analyze the relationship between serum levels 
of the TNF-α blocking agent and BASDAI, CRP, ESR, and ASDAS. Patients who had temporarily 
stopped their anti-TNF-α treatment in the period just before their 3, 6, or 12 month visit were 






Mean age of all patients (n=60) was 42.7 years (SD ± 11.4), median disease duration was 18 
years (range 1-49), and 63% were male. The 3 treatment groups were comparable for age, 
gender, HLA-B27 status, and baseline BASDAI, CRP, ESR, ASDAS, and concomitant 
medication. Disease duration was significantly longer in the IFX group. Patients with a history 
of inflammatory bowel disease (IBD) were absent in the ETA group as a results of a distinct 
preference of IFX and ADA for these patients. The percentage of patients with a history of 
uveitis was significantly higher in the IFX group compared to the ADA group (Table 1). 
 
 
Table 1. Baseline characteristics of the Ankylosing Spondylitis study population. 
 Total IFX ETA ADA 
N 60 20 20 20 
Gender (male) (%) 38 (63) 12 (60) 13 (65) 13 (65) 
Age (years) 42.7 ± 11.4 46.6 ± 11.0 39.4 ± 9.0 42.2 ± 13.1 
Duration of symptoms (years) 18 (1-49) 24 (3-49)* 15 (4-30) 8 (1-34) 
Time since diagnosis (years)  8 (0-35) 19 (1-35)† 8 (1-25) 5 (0-34) 
HLA B27 positive (%) 49 (84) 18 (90) 17 (85) 16 (80) 
History of IBD (%) 7 (12) 5 (25)‡ 0 (0) 2 (10) 
History of uveitis (%) 17 (28) 10 (50)† 5 (25) 2 (10) 
History of psoriasis (%) 6 (10) 3 (15) 1 (5) 2 (10) 
History of peripheral arthritis (%) 17 (28) 6 (30) 6 (30) 5 (25) 
Concomitant NSAID use (%) 53 (88) 19 (95) 18 (90) 16 (80) 
Concomitant DMARD use (%) 14 (23) 6 (30) 4 (20) 4 (20) 
BASDAI (range 0-10) 5.9 (2.1-9.8) 5.9 (3.6-8.4) 5.8 (3.5-9.0) 5.5 (2.1-9.8)  
CRP (mg/l) 17 (2-92) 18 (3-70) 14 (3-55) 18 (2-92) 
ESR (mm/h) 25 (2-90) 24 (4-90) 24 (3-80) 27 (2-74) 
ASDAS 3.8 (1.4-5.8) 3.8 (2.4-5.1) 3.8 (2.6-5.1) 3.8 (1.4-5.8) 
Values are mean ± SD or median (range) unless otherwise indicated.  
IFX: infliximab; ETA: etanercept; ADA: adalimumab; HLA B27: human leukocyte antigen B27; IBD: inflammatory 
bowel disease; NSAID: non-steroidal anti-inflammatory drug; DMARD: disease-modifying antirheumatic drug; 
BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; CRP: C-reactive protein; ESR: erythrocyte 
sedimentation rate; ASDAS: Ankylosing Spondylitis disease activity score. 
* Statistical difference (p<0.05) calculated with respect to values of the ETA and ADA groups. 
† Statistical difference (p<0.05) calculated with respect to values of the ADA group. 
‡ Statistical difference (p<0.05) calculated with respect to values of the ETA group. 
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Antibody formation to TNF-α blocking agents 
At baseline, 1 patient tested positive for anti-ADA antibodies (24 AU/ml) and these antibodies 
were still found after 3 months of treatment (18 AU/ml). In the treatment period of one year, 
antibodies to TNF-α blocking agents were induced in 4 (20%) patients treated with IFX and in 6 
(30%) patients treated with ADA. No antibodies to the TNF-α blocking agent were detected in 
patients treated with ETA (Table 2). In 6 patients (IFX, n=1; ADA, n=5), the antibodies were 
detected for the first time at 3 months. In the remaining 4 patients (IFX, n=3; ADA, n=1), the 
antibodies were detected for the first time at 6 months. Serum concentrations of antibodies 
were between 12 and 5154 AU/ml. The formation of antibodies to TNF-α blocking agents was 
not related to the use of concomitant non-steroidal anti-inflammatory drugs (NSAIDs) or 
disease-modifying antirheumatic drugs (DMARDs) (data not shown). 
 
Autoantibody formation 
No statistically significant differences were found in ANA, ANCA, and anti-dsDNA formation 
between the 3 treatment groups. ANA and ANCA were present at baseline and new ANA and 
ANCA were induced during anti-TNF-α treatment in all 3 groups (Table 2). ANA patterns 
varied between homogeneous, coarse speckled, and nucleolar. The majority of ANCA showed 
a p-ANCA fluorescence pattern. No anti-dsDNA antibodies were detected in the Farr assay at 
baseline. In all treatment groups, anti-dsDNA antibodies were induced during anti-TNF-α 
treatment in 20% to 30% of patients (Table 2). In 33% to 50% of these patients, the anti-dsDNA 
antibodies disappeared at 12 months. Serum concentrations of anti-dsDNA autoantibodies 
were low, ranging from 10 to 23 IU/ml. The anti-dsDNA autoantibodies detected in the Farr 
assay were of IgM isotype in 5 patients, of IgG isotype in 1 patient, and of both isotypes in  
5 patients, as determined by separate IgG and IgM assays on the Alegria. In the remaining  
5 patients, no positive IgG or IgM anti-dsDNA response was seen in the Alegria test, mostly 
due to responses just below the reference value of the assays. The seroconversion to IgG  
anti-dsDNA antibodies was not associated with the appearance of clinically relevant lupus-like 
symptoms. 
No statistically significant association was found between the presence of ANA, ANCA, or  
anti-dsDNA antibodies and the formation of antibodies to TNF-α blocking agents in both the 




Table 2. Antibodies to TNF-α blocking agents and autoantibodies in the IFX (n=20), ETA (n=20), and 
ADA (n=20) groups. 
 Present at baseline Induction during treatment 
IFX 
Anti-IFX (%) 0 (0) 4 (20) 
ANA (%) 10 (50) 6 (30) 
ANA ≥ 1:80 (%) 4 (20) 3 (15) 
ANCA (%)† 3 (15) 3 (15) 
Anti-dsDNA Farr (%) 
     Only IgM 
     Only IgG 
     Both IgM and IgG 












Anti-ETA (%) 0 (0) 0 (0) 
ANA (%) 12 (60) 3 (15) 
ANA ≥ 1:80 (%) 4 (20) 1 (5) 
ANCA (%)† 1 (5) 3 (15) 
Anti-dsDNA Farr (%) 
     Only IgM 
     Only IgG 
     Both IgM and IgG 












Anti-ADA (%) 0 (0) 6 (30) 
ANA (%) 6 (30) 4 (20) 
ANA ≥ 1:80 (%) 4 (20) 3 (15) 
ANCA (%)† 1 (5) 3 (15) 
Anti-dsDNA Farr (%) 
     Only IgM 
     Only IgG 
     Both IgM and IgG 











ANA: antinuclear antibodies; ANCA: anti-neutrophil cytoplasmatic antibodies; anti-dsDNA Farr:  
anti-double-stranded DNA measured by Farr. See Table 1 for other definitions. 
† The majority of positive ANCA showed a p-ANCA pattern of fluorescence. 
‡ No positive IgG or IgM anti-dsDNA response was seen in the Alegria test, mostly due to responses 
just below the reference value of the assays. 
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Antibody formation to TNF-α blocking agents and ASAS20 response 
In all 3 groups, BASDAI, CRP, ESR, and ASDAS significantly improved after 3, 6, and 12 months 
of anti-TNF-α treatment compared with baseline, except for ESR in the ADA group after 12 
months of treatment (data not shown). The percentage of patients that reached BASDAI 
response ranged from 60% to 85% for IFX, from 60% to 75% for ETA, and from 45% to 55% for 
ADA over time. At 3 months, the percentage of BASDAI responders was significantly lower for 
ADA compared to IFX. Furthermore, there was a trend suggesting a lower percentage of 
BASDAI responders to ADA compared to IFX at 12 months (p=0.053). The percentage of 
patients that reached ASAS20 response ranged from 65% to 85% for IFX, from 70% to 75% for 
ETA, and from 45% to 65% for ADA over time. At 6 months, there was a trend suggesting a 
lower percentage of ASAS20 responders to ADA compared to both IFX and ETA (p=0.053) 
(Table 3).  
During the first year, 15 patients discontinued anti-TNF-α treatment because inefficacy (IFX, 
n=3; ETA, n=1; ADA, n=7), adverse events (ETA, n=1; ADA, n=1), inefficacy and adverse events 
(IFX, n=1), or other reasons (IFX, n=1). There was a trend suggesting a higher percentage of 
patients that discontinued ADA treatment compared to ETA treatment (p=0.065) (Table 3). 
Of patients who discontinued anti-TNF-α treatment because of inefficacy, antibodies to TNF-α 
blocking agents were detected in 3 of 4 patients treated with IFX and in 4 of 7 patients treated 
with ADA. No antibodies were detected in the patient treated with ETA. 
Antibodies to TNF-α blocking agents were also detected in 3 patients who continued  
anti-TNF-α treatment. One patient was BASDAI and ASAS20 responder at all time points, 
although anti-IFX antibodies were detected at 6 and 12 months (24 and 20 AU/ml, 
respectively), resulting in very low serum IFX levels (1.05 and 1.22 μg/ml, respectively). Also an 
increased ESR level was found in this patient at 12 months. In the second patient, anti-ADA 
antibodies were detected at 3 and 6 months (60 and 18 AU/ml, respectively), resulting in low 
serum ADA levels (1.81 and 1.64 μg/ml, respectively) and non-response. At 12 months, this 
patient reached BASDAI and ASAS20 response and antibodies were not found anymore. In the 
final patient, anti-ADA antibodies were detected at 3, 6 and 12 months (12, 5154 and 1120 
AU/ml, respectively), resulting in low and undetectable serum ADA levels (2.77, 0.02 and 0.02 
μg/ml, respectively) and increased ESR levels. However, the patient reached BASDAI and 




Table 3. Serum TNF-α blocker levels, treatment response and reasons for treatment discontinuation of 
the IFX (n=20), ETA (n=20), and ADA (n=20) groups at 3, 6 and 12 months of anti-TNF-α treatment. 
 At 3 months At 6 months At 12 months Total 
IFX 
Serum IFX levels (μg/ml) 30.6 ± 30.0 36.3 ± 43.2 23.4 ± 26.9  
BASDAI response (%) 17 (85) 14 (70) 12 (60)  
ASAS20 response (%) 17 (85) 15 (75) 13 (65)  
Treatment discontinuation (%) 
     Allergic reaction, inefficacy 
     Inefficacy 
     Pregnancy wish 
1 (5) 
1 









Serum ETA levels (μg/ml) 3.1 ± 1.2 2.8 ± 1.6* 2.9 ± 1.0  
BASDAI response (%) 15 (75) 12 (60) 15 (75)  
ASAS20 response (%) 15 (75) 15 (75) 14 (70)  
Treatment discontinuation (%) 
     Inefficacy 








Serum ADA levels (μg/ml) 5.7 ± 4.0 5.5 ± 3.8 8.0 ± 5.1  
BASDAI response (%) 11 (55) † 11 (55) 9 (45) †††  
ASAS20 response (%) 13 (65) 9 (45) †† 10 (50)  
Treatment discontinuation (%) 
     Inefficacy 











Values are mean ± SD unless otherwise indicated. See Table 1 for definitions. 
* Statistical difference (p<0.05) calculated with respect to values at 3 months. 
† Statistical difference (p<0.05) calculated with respect to values of the IFX group. 
†† Trend to statistical difference (p=0.053) calculated with respect to values of the IFX and ETA groups. 
††† Trend to statistical difference (p=0.053) calculated with respect to values of the ETA group. 
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Serum TNF-α blocker levels and disease activity 
No significant differences were found in serum IFX or ADA levels over time. Serum ETA levels 
were significantly lower at 6 months compared to levels at 3 months (Table 3). Patients with 
antibody formation to IFX or ADA had significantly lower serum TNF-α blocker levels 
compared to patients without these antibodies (Table 4). 
Spearman correlations between serum levels of the TNF-α blocking agent and disease activity 
measured by BASDAI, CRP, ESR, and ASDAS are presented in Table 5. No significant 
correlations were found between serum IFX levels and BASDAI, CRP, ESR, or ASDAS. Serum 
ETA levels were negatively correlated with CRP after 12 months and with ESR after 3, 6, and 12 
months (p<0.05). Serum ADA levels were negatively correlated with BASDAI after 6 months, 
with CRP after 12 months, with ESR after 6 months, and with ASDAS after 3 months (p<0.05). 
 
 
Table 4. Serum TNF-α blocker levels of patients with and without anti-IFX or anti-ADA antibodies at 3, 6, 
and 12 months of treatment. 
 At 3 months At 6 months At 12 months 
Serum IFX levels (μg/ml) 
Patients with anti-IFX antibodies 0.1† 0.0 (0.0-1.1)* 0.6 (0.0-1.2)* 
Patient without anti-IFX antibodies 20.3 (0.0-99.9) 32.7 (3.7-153.9) 15.1 (2.4-93.2) 
Serum ADA levels (μg/ml) 
Patient with anti-ADA antibodies 1.5 (0.0-4.0)* 1.6 (0.0-2.4)* 0.0† 
Patient without anti-ADA antibodies 6.4 (3.5-16.6) 6.8 (5.9-11.4) 8.0 (3.2-16.3) 
Values are median (range). See Table 1 for definitions. 
* Statistical difference (p<0.05) calculated with respect to values of patients without anti-IFX or  
anti-ADA antibodies.  





Table 5. Spearman correlations between serum TNF-α blocker levels and BASDAI, CRP, ESR, and ASDAS 
of the IFX (n=20), ETA (n=20), and ADA (n=20) groups at 3, 6, and 12 months of anti-TNF-α treatment. 
 BASDAI CRP ESR ASDAS 
IFX     
Serum IFX levels at 3 months NS NS NS NS 
Serum IFX levels at 6 months NS NS NS NS 
Serum IFX levels at 12 months NS NS NS NS 
ETA     
Serum ETA levels at 3 months NS NS -.561* NS 
Serum ETA levels at 6 months NS NS -.519* NS 
Serum ETA levels at 12 months NS -.599* -.808* NS 
ADA     
Serum ADA levels at 3 months NS NS NS -0.552* 
Serum ADA levels at 6 months -.570* NS -.604* NS 
Serum ADA levels at 12 months NS -.848* NS NS 
NS : not significant. See Table 1 for other definitions. 




The present study indicates that antibody formation to IFX or ADA is related to a decrease in 
efficacy and early discontinuation of anti-TNF-α treatment in daily clinical practice, since 
antibodies were detected in the majority of patients who discontinued IFX or ADA treatment 
due to inefficacy. Furthermore, patients with anti-IFX or anti-ADA antibodies had significantly 
lower serum TNF-α blocker levels compared to patients without these antibodies. Significant 
negative correlations were observed between serum ADA levels and BASDAI, CRP, ESR, or 
ASDAS, which suggests the importance of sufficiently high serum TNF-α blocker levels to 
obtain clinical response. 
The percentage of patients that developed anti-IFX and anti-ADA antibodies was comparable. 
No anti-ETA antibodies were detected in this study, which is consistent with the report of de 
Vries et al..9 The absence of antibodies to ETA may be explained by the fact that the dimeric 
fusion protein ETA has a less immunogenic structure in comparison with the 2 monoclonal 
antibodies IFX and ADA. Significant negative correlations between serum ETA levels and CRP 
or ESR were found, which again seems to reflect the importance of sufficiently high serum 
anti-TNF-α levels to obtain response in terms of decreased inflammation. However, no 
significant correlation between serum ETA levels and BASDAI was found. BASDAI is a disease 
activity score solely based on the opinion of the patient. A possible explanation for these 
findings may thus be that patients with fewer subjective complaints are less compliant to 
therapy, which results in low serum ETA levels, high CRP and ESR levels, and normal BASDAI 
scores. 
Interestingly, anti-ADA antibodies first appeared and then disappeared in one patient. This 
finding is in accordance with Wolbink et al., who found that treatment continuation with IFX 
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resulted in a decrease of anti-IFX antibodies in RA patients.6 However, they continued IFX 
treatment with increased dosages after the detection of anti-IFX antibodies and in the present 
study we did not change the dose of ADA. Our patient had relatively low anti-ADA antibody 
titers and low, but detectable serum ADA levels. Therefore, continuation of treatment may be 
effective in patients with low antibody titers, whereas switching to another TNF-α blocking 
agent may be a better therapeutic option in patients with high antibody titers. 
When we compare clinical data of the IFX, ETA, and ADA groups, the response to ADA 
treatment seems to be somewhat lower in comparison with the other two agents, and the 
percentage of patients that discontinued ADA treatment seems to be somewhat higher in 
comparison with ETA. However, the response rates to IFX and ETA found in this observational 
study were comparable to those reported in randomized clinical trials,24,25 while the response 
rate to ADA was somewhat inferior to that reported in the literature.4 The small-sized 
treatment groups may have contributed to the differences in response rates in this study. 
There were two unexpected findings in our study. First, one baseline sample behaved in an 
atypical manner, showing a slightly positive test result for antibodies against ADA. This is 
remarkable, since this patient had not yet received the drug at the time when the blood sample 
was drawn. Inhibition experiments did not lead to conclusive results, which means that we 
have to consider this sample as false-positive. This is a rare phenomenon which we have not 
encountered previously, neither during test validation using 100 supposedly negative samples, 
nor during extensive ADA testing which we perform routinely. Second, we found that  
2 patients were responders to treatment according to the BASDAI and ASAS20 criteria, 
despite the presence of antibodies to the TNF-α blocking agent and low or undetectable 
serum TNF-α blocker levels. Moreover, ESR levels were increased in these patients. This 
indicates that it may be useful to consider more objective measures such as acute phase 
reactants as well as patient-related outcome measures when assessing clinical response to 
anti-TNF-α treatment in AS. 
ANA and ANCA antibodies were present at baseline and additionally developed during  
anti-TNF-α treatment in all 3 groups. Anti-dsDNA antibodies were not present at baseline, but 
were induced during anti-TNF-α treatment in all 3 groups. Interestingly, the anti-dsDNA 
antibodies disappeared in approximately half of the patients after 12 months of treatment. The 
presence of anti-dsDNA antibodies did not seem to be clinically relevant in this study since 
serum concentrations were low and seroconversion to the more pathogenic IgG class  
anti-dsDNA antibodies was not associated with the appearance of lupus-like symptoms. These 
findings are in agreement with previous studies.12,13,26 To our knowledge, this is the first study 
that investigates the relation between autoantibodies and antibodies to TNF-α blocking 
agents. Although ANA, ANCA, and anti-dsDNA antibodies were detected in AS patients 
treated with TNF-α blocking agents, no significant association was found between the 
presence of these autoantibodies and the induction of antibodies to TNF-α blocking agents. 
There are some limitations to this study. First, the 3 treatment groups were small and differed 
significantly in disease duration as well as in the percentage of patients with extra-articular 
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manifestations. Second, the collection of blood samples was not linked to the timing of 
administration of the TNF-α blocking agent. The administration of anti-TNF-α treatment to 
patients with antibodies to TNF-α blocking agents results in the formation of immune 
complexes, which may accelerate the clearance of the applied agent and the antibodies.7 
Therefore, the frequency of antibody formation to TNF-α blocking agents may have been 
underestimated in our study. In addition, the lack of standardization of the collection of blood 
samples increases the variation in measured serum TNF-α blocker levels. Despite this variation, 
we still found significant negative correlations between serum anti-TNF-α levels and 
assessments of disease activity. Only in the IFX group, no significant correlation was found. 
This may be explained by the fact that the lack of standardization of the collection of blood 
samples influences the results of the IFX group most since IFX is administered every 8 weeks. 
In conclusion, this longitudinal observational study in daily clinical practice indicates that the 
presence of ANA, ANCA, or anti-dsDNA antibodies is not associated with the formation of 
antibodies to TNF-α blocking agents. The percentage of patients that developed anti-IFX and 
anti-ADA antibodies was comparable in this study, while no anti-ETA antibodies were 
detected. The formation of anti-IFX and anti-ADA antibodies seems to be related to a decrease 
in efficacy and early discontinuation of anti-TNF-α treatment in AS patients, since anti-IFX or 
anti-ADA antibodies were detected in the majority patients who discontinued treatment due 
to inefficacy. Furthermore, patients with antibodies had significantly lower serum TNF-α 
blocker levels compared to patients without antibodies. Finally, significant negative 
correlations were found between serum levels of TNF-α blocking agents and assessments of 
disease activity. Further studies in larger groups of AS patients are needed to confirm the 
relation between antibody formation to TNF-α blocking agents, serum TNF-α blocker levels, 
and assessments of disease activity. In these studies, blood samples should be taken 
immediately before administration of the TNF-α blocking agent. However, based on the results 
of this study it seems useful to determine antibody formation to TNF-α blocking agents in  
non-responsive AS patients. 
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Objectives: To investigate the construct validity and test-retest reliability of the International 
Physical Activity Questionnaire (IPAQ; long form) and the Short QUestionnaire to ASsess 
Health-enhancing physical activity (SQUASH) and to investigate the relation between daily 
physical activity and clinical assessments in patients with ankylosing spondylitis (AS).  
Methods: The self-report questionnaires IPAQ and SQUASH were compared with daily 
physical activity assessed with the ActiGraph accelerometer during 7 consecutive days in 63 
AS outpatients. The IPAQ and SQUASH were administered on two different occasions 
approximately one week apart in 52 AS outpatients. In all 115 patients, clinical assessments 
were performed at the outpatient clinic. 
Results: IPAQ and SQUASH total scores correlated significantly with accelerometer outcome: 
ρ=0.38 and r=0.35, respectively. Intraclass correlation coefficients between first and second 
assessments of the IPAQ and SQUASH were 0.83 and 0.89, respectively. Bland-Altman 
analyses showed no systemic bias, but in particular for the IPAQ the 95% limits of agreement 
were wide. Daily physical activity assessed by accelerometer, IPAQ, and SQUASH correlated 
significantly with disease activity, physical activity, and quality of life. A relation with spinal 
mobility was found only for the accelerometer and SQUASH. 
Conclusion: Both physical activity questionnaires showed moderate construct validity. The 
SQUASH showed good test-retest reliability, superior to the IPAQ. These results indicate that 
the SQUASH can be used in AS population studies, but the development of a disease-specific 
physical activity questionnaire may be desirable. Further studies are needed to investigate the 
causality of the relation between daily physical activity and clinical assessments. 
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INTRODUCTION 
Ankylosing spondylitis (AS) is a chronic, progressive, inflammatory disease that primarily 
affects the axial skeleton. The disease causes pain and reduced spinal mobility, which can lead 
to limitations in physical functioning. AS usually starts from early adult age up to the fourth 
decade of life.1 Consequently, AS patients can become limited in their professional and leisure 
time activities at a relatively early age.  
Besides pharmacological treatment, exercise and physical therapy are considered essential 
components of treatment.2 A Cochrane review on exercise programs and physical therapy 
revealed small, but beneficial effects on physical function, spinal mobility, and patient global 
assessments in AS.3 Data concerning the relation between the total amount of daily physical 
activity and clinical assessments are lacking.  
Physical activity is a complex and multidimensional exposure variable, which makes 
population-based measurement difficult.4 Multiple measurement techniques are used to 
quantify physical activity. These techniques can be subdivided into two categories: direct 
methods such as stable isotopes to assess total energy expenditure and accelerometers or 
pedometers, and indirect methods such as oxygen uptake or heart rate monitoring and 
questionnaires or logs. Physical activity questionnaires are considered to be the most 
applicable method for population based studies because of participant convenience and 
minimal cost.4-7 
Recently, van Poppel et al. recommended that questionnaires assessing total physical activity 
should at least measure duration and frequency, and cover physical activity in all settings 
(household, work, transport, recreation, and sport) in order to reach sufficient content 
validity.8 The International Physical Activity Questionnaire (IPAQ) and the Short QUestionnaire 
to ASsess Health-enhancing physical activity (SQUASH) are recall questionnaires that fulfill 
these recommendations. Both questionnaires have acceptable construct validity and moderate 
to high test-retest reliability in healthy populations.9,10 However, in patients with AS, the 
validity and reliability of these physical activity questionnaires are not known. 
The aim of the present study was to investigate the construct validity and test-retest reliability 
of the IPAQ long form and the SQUASH in patients with AS. The second aim was to investigate 
the relation between daily physical activity and clinical assessments of disease activity, physical 
function, spinal mobility, and quality of life in these patients.  
 
 
PATIENTS AND METHODS 
Patients 
Between March 2010 and May 2011, 115 consecutive AS outpatients from the Medical 
Center Leeuwarden (MCL; n=63) and the University Medical Center Groningen (UMCG; 
n=52) were included. All patients were over 18 years of age and fulfilled the modified New 
York criteria for AS11 or the Assessments in Ankylosing Spondylitis (ASAS) criteria for axial 
spondyloarthritis including MRI.12 Patients with concomitant conditions restricting physical 
activity or who were not able to read Dutch were excluded. The study was approved by the 
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local ethics committees of the MCL and UMCG and written informed consent according to 
the Declaration of Helsinki was obtained from all patients. 
 
Construct validity 
Construct validity of the physical activity questionnaires was examined by correlating the IPAQ 
and SQUASH total scores to the accelerometer outcome. The accelerometer provides an 
objective and valid estimate of overall physical activity.5 On the first day, the long version of 
the IPAQ and the SQUASH were administered at the outpatient clinic in 63 AS patients. In 
succession, daily physical activity was assessed using the ActiGraph accelerometer during 7 
consecutive days. 
IPAQ. The IPAQ long form refers to an average week in the past month and comprises 
questions in the following domains: occupational, household and gardening, transport, and 
leisure time.9 Each of these domains provides a specific activity score calculated by multiplying 
the number of minutes per week of the performed activities with the accompanying mean 
metabolic equivalent (MET)-value of these activities.13,14 The total activity score was calculated 
by the sum of these domain scores and was reported in MET-minutes/week. According to the 
IPAQ guidelines, data were excluded if the total minutes of activity per day exceeded 960 or 
when missing values were present.9 
SQUASH. The SQUASH refers to an average week in the past month and contains questions in 
the following domains: commuting activities, household activities, leisure time and sports 
activities, and activities at work and school. Activity scores per domain were calculated by 
multiplying the number of minutes per week with an intensity score (range 1-9) of the 
activities performed.10 The intensity score was based on the reported intensity of an activity 
combined with the activity intensity classification according to Ainsworth’s Compendium of 
Physical Activities.13,14 The total activity score was calculated as the sum of the scores per 
domain. According to the SQUASH protocol, data were excluded if the total minutes of 
activity per day exceeded 960.10 Since the present study investigates the validity and reliability 
of the SQUASH, data were also excluded if missing values were present.  
Accelerometer. The ActiGraph accelerometer (GT1M, MTI, Fort Walton Beach, FI) is a small, 
lightweight, uniaxial accelerometer, which senses vertical accelerations between 0.05 and 2.0 
gravitational acceleration (ĝ) with a sample frequency of once per minute. The accelerometer 
was worn on the right hip during waking hours, except for periods of showering or other water 
activities. The duration of accelerometer wearing periods and the performed physical activities 
lasting over 10 minutes were noted in a diary. The outcome of the accelerometer was 
expressed in average kilo counts per day (kcounts/day), calculated by dividing the total activity 
kcounts by the total number of days the monitor was worn. Data were excluded if the 
accelerometer was worn for less than 10 hours per day, less than five days, or when it was not 
worn during both weekend days.15 
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Test-retest reliability 
The test-retest reliability of an instrument is based on the assumption that the construct has 
not changed over time and thus the outcome of the measure can be reproduced. To test the 
reproducibility of the IPAQ and SQUASH over time, the questionnaires were filled out by 52 
AS patients on two different occasions approximately one week apart. This time period was 
chosen because it is unlikely that the disease status will change in a week and this period is 
long enough to avoid re-call bias. The first assessment was performed at the outpatient clinic 
and the second assessment was conducted at home. 
 
Clinical assessments 
In all 115 patients, clinical assessments were performed at the outpatient clinic on the first day 
of the questionnaire assessments. Disease activity was assessed using the Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI; on a scale of 0-10), erythrocyte sedimentation rate 
(ESR), C-reactive protein (CRP), and the Ankylosing Spondylitis Disease Activity Score 
(ASDASCRP; calculated from BASDAI questions 2, 3, and 6, patient’s global assessment of 
disease activity, and CRP).16,17 Physical function was assessed using the Bath Ankylosing 
Spondylitis Functional Index (BASFI; on a scale of 0-10). Spinal mobility assessments included 
occiput-to-wall distance, chest expansion, modified Schober test, lateral spinal flexion (left and 
right) and cervical rotation (left and right). Quality of life was assessed using the Ankylosing 
Spondylitis Quality of Life questionnaire (ASQoL; on a scale of 0-18).  
 
Statistical analysis 
Data were analyzed using PASW Statistics 18 (SPSS, Chicago, IL, USA). Construct validity was 
examined by calculating Spearman’s and Pearson’s correlation coefficients between 
accelerometer activity counts and IPAQ and SQUASH total scores, respectively. Correlations 
below 0.3 were interpreted as poor association, between 0.3 and 0.6 as moderate association, 
between 0.6 and 0.8 as good association and above 0.8 as excellent association. The ActiGraph 
accelerometer is limited in measuring cycling and fitness activities and is not capable of 
measuring swimming or other water activities. Therefore, the accelerometer outcome was also 
correlated with an adjusted total score of the SQUASH without these activities. A z-test with 
Fisher’s transformation was used to compare this correlation with the correlation of the 
unadjusted SQUASH total score.  
Test-retest reliability of the IPAQ and SQUASH was investigated by calculating intraclass 
correlation coefficients (ICCagreement; two way random effects model) between the first and 
the second assessments of the questionnaires. Reliability was assessed for both total scores 
and activity scores per domain. ICC values of at least 0.70 indicate good reliability.18 
Additionally, Bland-Altman analysis was performed on the total scores.19 Differences between 
first and second IPAQ and SQUASH assessments were examined using Wilcoxon signed rank 
and paired t-tests, respectively.  
Chapter 8 
 114
Pearson’s and Spearman’s correlation coefficients were used as appropriate to analyze the 
relation between daily physical activity and clinical assessments. P values <0.05 were 




Characteristics of the 115 AS patients included in the validity (n=63) and reliability (n=52) 
studies are presented in Table 1. 
 
 
Table 1. Characteristics of the AS study population  
 Total group Validity study Reliability study 
Number of patients 115 63 52 
Age (years) 44.6 ± 12.1 43.2 ± 12.3 46.3 ± 11.8 
Gender (male) (n, %) 71 (62) 40 (64) 31 (60) 
BMI 26.4 ± 4.4 26.2 ± 4.8 26.6 ± 3.9 
Duration of symptoms (years) 16 (0-54) 18 (2-54) 16 (0-53) 
Time since diagnosis 10 (0-42) 11 (1-42) 9 (0-37) 
HLA-B27+ (n, %) 82 (76) 49 (82) 33 (69) 
Anti-TNF use (n, %) 78 (70) 39 (62) 39 (81)* 
NSAID use (n, %) 44 (40) 24 (39) 20 (42) 
DMARD use (n, %) 17 (15) 13 (21) 4 (8) 
BASDAI (range 0-10) 3.7 (0.0-9.0) 3.8 (0.4-8.6) 3.5 (0.0-9.0) 
ESR (mm/h) 11 (2-60) 13 (2-60) 10 (2-39) 
CRP (mg/l) 3 (2-46) 3 (2-44) 4 (2-46) 
ASDASCRP 2.3 (0.7-4.4) 2.3 (0.9-4.2) 2.3 (0.7-4.4) 
BASFI (range 0-10) 3.8 ± 2.4 3.6 ± 2.4 4.2 ± 2.4 
Occiput-to-wall distance (cm) 0.0 (0.0-29.0) 0.0 (0.0-29.0) 0.0 (0.0-20.0) 
Chest expansion (cm) 5.0 (1.0-14.0) 6.0 (1.0-10.5) 4.0 (1.0-14.0)** 
Modified Schober test (cm) 4.0 (0.4-7.0) 4.0 (0.4-6.2) 3.9 (0.0-7.0) 
Lateral spinal flexion left (cm) 10.5 (0.0-28.0) 11.0 (0.0-28.0) 10.0 (0.5-27.5) 
Lateral spinal flexion right (cm) 10.0 (0.0-27.0) 10.5 (0.0-22.0) 10.0 (1.0-27.0) 
Cervical rotation left (degrees) 60 (0-100) 74 (5-100) 55 (0-95)* 
Cervical rotation right (degrees) 62 (5-100) 65 (5-100) 61 (10-100) 
ASQoL (range 0-18) 6 (0-18) 6 (0-17) 6 (0-18) 
* Statistically significant difference compared to the validity study (p<0.05). 
** Statistically significant difference compared to the validity study (p<0.01). 
Values are mean ± SD or median (range) unless otherwise indicated. 
AS: ankylosing spondylitis; BMI: body mass index; HLA-B27+: human leukocyte antigen B27 positive; 
TNF: tumor necrosis factor; NSAID: non-steroidal anti-inflammatory drug; DMARD: disease modifying 
antirheumatic drug; BASDAI: Bath ankylosing spondylitis disease activity index; ESR: erythrocyte 
sedimentation rate; CRP: C-reactive protein; ASDAS: ankylosing spondylitis disease activity score;  
BASFI: Bath ankylosing spondylitis functional index; ASQoL: ankylosing spondylitis quality of life. 
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Construct validity 
Complete data to examine the validity of the IPAQ were available for 45 of the 63 (71%) 
patients. In these patients, the median IPAQ total score was 5937 (MET-minutes/week) 
(interquartile range (IQR) 2126-11601) and mean accelerometer outcome was 234 
kcounts/day (SD±107). The remaining patients had missing IPAQ values (n=12) and/or did not 
meet the accelerometer criteria (n=7). The correlation between IPAQ total score and 
accelerometer activity counts was 0.38, (p<0.05), which indicates moderate validity of the 
IPAQ.  
Complete data to examine the validity of the SQUASH were available for 53 of the 63 (84%) 
patients. In these patients, the mean SQUASH total score was 7267 (SD±3453) and mean 
accelerometer outcome was 236 kcounts/day (SD±107). The remaining patients had missing 
(n=2) or invalid (n=1) SQUASH values or did not meet the accelerometer criteria (n=7). The 
correlation between SQUASH total score and accelerometer activity counts was 0.35 (p<0.05), 
which indicates moderate validity of the SQUASH.  
According to the SQUASH, 68%, 34%, and 19% of AS patients reported cycling, fitness, and 
swimming, respectively, which are activities that cannot be (properly) registered by the 
accelerometer. The correlation between SQUASH total score adjusted for these activities and 
accelerometer outcome was 0.39 (p<0.01). This correlation did not significantly differ from the 





Complete data for the first and second assessment of the IPAQ were available for 32 of the 52 
(62%) patients. The remaining patients had missing values (n=18) or the total minutes of 
activity per day exceeded 960 (n=2). The ICC for the IPAQ total score was 0.83, indicating 
good reliability. ICCs for the sub scores ranged from 0.60 (household and garden activities) to 
0.88 (transport activities) (Table 2). 
Complete data for the first and second assessment of the SQUASH were available for 33 of the 
52 (63%) patients. The remaining patients had missing values (n=16), the total minutes of 
activity per day exceeded 960 (n=2), or the second questionnaire was missing (n=1). The ICC 
for the SQUASH total score was 0.89, indicating good reliability. ICCs for sub scores of the 
SQUASH ranged from 0.48 (commuting activities) to 0.88 (work and school activities) (Table 
2).  
Bland-Altman analyses for the IPAQ and SQUASH total scores showed that the mean 
difference between the first and second assessment was small and not significantly different 
from zero, which implies that no systematic bias was present. However, in particular for the 
IPAQ, the 95% limits of agreement (LOA) were wide, indicating that only large changes can be 
considered as true changes (Figure 1). 
 
 
Table 2. Physical activity of the AS patients (with complete data) included in the reliability study  
 1st assessment 2nd assessment ICC 95% CI 
IPAQ (MET-mins/week) (n=32)     
Total activity score 3849 (1470-8132) 4349 (2120-7508) 0.83* 0.68-0.91 
 Work activity score 0 (0-3710) 50 (0-3197) 0.80* 0.63-0.90 
 Transport activity score 653 (284-1607) 737 (209-1589) 0.88* 0.77-0.94 
 Household & garden activity score 580 (53-1481) 245 (90-1406) 0.60* 0.33-0.79 
 Leisure time activity score 657 (195-1718) 678 (111-1832) 0.73* 0.52-0.86 
SQUASH (n=33)     
Total activity score 5760 (3360-6890) 5600 (3715-7540) 0.89* 0.79-0.95 
 Work and school activity score 1080 (0-4440) 600 (0-4680) 0.88* 0.77-0.94 
 Commuting activity score 0 (0-341) 0 (0-438) 0.48* 0.17-0.70 
 Household activity score 900 (420-1815) 840 (240-1635) 0.77* 0.59-0.88 
 Leisure time & sports activity score 1350 (775-1795) 1410 (480-2635) 0.87* 0.76-0.93 
* Statistically significant intraclass correlation (p<0.001). 
No significant differences were found between the first and second assessments of the physical activity 
questionnaires. 
Values are median (interquartile range) unless otherwise indicated.  
AS: ankylosing spondylitis; IPAQ: International Physical Activity Questionnaire; SQUASH: Short 








Figure 1.  Bland-Altman plots. Difference between the total scores on the first and second IPAQ (A) and 




Relation between daily physical activity and clinical assessments 
Accelerometer, IPAQ and SQUASH total scores correlated significantly with disease activity 
assessed using ASDASCRP. In addition, the IPAQ and SQUASH correlated significantly with 
BASDAI and the accelerometer correlated significantly with ESR and CRP. All three daily 
physical activity measures correlated significantly with physical function and quality of life, 
while a significant correlation with spinal mobility was found only for the accelerometer and 
SQUASH (Table 3). 
 
 





Number of patients 86a 94a 55b 
Disease activity    
   BASDAI (range 0-10) -0.220*c -0.326**c NS 
   ESR (mm/h) NS NS -0.460***c 
   CRP (mg/l) NS NS -0.289*c 
   ASDASCRP -0.243*
c -0.311**c -0.283*c 
Physical function    
   BASFI (range 0-10) -0.387***c -0.476***d -0.274*d 
Spinal mobility    
   Occiput-to-wall distance (cm) NS -0.297**c NS 
   Chest expansion (cm) NS NS NS 
   Modified Schober test (cm) NS 0.260*c 0.338*c 
   Lateral spinal flexion left (cm) NS NS 0.344*d 
   Lateral spinal flexion right (cm) NS NS 0.385**d 
   Cervical rotation left (degrees) NS 0.286**c 0.358**c 
   Cervical rotation right (degrees) NS 0.296**c 0.285*c 
Quality of life    
   ASQoL -0.282**c -0.500***c -0.356**c 
*   Statistically significant correlation (p<0.05) 
**  Statistically significant correlation (p<0.01) 
*** Statistically significant correlation (p<0.001) 
a Only patients with complete data on the first IPAQ or SQUASH assessment and available clinical 
data were included 
b Only patients with complete accelerometers data and available clinical data were included.  
c Spearman’s correlation coefficient 
d Pearson’s correlation coefficient 
See Tables 1 and 2 for abbreviations. 
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DISCUSSION 
This is the first study that investigates the measurement properties of physical activity 
questionnaires in AS. The construct validity of the IPAQ (long form) and SQUASH compared 
with accelerometer activity counts was found to be moderate, with correlations of 0.38 and 
0.35, respectively. A large study in healthy populations from different countries showed 
comparable agreement between the IPAQ total score and accelerometer outcome (pooled 
correlation of 0.33).9 The results for the SQUASH total score were reported to be somewhat 
better, with correlations of 0.45 in healthy adults and 0.67 in patients after total hip 
arthroplasty.10,20 Recently, Terwee et al. have developed the Quality Assessment of Physical 
Activity Questionnaire (QAPAQ) checklist to appraise the qualitative attributes and 
measurement properties of physical activity questionnaires. They stated that the correlation 
between total physical activity assessed by a questionnaire and accelerometer total counts 
should be at least 0.50.21 Based on these guidelines, the standard to prove the construct 
validity of the IPAQ and SQUASH was not completely reached in patients with AS. 
Both questionnaires showed good test-retest reliability based on ICC values (0.83 and 0.89 for 
the IPAQ and SQUASH total scores, respectively). Previous studies reported Spearman’s 
correlation coefficients of 0.81 (pooled correlation) for the IPAQ long form9 and 0.58 and 0.57 
for the SQUASH.10,20 In the present study, ICC’s were used instead of correlation coefficients, 
because correlation coefficients do not take systematic measurement errors into account.21 
For the comparison with previous studies, correlation coefficients were also calculated, 
resulting in values of 0.74 for the IPAQ and 0.90 for the SQUASH (data not shown). Bland 
Altman analysis was performed in only one of the previous studies. In accordance with our 
results, the authors reported no systematic bias between SQUASH assessments, but their  
95% LOA were approximately 3 times larger than those found in the present study.20 We 
found wide 95% LOA for the IPAQ in comparison to the SQUASH, which indicates that only 
large changes can be considered as true changes.   
Interestingly, objective accelerometer daily activity was significantly correlated with the 
objective measures ESR and CRP and the subjective IPAQ and SQUASH were significantly 
correlated with the subjective measure BASDAI. Accelerometer, IPAQ, and SQUASH scores 
were all significantly correlated to the ASDASCRP, a composite score of patient-reported 
measures and CRP developed in order to capture both subjective and objective aspects of AS 
disease activity. The inverse relation between accelerometer outcome and CRP is in line with 
recent findings of Plasqui et al.,22 but the relation between daily physical activity and clinical 
assessments has not been studied before. Some support for the presence of these relations 
can be obtained from intervention studies concerning exercise programs and physical therapy 
in AS. Although exercise is only a part of a person’s total physical activity,23 an increase in 
exercise means in general an increase in total physical activity. Until now, conflicting data have 
been published about the relation between physical activity and disease activity in intervention 
studies.24,25 Randomized controlled trials showed an improvement in physical function and 
spinal mobility after an 8-week to 4-month exercise program,26-28 which supports a relation 
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between these clinical assessments and daily physical activity in AS. Further studies are needed 
to investigate the causality of the relation between higher daily physical activity and lower 
disease activity and better physical function, spinal mobility, and quality of life found in the 
present study. 
A limitation of this study was the multitude of missing values in both questionnaires. 
Therefore, a relatively large group of patients was excluded from the analyses. The frequent 
occurrence of missing values may hamper the use of these physical activity questionnaires in 
daily practice. In contrast to the IPAQ, the SQUASH guidelines clearly prescribe how to deal 
with missing data.10 However, the reliability of the SQUASH total score was insufficient 
(ICC=0.60) in our analysis including patients with imputation for missing values according to 
the SQUASH guidelines (data not shown). A second limitation is that the ActiGraph 
accelerometer is an uniaxial accelerometer and therefore is limited in the measurement of 
physical activities that require little vertical movement, such as cycling or fitness. In addition, 
the accelerometer is not waterproof and therefore swimming and other water-related 
activities could not be measured. Even though, the correlation between the accelerometer 
outcome and the SQUASH score without these activities was comparable to the correlation of 
the total SQUASH score. The IPAQ only discriminates between moderate and vigorous leisure 
time physical activities. For that reason, a correction for cycling, fitness, and swimming on the 
IPAQ total score could not be performed. Finally, the timeframes for the questionnaires and 
accelerometer were not completely comparable. Both questionnaires referred to a usual week 
in the past month (retrospective assessment), whereas the accelerometer daily activity was 
assessed prospectively for 5 to 7 days. Strength of our study is that wearing the accelerometer 
could not influence the reliability assessments of the physical activity questionnaires, since 
validity and reliability were examined in two different groups of AS patients. 
In conclusion, the construct validity of the IPAQ (long form) and SQUASH was found to be 
moderate in patients with AS. Both questionnaires showed good test-retest reliability based 
on ICC values and Bland-Altman analyses showed no systemic bias between assessments. In 
particular for the IPAQ the 95% LOA were wide, which indicates that the degree of 
repeatability is not sufficient for this questionnaire. Daily physical activity assessed by 
accelerometer outcome (objective) and IPAQ and SQUASH total scores (subjective) was 
found to be significantly related to clinical assessments of disease activity, physical function, 
and quality of life. A relation with spinal mobility was found only for the accelerometer and 
SQUASH. Based on these results, the SQUASH seems superior to the IPAQ to assess daily 
physical activity in AS population studies. However, the development of a disease-specific 
physical activity questionnaire may be desirable. Further studies are needed to investigate the 
causality of the relation between higher daily physical activity and better clinical assessments in 
AS. 
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This thesis covers several important topics of AS. The first part (chapters 2-3) concerns 
different aspects of bone turnover in AS. The second part (chapters 3-7) focuses on the 
identification of predictors of response and investigates antibody formation to TNF-α blocking 
agents in AS. The final study of this thesis (chapter 8) concerns the assessment of daily physical 
activity in patients with AS. 
 
GLAS study 
All manuscripts from this thesis are based on data derived from the Groningen Leeuwarden 
Ankylosing Spondylitis (GLAS) study. This is an ongoing prospective longitudinal observational 
cohort study of AS patients from the outpatient clinics of the Medical Center Leeuwarden 
(MCL) and the University Medical Center Groningen (UMCG), which started in November 
2004. The general research goals of the GLAS study are to obtain more knowledge on  
AS-related bone formation and bone resorption, and to evaluate the effect of tumor necrosis 
factor-alpha (TNF-α) blocking therapy in AS patients in daily clinical practice.  
The GLAS study is conducted according to the operative guidelines established by the 
Assessment in SpondyloArthritis international Society (ASAS) working group.1 Patients 
treated with TNF-α blocking therapy (n=260 until 2012) are evaluated at baseline, after 3 and 6 
months, and then every 6 to 12 months. Patients without anti-TNF-α treatment (inclusion 
started in 2009; n=140 until 2012) are evaluated yearly. Standardized follow-up visits include 
assessments of disease activity, physical function, spinal mobility, quality of life, inflammation 
of entheses, bone mineral density (BMD), and radiology. Furthermore, serum, plasma, and 
urine samples are collected and stored to measure e.g. bone turnover markers (BTM) and 
vitamin D levels. 
All patients from the GLAS cohort fulfill the modified New York criteria for AS2 (>95% of 
patients) and/or the ASAS criteria for axial spondyloarthritis.3,4 Approximately two-third of the 
patients is male. At study entry, the mean age was 43 years (standard deviation: 12 years), the 
median duration of symptoms was 15 years (range: 1-59 years), and the median time since 
diagnosis was 6 years (range: 0-54 years).  
 
Bone turnover 
In AS, excessive bone formation can lead to the formation of syndesmophytes and ankylosis of 
the spine and sacroiliac joints.5 On the other hand, excessive bone loss can result in low BMD 
(osteopenia or osteoporosis) and vertebral fractures.6,7 
BTM reflect the metabolic activity of bone and can easily be measured in blood or urine. 
Previous studies have demonstrated that measuring BTM can provide a better insight in the 
bone physiology of AS.8-10 A challenge of working with BTM (as well as BMD) is that they 
change with age and that there are differences for gender. To correct for these influences, we 
calculated BTM Z-scores using a Dutch healthy reference cohort. This corresponds to the 
methodology of interpreting BMD. 
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In order to obtain more knowledge on AS-related osteoporosis, we studied the relation 
between BMD, BTM, vitamin D levels, and clinical assessments of disease activity and physical 
function in a cross-sectional analysis of baseline data from AS patients with active disease. The 
results presented in chapter 2 show that higher levels of bone resorption marker serum type I 
collagen C-telopeptide (sCTX), bone formation marker osteocalcin (OC), and erythrocyte 
sedimentation rate (ESR) were independently related to low BMD. Furthermore, higher ESR 
and lower 25-hydroxyvitamin D levels were independently related to sCTX Z-score. Based on 
these results, high bone turnover, inflammatory processes, and low vitamin D levels seem all 
to play a role in AS-related bone loss. In addition, previous studies have suggested the 
importance of adverse effects of medication (for example glucocorticoids) and decreased 
mobility in relation to pain and stiffness in the multifactorial etiology of osteoporosis in AS.11 
Another important finding in chapter 2 was that the difference between lumbar spine and hip 
BMD T-score correlated positively with disease duration, which indicates that 
osteoproliferation in the lumbar spine has resulted in an overestimation of the lumbar spine 
BMD, measured by dual-energy x-ray absorptiometry (DXA), in patients with advanced AS. 
Therefore, measuring both BTM and BMD seems useful to identify osteoporosis in these 
patients. The high prevalence of vertebral fractures (39%) and low BMD (57%) in our study 
underlines the importance of monitoring bone loss in AS in daily clinical practice. 
 
Many randomized controlled trials (RCTs) have shown that TNF-α blocking agents are 
effective in controlling inflammation and improving clinical assessments in patients with 
AS.12,15 These improvements were also found in our cohort. Subsequently, we investigated the 
effect of TNF-α blocking therapy on BTM and BMD. The results of chapter 3 show that  
3 years of TNF-α blocking therapy resulted in a significant increase in bone-specific alkaline 
phosphatase (BALP), which plays a central role in the mineralization process of bone, while the 
effect on procollagen type 1 N-terminal peptide (PINP), a product of collagen formation, was 
less evident. Furthermore, a significant decrease in sCTX, a product of collagen degradation, 
was found. Interestingly, both lumbar spine and hip BMD improved significantly during 3 years 
of TNF-α blocking therapy, which may be explained by the increase in mineralization and 
decrease in bone resorption. 
 
Predictors of response to TNF-α blocking therapy 
In clinical practice, continuation of TNF-α blocking therapy is mainly based on subjective 
measures such as the Bath AS Disease Activity Index (BASDAI) and the global opinion of the 
patient and the physician. Recent studies showed the usefulness of the AS disease activity 
score (ASDAS) as a more objective measure of disease activity.16-19 However, if available, it 
would be useful to include also a purely objective measure in the evaluation of TNF-α blocking 
therapy in patients with AS. In search of such an objective biomarker, we investigated the 
predictive value of BTM and matrix metalloproteinase-3 (MMP-3), an enzyme involved in 
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degradation of extracellular matrix components, using longitudinal data from AS patients 
treated with TNF-α blocking agents.  
In chapter 3, we found that decrease in bone resorption marker sCTX and improvements in 
ASDAS and physician’s global disease activity (GDA) during the first 3 months of treatment 
were independently related to longer continuation of TNF-α blocking therapy. The accuracy of 
early change in sCTX to discriminate between patients who continued and discontinued TNF-α 
blocking therapy during the first 3 years was moderate and comparable to the accuracy of early 
change in ASDAS or physician’s GDA. In addition, baseline to 3 months decrease in sCTX was 
significantly associated with good long-term response regarding disease activity, physical 
function, spinal mobility, and quality of life. Based on these results, early change in sCTX seems 
useful as a purely objective biomarker in the evaluation of TNF-α blocking therapy in AS, in 
addition to the currently used more subjective measures. 
In chapter 4, we found that etanercept treatment resulted in a significant reduction in serum 
MMP-3 levels in male patients with AS. This decrease appeared to be significant in male 
patients with concomitant peripheral arthritis at baseline, but not in male patients with only 
axial disease. Data analysis was split for gender, since baseline serum MMP-3 levels were 
significantly different between male and female patients with AS. Subsequently, we showed 
that baseline serum MMP-3 levels had poor accuracy to discriminate between responders and 
nonresponders after 3 or 12 months of etanercept treatment. The accuracy of decrease in 
serum MMP-3 levels from baseline to 3 months to predict response after 3 or 12 months of 
treatment was poor to moderate. Furthermore, this accuracy was comparable to those of 
change in ESR and CRP, which are elevated only in a minority of patients with AS.20,21 
Therefore, measuring serum MMP-3 levels seems not very useful for monitoring and 
predicting response to etanercept treatment in AS patients in daily clinical practice. 
 
Besides biomarkers to evaluate treatment in AS, it is relevant to identify patient characteristics 
before start of treatment which are able to predict a beneficial response to TNF-α blocking 
therapy, especially in view of the high costs and potential side effects of these agents.  
In chapter 5, we identified male gender, higher ESR or CRP level, and the presence of 
peripheral arthritis as independent baseline predictors of both treatment response and 
continuation of TNF-α blocking therapy in daily clinical practice. Furthermore, a higher ASDAS 
score was found to be a significant baseline predictor of response to TNF-α blocking therapy. 
In contrast, a higher BASDAI score at baseline was independently associated with treatment 
discontinuation. Currently, starting and continuation TNF-α blocking therapy is mainly based 
on the BASDAI, but these results suggest that more objective measures should be included in 
this process. 
Chapter 6 provided an overview of clinical trials and observational studies investigating 
baseline predictors of response after 3-6 months of TNF-α blocking therapy and baseline 
predictors of long-term anti-TNF-α treatment continuation in AS. Multiple studies have 
identified increased acute phase reactants, presence of peripheral arthritis, higher disease 
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activity, higher functional status, younger age, male sex, and HLA-B27 positivity as 
independent baseline predictors for achieving clinical response after 3-6 months and/or for 
long-term continuation of TNF-α blocking therapy in multivariate analyses. Furthermore, 
several studies reported promising data regarding the potential value of biomarkers, for 
example markers of inflammation or bone and cartilage metabolism, as baseline predictors of 
response to TNF-α blocking therapy. Until now, the results of these studies are either not 
confirmed by other study groups or confirmed in studies that used less robust techniques of 
data analysis. Further studies using multivariate analyses are needed to confirm the predictive 
value of these biomarkers, in addition to the currently known predictors. 
 
Although the majority of AS patients respond very well to TNF-α blocking therapy, 
approximately 30% fail to reach efficacy. This may in part be explained by the formation of 
antibodies against these agents.22,23 Chapter 7 showed that during one year of treatment, 
antibodies against infliximab, etanercept, and adalimumab were induced in 20%, 0%, and 30% 
of patients, respectively. This antibody formation was related to a decrease in efficacy and early 
discontinuation of anti-TNF-α treatment, since antibodies were detected in the majority of 
patients who discontinued treatment due to inefficacy. Furthermore, patients with these 
antibodies had significantly lower serum TNF-α blocker levels compared to patients without 
these antibodies. Significant negative correlations were found between serum TNF-α blocker 
levels and assessments of disease activity, which suggests the importance of sufficiently high 
serum TNF-α blocker levels to obtain clinical response. 
 
Daily physical activity 
Besides pharmacological treatment, exercise and physical therapy are essential components of 
treatment. Physical activity questionnaires are considered to be the most applicable method to 
assess daily physical activity in population studies because of participant convenience and 
minimal cost.24,25 The International Physical Activity Questionnaire (IPAQ) and the Short 
QUestionnaire to ASsess Health-enhancing physical activity (SQUASH) are recall 
questionnaires with acceptable construct validity and moderate to high test-retest reliability in 
healthy populations. In chapter 8, we investigated the measurement properties of these 
physical activity questionnaires in patients with AS. The results showed that the construct 
validity of the IPAQ and SQUASH compared with accelerometer activity counts was moderate. 
Furthermore, both questionnaires had good test-retest reliability based on intraclass 
correlation coefficients. Bland-Altman analyses showed no systemic bias, but in particular for 
the IPAQ the 95% limits of agreement were wide, which indicates that only large changes can 
be considered as true changes. A limitation of the study was the multitude of missing values in 
both questionnaires, which may hamper the use of these physical activity questionnaires in 
daily practice. Based on our results, the SQUASH seems superior to the IPAQ to assess daily 
physical activity in AS population studies. However, the development of a disease-specific 
physical activity questionnaire may be desirable. Finally, we showed that higher daily physical 
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activity was significantly related to lower disease activity and better physical function, spinal 
mobility, and quality of life. 
 
Resume and perspective 
The present thesis describes different aspects of bone turnover in AS as well as several topics 
in relation to the clinical management of this disease in daily clinical practice.  
First, we demonstrated that BTM can be useful to identify bone loss in AS, especially in 
patients with advanced disease. Further longitudinal studies are needed to investigate the 
usefulness of BTM in predicting outcome such as osteoporosis and/or radiographic damage in 
AS. A major advantage of BTM is that they can easily be measured in the blood of patients at 
different time points with relatively low costs. However, it is important to standardize serum 
sample collection and the assays used for BTM measurements to reduce variability within and 
between patients.26,27 The use of T-scores and Z-scores helps to interpret BTM and BMD. 
The introduction of TNF-α blocking agents has been the most important development in the 
treatment of AS in the past decades. RCTs have demonstrated that these agents are effective 
in controlling inflammation and improving clinical assessments.12-15 Data from observational 
studies such as the GLAS cohort are also important, since they provide information closer to 
clinical practice than RCTs. Furthermore, follow-up is often longer in cohort studies and it 
gives, in case of a sufficient amount of included patients, the possibility of head to head 
comparison of several different expensive therapies such as TNF-α blocking agents.  
A limitation of observational studies in clinical practice is the introduction of bias, but this 
problem can partly be solved by using sophisticated analysis techniques. 
Besides improvements in clinical assessments, it was shown that TNF-α blocking therapy also 
has a beneficial effect on lumbar spine and hip BMD. Based on our BTM analysis, this can 
largely be explained by an increase in mineralization and decrease in bone resorption. Still, the 
important question remains whether TNF-α blocking agents can diminish or stop radiographic 
progression and can prevent vertebral fractures in AS. There are concerns that, although 
inflammation will resolve after TNF-α blocking therapy, the focal fatty lesions seen on 
magnetic resonance imaging (MRI) will persist. This may lead to ongoing repair processes, 
resulting in formation of syndesmophytes and progression of radiographic damage.28 Recent 
studies did not show a significant difference in radiographic progression after 2 years of TNF-α 
blocking therapy, when compared to radiographic data of TNF-α blocker naive patients from 
historical cohorts.29-31 It may be hypothesized that long-term treatment with TNF-α blocking 
agents will decelerate radiographic progression over time, since by preventing new 
inflammatory lesions, repair processes will extinguish over time. In line with this hypothesis, 
less radiographic progression was reported between 4 and 8 years of infliximab treatment 
compared to a historical cohort.32 Further studies with long-term follow-up are needed to 
confirm these findings. The influence of long-term TNF-α blocking therapy on radiographic 
progression will also be an important research question in our longitudinal GLAS study. 
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In clinical practice, continuation of TNF-α blocking therapy is mainly based on subjective 
measures such as the BASDAI and the global opinion of the patient and the physician. In our 
opinion, it would be useful to also include an objective measure in this evaluation process.  
This thesis confirmed the usefulness of the ASDAS, a composite score of patient-reported 
measures and an acute phase reactant developed in order to capture both subjective and 
objective aspects of AS disease activity. Besides, we identified early decrease in bone 
resorption marker sCTX as a significant predictor of continuation of TNF-α blocking therapy, 
independent from ASDAS and physician’s GDA. Of course, confirmation of these results in an 
independent cohort will strengthen sCTX as an objective measure. 
At this moment, recommendations for starting TNF-α blocking therapy in AS are primarily 
based on inadequate response to conventional treatment and less on the expectation that 
anti-TNF-α treatment will be effective in a particular patient. In the last few years, several 
studies including our own study focused on the identification of characteristics of AS patients 
before start of treatment which are able to predict a beneficial response to TNF-α blocking 
therapy. However, the predictive value of single parameters identified is not strong enough to 
predict treatment response in the individual patient. The development of a prediction model33 
may lead to an instrument that can support physicians to make evidence-based decisions to 
start TNF-α blocking therapy in patients with AS in daily clinical practice.  
The fact that some patients with AS fail to reach efficacy to TNF-α blocking therapy can in part 
be explained by the immunogenicity of these agents. In our study, antibody formation to 
infliximab or adalimumab was associated with treatment discontinuation and lower serum 
TNF-α blocker levels. Sufficiently high serum TNF-α blocker levels seem to be important to 
obtain clinical response, since significant negative correlations were found between serum 
TNF-α blocker levels and assessments of disease activity. In line with our findings, a recent 
study in a large group of patients with rheumatoid arthritis (RA) showed that the development 
of antibodies against adalimumab was associated with lower serum levels of adalimumab, 
earlier treatment discontinuation, higher disease activity, and absence of clinical remission.  
The authors also reported that antibodies against adalimumab were already detectable long 
before the patient discontinued anti-TNF-α treatment.34 It can therefore be useful to measure 
serum TNF-α blocker levels and antibodies to TNF-α blocking agents in all patients, so that 
treatment regimens can be adapted if necessary. 
Finally, our results demonstrated that the amount of daily physical activity (i.e. household, 
work, transport, and leisure time activities) is related to disease activity, physical function, 
spinal mobility, and quality of life in patients with AS. Further studies are needed to investigate 
the causality of these relations. Furthermore, we showed reasonable measurement properties 
for the SQUASH, a general physical activity questionnaire, in these patients. However, the 
exact measurement of daily physical activity remains difficult and the development of an  
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In dit proefschrift worden de resultaten beschreven van een onderzoek betreffende patiënten 
met ankyloserende spondylitis (AS), ook wel de ziekte van Bechterew genoemd. AS is een 
chronische reumatische aandoening, waarbij vooral de wervelkolom is aangedaan. De ziekte 
wordt gekenmerkt door ontsteking in combinatie met botvorming en botverlies. De vorming 
van nieuw bot kan leiden tot ankylose (verstijving) van de wervelkolom en de sacroiliacale (SI; 
heiligbeen) gewrichten. Tegelijkertijd kan botverlies resulteren in osteoporose (botontkalking). 
De meest voorkomende klachten bij AS zijn stijfheid en pijn onder in de rug, vaak met 
uitstraling in de bil. Kenmerkend is dat deze klachten verbeteren door bewegen en verergeren 
tijdens rust. Naast de betrokkenheid van de wervelkolom en het bekken kunnen ook 
ontstekingen optreden in andere gewrichten zoals de schouders, heupen of knieën (perifere 
artritis), de peesaanhechtingen (enthesitis), het regenboogvlies van het oog (uveitis), de huid 
(psoriasis) en de darmen (ziekte van Crohn of colitis ulcerosa). 
AS kan niet worden genezen, maar door behandeling kunnen de klachten wel aanzienlijk 
worden verlicht. Oefentherapie gericht op het behouden van de beweeglijkheid en het 
voorkomen van vergroeiingen is een belangrijk onderdeel van de behandeling. Om de 
ontsteking en daarmee ook de pijn te verminderen worden vaak ontstekingsremmers 
(NSAID’s) gebruikt. Daarnaast zijn ongeveer 10 jaar geleden geneesmiddelen beschikbaar 
gekomen die het ontstekingseiwit tumor necrosis factor-alfa (TNF-α) remmen. Op dit moment 
zijn er vier TNF-α blokkerende geneesmiddelen geregistreerd voor AS: infliximab, etanercept, 
adalimumab en golimumab. Een patiënt komt pas in aanmerking voor behandeling met deze 




Alle hoofdstukken in dit proefschrift zijn gebaseerd op gegevens van de Groningen 
Leeuwarden AS (GLAS) studie. De GLAS studie is een prospectief observationeel cohort 
onderzoek (d.w.z. het vervolgen van een groep patiënten in de tijd zonder de mogelijke 
uitkomsten te beïnvloeden) van patiënten met AS die worden behandeld op de poliklinieken 
van het Medisch Centrum Leeuwarden (MCL) en het Universitair Medisch Centrum 
Groningen (UMCG). Het algemene doel van de GLAS studie is om meer informatie te 
verkrijgen over de processen van botvorming en botafbraak bij AS en om het effect van de 
verschillende TNF-α blokkerende geneesmiddelen te evalueren bij een grote groep AS 
patiënten in de dagelijkse klinische praktijk. 
De GLAS studie wordt uitgevoerd volgens de tot nu toe beschikbare richtlijnen van de ASAS 
werkgroep (groep van internationale experts op het gebied van AS). Vanaf 2004 zijn 260 AS 
patiënten, behandeld met TNF-α blokkerende geneesmiddelen, opgenomen in het onderzoek. 
Ze worden voor start van de behandeling, na 3 en 6 maanden en vervolgens elke 6-12 
maanden gezien op geprotocolleerde spreekuren. Vanaf 2009 doen ook 140 AS patiënten 
zonder anti-TNF behandeling mee aan de studie, die jaarlijks op het speciale spreekuur komen. 
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Tijdens alle bezoeken vult de patiënt een aantal vragenlijsten in met betrekking tot 
ziekteactiviteit, fysiek functioneren en kwaliteit van leven. Daarnaast vindt er een uitgebreid 
lichamelijk onderzoek plaats en wordt bloed afgenomen en opgeslagen om o.a. botmarkers en 
vitamine D spiegels te meten. Tot slot worden iedere 2 tot 4 jaar botdichtheidmetingen 
gedaan en röntgenfoto’s gemaakt. 
Alle patiënten van de GLAS studie voldoen aan de gemodificeerde New York criteria voor AS 
(>95% van de patiënten) en/of aan de ASAS criteria voor axiale spondylarthropathie (SpA). 
Ongeveer tweederde van de patiënten is man en bij de aanvang van het onderzoek was de 
gemiddelde leeftijd 43 jaar (variërend van 18-79 jaar), de duur van symptomen 15 jaar 
(variërend van 1-59 jaar) en de tijd sinds diagnose 6 jaar (variërend van 0-54 jaar). 
 
Botmetabolisme 
Bij patiënten met AS kan overmatige botvorming leiden tot de vorming van syndesmofyten 
(botvorming in de ligamenten van de tussenwervelgewrichten van de wervelkolom) en 
ankylose (verstijving) van de wervelkolom en de SI gewrichten. Daarnaast kan overmatig 
botverlies resulteren in een lage botmineraaldichtheid (BMD) en wervelfracturen. 
De BMD kan worden gemeten met behulp van een DEXA scan (soort röntgenonderzoek). De 
uitslag wordt vergeleken met de gemiddelde piekbotmassa van jonge volwassenen (T-score) 
en de gemiddelde botmassa van mensen met dezelfde leeftijd en geslacht (Z-score). Een  
T-score tussen de -1 en -2.5 wordt geïnterpreteerd als osteopenie (verminderde botmassa) en 
bij een T-score lager dan -2.5 is er sprake van osteoporose. 
Botmarkers weerspiegelen de aanmaak en afbraak van het bot en kunnen gemakkelijk worden 
gemeten in bloed of urine. Procollageen type N-terminale peptide (PINP; een product van 
collageenaanmaak, het hoofdbestanddeel van de botstructuur), botspecifieke alkalische 
fosfatase (BALP; een enzym dat een belangrijke rol speelt in het mineralisatieproces van bot) 
en osteocalcine (OC; een eiwit met een regulerende functie in het proces van botaanmaak) 
worden vaak gebruikt als markers van botaanmaak. Daarnaast is serum type I collageen  
C-telopeptide (sCTX; komt in het bloed bij collageenafbraak) een bekende marker van 
botafbraak. Het lastige van het werken met botmarkers is dat ze net als de BMD veranderen 
met de leeftijd en dat er verschillen zijn tussen mannen en vrouwen. Om hiervoor te 
corrigeren, berekenen we Z-scores met behulp van een referentiegroep. Deze Z-score wordt 
als volgt berekend: (waarde botmarker van de patiënt — gemiddelde waarde van een 
referentiegroep met vergelijkbare leeftijd en geslacht) / standaard deviatie (SD) van deze 
referentiegroep. 
 
In hoofdstuk 2 hebben we de relatie tussen BMD, botmarkers, vitamine D spiegels en 
klinische maten van ziekteactiviteit en fysiek functioneren onderzocht in een cross-sectionele 
analyse (d.w.z. één meetmoment per patiënt) van AS patiënten met actieve ziekte (voor start 
van de behandeling met TNF-α blokkerende geneesmiddelen). De resultaten laten zien dat 
hogere waardes van botafbraak marker sCTX, botaanmaak marker OC en bezinking in het 
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bloed onafhankelijk van elkaar gerelateerd zijn aan een lage BMD. Daarnaast zijn lagere 
vitamine D spiegels en een hogere bezinking onafhankelijk gerelateerd aan botafbraak (sCTX 
Z-score). Zowel een hoog botmetabolisme als ontstekingsprocessen en lage vitamine D 
spiegels lijken dus een rol te spelen tijdens botverlies bij AS. Eerdere studies hebben 
gesuggereerd dat ook de nadelige effecten van medicijnen (bijvoorbeeld glucocorticoïden 
zoals prednison) en een verminderde mobiliteit in relatie tot pijn en stijfheid van belang zijn 
tijdens het ontstaan van osteoporose bij patiënten met AS.  
Belangrijk is dat het verschil tussen de BMD van de lumbale wervelkolom (onderste deel van 
de wervelkolom) en de heup positief gerelateerd is aan de ziekteduur. Dit kan betekenen dat 
de vorming van nieuw bot heeft geleid tot een overschatting van de BMD in de lumbale 
wervelkolom, gemeten met behulp van een DEXA-scan, bij AS patiënten met gevorderde 
ziekte. Daarom concluderen we in hoofdstuk 2 dat het bij deze patiënten zinvol is zowel 
botmarkers als BMD te meten om osteoporose op te sporen. Het grote aantal patiënten met 
wervelfracturen (39%) en een lage BMD (57%) in ons onderzoek onderstreept het belang van 
het monitoren van botverlies bij AS in de dagelijkse klinische praktijk. 
 
Meerdere gerandomiseerde klinische studies (studies waarbij het toeval beslist welke patiënt 
in welke behandelgroep komt) hebben aangetoond dat TNF-α blokkerende geneesmiddelen 
verbetering geven in klinische uitkomstmaten bij patiënten met AS. Deze klinische respons op 
anti-TNF behandeling zien we ook bij de patiënten die deelnemen aan de GLAS studie. 
Daarnaast hebben we het effect van TNF-α blokkerende geneesmiddelen op het 
botmetabolisme en de BMD onderzocht. De resultaten in hoofdstuk 3 laten zien dat 3 jaar 
anti-TNF behandeling een significante verhoging geeft in BALP (belangrijk voor 
botmineralisatie), terwijl het effect op PINP (product van botaanmaak) minder duidelijk is. 
Tevens is er een significante afname gevonden in sCTX (product van botafbraak). De BMD van 
de lumbale wervelkolom en de heup zijn aanzienlijk verbeterd gedurende 3 jaar behandeling 
met TNF-α blokkerende geneesmiddelen, waarschijnlijk als gevolg van de toename in 
botmineralisatie en de afname in botafbraak.  
 
Het voorspellen van respons op anti-TNF behandeling 
Op dit moment zijn de BASDAI (vragenlijst in te vullen door de patiënt met vragen over 
vermoeidheid, pijn en stijfheid) en het algemene oordeel van de patiënt en de arts over de 
mate van ziekteactiviteit bepalend voor het continueren van de anti-TNF behandeling in de 
klinische praktijk. Dit zijn echter allemaal subjectieve maten. Recente studies hebben 
aangetoond dat de ASDAS, een combinatie van een vragenlijst en de ontstekingswaarde in het 
bloed, kan worden gebruikt als een meer objectieve maat voor ziekteactiviteit. Het zou echter 
nuttig zijn om, indien beschikbaar, ook een volledig objectieve maat te gebruiken bij de 
beoordeling van het effect van anti-TNF behandeling bij patiënten met AS. Op zoek naar een 
dergelijke objectieve maat hebben we gekeken naar de waarde van de eerder genoemde 
botmarkers en van matrix metalloproteinase-3 (MMP-3), een enzym dat betrokken is bij de 
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afbraak van extracellulaire matrix componenten (structuren die deel uitmaken van biologische 
weefsels maar die zich buiten de cellen bevinden). Hiervoor hebben we de longitudinale 
gegevens (d.w.z. meerdere achtereenvolgende meetmomenten per patiënt) gebruikt van AS 
patiënten die zijn behandeld met TNF-α blokkerende geneesmiddelen.  
In hoofdstuk 3 hebben we aangetoond dat de afname in botafbraak marker sCTX en de 
verbetering in ASDAS en het algemene oordeel van de arts tijdens de eerste 3 maanden van de 
anti-TNF behandeling onafhankelijk van elkaar het voorzetten van deze behandeling kunnen 
voorspellen. Het vermogen van de vroege verandering in sCTX om onderscheid te maken 
tussen patiënten die stoppen en doorgaan met de behandeling is redelijk en vergelijkbaar met 
het onderscheidend vermogen van de vroege verandering in ASDAS of in het algemene 
oordeel van de arts. Daarnaast is deze vroege afname in sCTX geassocieerd met een goede 
lange termijn respons met betrekking tot ziekteactiviteit, fysieke functie, beweeglijkheid van 
de wervelkolom en kwaliteit van leven. Op basis van deze resultaten lijkt een vroege 
verandering in sCTX bruikbaar als objectieve maat tijdens de klinische evaluatie van anti-TNF 
behandeling, in aanvulling op de momenteel gebruikte meer subjectieve maten. 
In hoofdstuk 4 wordt beschreven dat behandeling met etanercept een afname geeft van 
MMP-3 spiegels in het bloed bij mannen met AS. Deze daling bleek statistisch significant te 
zijn bij mannelijke AS patiënten met perifere artritis, maar niet bij mannelijke AS patiënten met 
alleen betrokkenheid van de wervelkolom. De data-analyse werd opgesplitst voor geslacht, 
omdat de MMP-3 spiegels voor start van de behandeling verschillend zijn tussen mannen en 
vrouwen. Vervolgens vonden we dat zowel de MMP-3 spiegels voor start van de behandeling 
als de afname in MMP-3 spiegels tijdens de eerste 3 maanden van de behandeling geen 
duidelijk onderscheid kunnen maken tussen patiënten die wel of geen goede respons bereiken 
na 3 en/of 12 maanden behandeling met etanercept. Het meten van MMP-3 spiegels in het 
bloed lijkt dan ook niet erg zinvol voor het monitoren en voorspellen van respons op anti-TNF 
behandeling bij AS patiënten in de dagelijkse klinische praktijk. 
 
Naast biologische markers om de respons op anti-TNF behandeling objectief te kunnen 
beoordelen, is het ook van belang om patiëntkarakteristieken en labwaarden te vinden die in 
staat zijn om vooraf een goede respons op deze behandeling te voorspellen. Dit geldt zeker 
met het oog op de hoge kosten en mogelijke bijwerkingen van deze geneesmiddelen. In de 
longitudinale studie beschreven in hoofdstuk 5 vonden we dat mannelijk geslacht, 
aanwezigheid van perifere artritis en hogere bezinking of CRP voor start van de behandeling 
onafhankelijk van elkaar het optreden van respons en het voorzetten van de behandeling 
kunnen voorspellen. Tevens bleek een hogere ASDAS score voor start van de behandeling een 
belangrijke voorspeller te zijn voor een goede respons op anti-TNF behandeling, terwijl een 
hogere BASDAI score voor start van de behandeling geassocieerd was met het staken van de 
behandeling in de dagelijkse klinische praktijk. Op dit moment wordt de BASDAI in combinatie 
met de mening van de arts gebruikt voor het starten en continueren van de behandeling met 
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TNF-α blokkerende geneesmiddelen. De bovengenoemde resultaten suggereren echter dat er 
meer objectieve maten moeten worden meegenomen in dit proces. 
Hoofdstuk 6 geeft een overzicht van de gerandomiseerde klinische studies en observationele 
onderzoeken naar voorspellende variabelen voor respons na 3-6 maanden behandeling met 
TNF-α blokkerende geneesmiddelen en voor het langdurig voorzetten van deze behandeling 
bij patiënten met AS. Meerdere studies hebben met behulp van multivariate analyses (analyses 
om het verband tussen meerdere variabelen te onderzoeken) hogere bezinking of CRP in het 
bloed, aanwezigheid van perifere artritis, hogere ziekteactiviteit, betere functionele status, 
jongere leeftijd, mannelijk geslacht en aanwezigheid van HLA-B27 (een genetische factor) 
geïdentificeerd als variabelen voor de start van de behandeling die onafhankelijk het optreden 
van klinische respons na 3-6 maanden en/of het langdurig voortzetten van anti-TNF 
behandeling kunnen voorspellen. Tevens laten verschillende studies veelbelovende gegevens 
zien met betrekking tot potentiële biologische markers, bijvoorbeeld ontstekingsmarkers of 
markers van het bot- en kraakbeenmetabolisme, als voorspellers van respons op anti-TNF 
behandeling. Tot nu toe zijn de resultaten van deze onderzoeken echter nog niet door andere 
onderzoeksgroepen bevestigd of zijn ze bevestigd met behulp van minder robuuste  
data-analyse technieken. Verder onderzoek met multivariate analyses is daarom nodig om de 
voorspellende waarde van deze biologische markers te bevestigen, in aanvulling op de reeds 
bekende voorspellende variabelen. 
 
Hoewel de meerderheid van de patiënten met AS goed reageren op TNF-α blokkerende 
geneesmiddelen is het effect van deze medicatie onvoldoende bij ongeveer 30% van de 
patiënten. Dit kan deels worden verklaard door het ontstaan van antistoffen tegen deze 
geneesmiddelen. In hoofdstuk 7 bleek dat gedurende één jaar behandeling 20%, 0% en 30% 
van de patiënten antistoffen vormen tegen respectievelijk infliximab, etanercept en 
adalimumab. De vorming van antistoffen is gerelateerd aan een afname van de effectiviteit en 
het vroegtijdig staken van de anti-TNF behandeling. Er zijn antistoffen gevonden bij de meeste 
patiënten die moesten stoppen met infliximab en adalimumab behandeling wegens 
ineffectiviteit. Bovendien hebben patiënten met deze antistoffen lagere medicatiespiegels in 
het bloed dan patiënten zonder antistoffen. Een interessante bevinding is dat lagere 
medicatiespiegels in het bloed gerelateerd zijn aan hogere ziekteactiviteit, wat het belang van 
voldoende hoge medicatiespiegels impliceert voor het bereiken van klinische respons. 
 
Dagelijkse fysieke activiteit 
Naast geneesmiddelen zijn lichaamsoefeningen en fysiotherapie essentiële onderdelen van de 
behandeling van AS. Vragenlijsten worden beschouwd als de meest geschikte methode om 
dagelijkse fysieke activiteit te meten in populatieonderzoek, vanwege de 
gebruiksvriendelijkheid en de relatief lage kosten. De IPAQ en SQUASH zijn vragenlijsten voor 
het meten van fysieke activiteit met aanvaardbare validiteit (d.w.z. dat er wordt gemeten wat 
de bedoeling is) en gemiddelde tot hoge betrouwbaarheid (d.w.z. dat als de meting wordt 
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herhaald, dit dezelfde resultaten oplevert; de resultaten zijn reproduceerbaar) bij gezonde 
proefpersonen. In hoofdstuk 8 hebben we deze eigenschappen van de IPAQ en SQUASH 
onderzocht bij patiënten met AS. Onze resultaten tonen aan dat de validiteit van de IPAQ en 
SQUASH vergeleken met een beweegmeter redelijk is. Daarnaast hebben beide vragenlijsten 
een goede test-hertest betrouwbaarheid op basis van de intraclass correlatie coëfficiënt (ICC; 
een statistische maat voor reproduceerbaarheid). De Bland-Altman grafiek laat zien dat er geen 
sprake is van een systematische meetfout. De 95% grenzen van overeenstemming (d.w.z. de 
waarden waarbinnen 95% van de gevonden verschillen zich bevinden) zijn echter erg breed, 
vooral voor de IPAQ. Dit betekent dat alleen grote veranderingen kunnen worden beschouwd 
als werkelijke veranderingen. Een beperking van onze studie is dat er relatief veel ontbrekende 
waarden waren in beide vragenlijsten. Dit kan het gebruik van deze vragenlijsten in de 
dagelijkse klinische praktijk belemmeren. De huidige resultaten geven aan dat de SQUASH 
geschikter is dan de IPAQ voor het meten van dagelijkse fysieke activiteit in AS 
populatiestudies. Het lijkt echter wenselijk om een ziektespecifieke vragenlijst betreffende 
fysieke activiteit te ontwikkelen voor patiënten met AS. Tot slot hebben we gevonden dat 
hogere dagelijkse fysieke activiteit gerelateerd is aan lagere ziekteactiviteit en betere fysieke 
functie, beweeglijkheid van de wervelkolom en kwaliteit van leven. 
 
Samenvatting en verder onderzoek 
Dit proefschrift beschrijft verschillende aspecten van het botmetabolisme in AS en een aantal 
onderwerpen met betrekking tot de behandeling van deze ziekte in de dagelijkse klinische 
praktijk. 
Allereerst hebben we aangetoond dat het meten van botmarkers nuttig kan zijn om botverlies 
op te sporen in AS, vooral bij patiënten met gevorderde ziekte. Verdere longitudinale studies 
zijn nodig om de waarde van botmarkers te onderzoeken voor het voorspellen van ziekte-
uitkomst, zoals osteoporose en/of röntgenschade. Een groot voordeel van botmarkers is dat 
ze gemakkelijk op meerdere tijdstippen kunnen worden gemeten in het bloed van patiënten 
tegen relatief lage kosten. Het is echter belangrijk de afname van bloed en de 
laboratoriumtesten te standaardiseren om de variatie in de uitslagen binnen en tussen 
patiënten te verminderen. Het gebruik van T-scores en/of Z-scores om te corrigeren voor de 
invloed van leeftijd en geslacht helpt bij de interpretatie van botmarkers en BMD. 
De introductie van TNF-α blokkerende geneesmiddelen is de belangrijkste ontwikkeling 
geweest voor de behandeling van AS in de afgelopen decennia. Gerandomiseerde klinische 
studies hebben aangetoond dat deze geneesmiddelen effectief zijn tegen ontstekingen en dat 
ze verbetering geven in klinische uitkomstmaten. Observationele studies zoals de GLAS studie 
zijn echter ook van belang, aangezien deze studies informatie geven vanuit de klinische praktijk 
en de follow-up vaak lang is. Mits er voldoende patiënten meedoen, geven ze tevens de 
mogelijkheid om verschillende kostbare geneesmiddelen zoals TNF-α blokkerende 
geneesmiddelen te vergelijken. Een beperking van observationele studies in de klinische 
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praktijk is de introductie van bias (vertekening van resultaten), maar dit probleem kan deels 
worden opgelost door het gebruik van geavanceerde analysetechnieken. 
We hebben aangetoond dat TNF-α blokkerende geneesmiddelen een gunstig effect hebben 
op de BMD van de lumbale wervelkolom en de heup bij patiënten met AS. Op basis van onze 
botmarker analyse lijkt dit grotendeels verklaard te kunnen worden door een toename in de 
botmineralisatie en een afname in de botafbraak. Een belangrijke vraag blijft echter of anti-TNF 
behandeling de radiologische progressie (toename van de afwijkingen die zichtbaar zijn op 
röntgenfoto’s) kan verminderen of stoppen en wervelfracturen kan voorkomen. Meerdere 
studies hebben geen significant verschil gevonden in radiologische progressie tussen AS 
patiënten die twee jaar behandeld werden met TNF-α blokkerende geneesmiddelen en  
AS patiënten zonder anti-TNF behandeling (historisch cohort). Een recente studie 
rapporteerde wel minder radiologische progressie tijdens de periode van 4 tot 8 jaar 
behandeling met infliximab in vergelijking met een historisch cohort. Deze bevinding 
suggereert dat langdurige anti-TNF behandeling radiologische progressie kan remmen. 
Verdere onderzoeken waarin patiënten zeer lang worden vervolgd zijn nodig om deze 
bevinding te bevestigen. Het effect van langdurige behandeling met TNF-α blokkerende 
geneesmiddelen op het ontstaan van radiologische schade zal de komende jaren een 
belangrijke onderzoeksvraag zijn binnen onze GLAS studie. 
De voortzetting van anti-TNF behandeling wordt in de klinische praktijk vooral gebaseerd op 
subjectieve maten, zoals de BASDAI en het algemene oordeel van de patiënt en de arts. 
Volgens ons zou het zinvol zijn om tevens een objectieve maat mee te nemen in dit 
evaluatieproces. Onze studie bevestigt de bruikbaarheid van de ASDAS, een samengestelde 
score van vragen ingevuld door de patiënt en de ontstekingswaarde in het bloed om zowel 
subjectieve als objectieve aspecten van ziekteactiviteit te meten. Daarnaast vonden we dat de 
afname in botafbraak marker sCTX tijdens de eerste 3 maanden van anti-TNF behandeling het 
voortzetten van deze behandeling kan voorspellen, onafhankelijk van de ASDAS en het 
algemene oordeel van de arts. Natuurlijk zal bevestiging van deze resultaten in een 
onafhankelijk cohort de betekenis van sCTX als objectieve maat versterken. 
Op dit moment zijn de richtlijnen voor het starten van anti-TNF behandeling bij AS 
voornamelijk gebaseerd op onvoldoende respons op de standaard behandeling en minder op 
de verwachting dat anti-TNF behandeling effectief zal zijn in een bepaalde patiënt. In de 
afgelopen jaren hebben verschillende studies, waaronder ons eigen onderzoek, zich gericht op 
de identificatie van patiëntkarakteristieken die in staat zijn om vooraf een goede respons op 
behandeling met TNF-α blokkerende geneesmiddelen te voorspellen. Helaas is de 
voorspellende waarde van de huidige parameters niet sterk genoeg om de respons op deze 
behandeling te kunnen voorspellen in de individuele AS patiënt. De ontwikkeling van een 
predictiemodel kan echter leiden tot een instrument dat artsen ondersteuning kan bieden bij 
de besluitvorming rond het starten van anti-TNF behandeling in de dagelijkse klinische praktijk. 
Het feit dat sommige patiënten met AS geen baat (meer) hebben bij anti-TNF behandeling kan 
voor een deel worden verklaard door het ontstaan van antistoffen. In onze studie hebben we 
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een duidelijke relatie gevonden tussen het ontstaan van antistoffen tegen infliximab of 
adalimumab en het staken van de behandeling en lagere medicatiespiegels in het bloed. 
Daarnaast waren de medicatiespiegels gerelateerd aan ziekteactiviteit. Het hebben van 
voldoende hoge medicatiespiegels lijkt dus van belang te zijn voor het bereiken van een 
klinische respons. In lijn met onze bevindingen heeft een recente studie in een grote groep 
patiënten met reumatoïde artritis (RA) laten zien dat de vorming van antistoffen tegen 
adalimumab geassocieerd is met lagere medicatiespiegels, eerder stoppen van de behandeling, 
hogere ziekteactiviteit en afwezigheid van klinische remissie (vermindering van 
ziekteverschijnselen). De onderzoekers melden ook dat de antistoffen tegen adalimumab al 
waarneembaar waren lang voordat de patiënt stopte met de behandeling. Het lijkt daarom 
zinvol om medicatiespiegels en antistoffen te meten bij alle patiënten met AS, zodat indien 
nodig de behandeling vroegtijdig kan worden aangepast. 
Tot slot laten onze resultaten zien dat de totale hoeveelheid dagelijkse fysieke activiteit 
(huishouden, werk, vervoer en vrije tijd) geassocieerd is met klinische maten van 
ziekteactiviteit, fysieke functie, beweeglijkheid van de wervelkolom en kwaliteit van leven bij 
patiënten met AS. Verdere studies zijn nodig om de oorzakelijkheid van deze relaties te 
onderzoeken. Daarnaast vonden we een redelijke validiteit en goede betrouwbaarheid van de 
SQUASH vragenlijst betreffende fysieke activiteit bij AS patiënten. Echter, het meten van 
dagelijkse fysieke activiteit blijft lastig met een algemene vragenlijst en de ontwikkeling van 
een AS-specifieke fysieke activiteit vragenlijst is daarom wenselijk. 
 
De rode draad in onze GLAS studie is de evaluatie van behandeling met TNF-α blokkerende 
geneesmiddelen bij patiënten met AS in de dagelijkse klinische praktijk. Belangrijke 
onderwerpen hierbij zijn het objectief kunnen beoordelen van de effectiviteit van anti-TNF 
behandeling en het vooraf kunnen voorspellen welke patiënten wel en niet goed zullen 
reageren op deze behandeling. De resultaten beschreven in dit proefschrift dragen bij aan de 
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Anti-dsDNA anti-double-stranded DNA 
AS  ankylosing spondylitis 
ASAS  Assessment in SpondyloArthritis international Society 
ASDAS  Ankylosing Spondylitis Disease Activity Score 
ASQoL  Ankylosing Spondylitis Quality of Life 
AUC  area under the curve 
B  regression coefficient 
BALP  bone-specific alkaline phosphatase 
BASDAI  Bath Ankylosing Spondylitis Disease Activity Index 
BASFI  Bath Ankylosing Spondylitis Functional Index 
BASMI  Bath Ankylosing Spondylitis Metrology Index 
BMD  bone mineral density 
BMI  body mass index 
BTM  bone turnover markers 
CI  confidence interval 
CRP  C-reactive protein 
CTX-II  C-terminal crosslinking telopeptide of type II collagen 
DMARD  disease-modifying antirheumatic drug 
DXA  dual-energy x-ray absorptiometry 
ECLIA  electrochemiluminescence immunoassay 
ELISA  enzyme-linked immunosorbent assay 
ESR  erythrocyte sedimentation rate 
ESSG  European Spondyloarthropathy Study Group 
ETA  etanercept 
GDA  global disease activity 
GEE  generalized estimating equations 
GLAS  Groningen Leeuwarden Ankylosing Spondylitis 
HLA  human leukocyte antigen 
HR  hazard ratio 
IBD  inflammatory bowel disease 
IBP  inflammatory back pain 
ICC  intraclass correlation coefficient 
IE-CV  inter-assay coefficient of variation 
IFX  infliximab 
IL-1  interleukin 1 
Abbreviations 
 155 
IL-6  interleukin 6 
IPAQ  International Physical Activity Questionnaire 
IRMA  immunoradiometric assay 
LOA  limits of agreements 
LS  lumbar spine 
MCL  Medical Center Leeuwarden 
MET  metabolic equivalent 
MHC  major histocompatibility complex 
MMP-3  matrix metalloproteinase-3 
MRI  magnetic resonance imaging 
mSASSS  modified Stoke Ankylosing Spondylitis Spinal Score 
NSAID  nonsteroidal anti-inflammatory drug 
OC  osteocalcin 
OR  odds ratio 
PINP  procollagen type 1 N-terminal peptide 
QAPAQ  Quality Assessment of Physical Activity Questionnaire 
QCT  quantitative computed tomography 
RA  rheumatoid arthritis 
RCT  randomized controlled trial 
RIA  radioimmunoassay 
ROC  receiver operating characteristic 
SAA  serum amyloid A 
sCTX  serum type I collagen C-telopeptide 
SD  standard deviation 
SQUASH Short QUestionnaire to ASsess Health-enhancing physical activity 
sNTX  serum type I collagen N-telopeptide 
SpA  spondyloarthritis 
TIMP  tissue inhibitor of metalloproteinase 
TNF-α  tumor necrosis factor-alpha 
UMCG  University Medical Center Groningen 
VAS  visual analogue scale 
VEGF  vascular endothelial growth factor 
VF  vertebral facture 
WHO  World Health Organization 
